kidney

INTERNATIONAL

Volume 23, 1983

Editor
Roscoe R. Robinson, Nashville

Assistant Editors
Claude Amiel, Paris
Vincent W. Dennis, Durham

Editorial Board
Thomas E. Andreoli, Houston
Vittorio E. Andreucci, Naples
A. W. Asscher, Cardiff
Peter Balint, Budapest
Jonas Bergstrom, Stockholm
Roland C. Blantz, San Diego
Adalbert Bohle, Tubingen
Jean-Philippe Bonjour, Berne
Vittorio Bonomini, Bologna
Barry M. Brenner, Boston
Neal S. Bricker, Los Angeles
Hans R. Brunner, Lausanne
J. S. Cameron, London
Jack W. Coburn, Los Angeles
Ramzi Cotran, Boston
William G. Couser, Seattle
Hugh E. deWardener, London
Jean Dormont, Clamart
R. Dzurik, Bratislava
Laurence E. Earley, Philadelphia
Bryan T. Emmerson, Brisbane
Marilyn G. Farquhar, New Haven
Thomas F. Ferris, Minneapolis
Eli A. Friedman, Brooklyn
Gerhard Giebisch, New Haven
Carmelo Giordano, Naples
Richard J. Glassock, Los Angeles
Jared J. Grantham, Kansas City
J. P. Grünfeld, Paris
Robert A. Gutman, Durham
Renée Habib, Paris
Jean Hamburger, Paris
John Hayslett, New Haven
Lee W. Henderson, San Diego
Robert H. Heptinstall, Baltimore
Norman K. Hollenberg, Boston
Malcolm A. Holliday, San Francisco
Nishio Honda, Hamamatsu
Rex L. Jamison, Stanford
Colin I. Johnston, Melbourne
Arthur C. Kennedy, Glasgow
D. N. S. Kerr, Newcastle-upon-Tyne
Fredrik Kiil, Oslo
Priscilla Kincaid-Smith, Melbourne
Saulo Klahr, St. Louis
Horst Klinkmann, Rostock
Franklyn G. Knox, Rochester, Minn.
Juha P. Kokko, Dallas
Franciszek Kokot, Katowice
W. Kriz, Heidelberg
Neil A. Kurtzman, Chicago
Paul H. Lambert, Geneva
Jacob Lemann, Jr., Milwaukee
David Z. Levine, Ottawa
Peter J. Little, Riyadh
Guy Lemieux, Montreal
Manuel Martinez-Maldonado, San Juan
Shaul G. Massry, Los Angeles
Joel Menard, Paris
Alfred F. Michael, Minneapolis
Paul Michielsen, Louvain
John F. Moorhead, London
François Morel, Paris
Liliane Morel-Maroger, Paris
L. Gabriel Navar, Birmingham
Alphonse Nizet, Liege
Karl D. Nolph, Columbia
Jack Orloff, Bethesda
Tadeusz Orlowski, Warsaw
D. Keith Peters, London
Georges Peters, Lausanne
R. T. Popovich, Austin
Mordecai M. Popovtzer, Jerusalem
Jaime Borrero Ramirez, Medellin
Gabriel Richet, Paris
George E. Schreiner, Washington, D.C.
Robert W. Schrier, Denver
Donald W. Seldin, Dallas
Fred L. Shapiro, Minneapolis
David P. Simpson, Madison
Jay H. Stein, San Antonio
Wadi N. Suki, Houston
Richard L. Tannen, Ann Arbor
Klaus Thurau, Munich
C. Craig Tisher, Gainesville
Bruno Truniger, Lucerne
Karl J. Ullrich, Frankfurt
Heinz Valtin, Hanover
Pierre Verroust, Paris
Herman Villarreal, Mexico, D.F.
Mackenzie Walser, Baltimore
Clark D. West, Cincinnati
Guillermo Whittembury, Caracas
Curtis B. Wilson, La Jolla
Douglas R. Wilson, Toronto

Manuscript Editor
Brenna Nichols, Nashville

Editorial Assistants
Sharon D. Lee, Durham
Helen B. Carter, Nashville
André Ulmann, Paris

Springer International

The exclusive copyright for all languages and for all countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Printed in the United States of America by The William Byrd Press Inc., Richmond, Virginia

© 1983 by International Society of Nephrology

Author Index For Volume 23

Abbad FCB (abst) 556
Abibol C (abst) 220
Adorno D (abst) 656
Abraham PA (abst) 115
Abrams SML (abst) 563
Abreo K (abst) 141
Abu-Hamden D (abst) 129
Abuelo JG (abst) 122
Ackrill P (abst) 552
Adami S (abst) 563
Adams PL (abst) 149
Adamson J (abst) 213
Adhikari M (abst) ..... 434(2)
Adler AJ (abst) 95, 210, 213
Adler S: *see* Madaio et al 498
Adler S (abst) 120, 182, 228
Adler S, Salant DJ, Dittmer JE, Rennke HG, Madaio MP, Couser WG: Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen 807
Adorati M (abst) 659
Adrogue HJ (abst) 228, 236
Adorno D (abst) 656
Agishi T (abst) 115, 130, 241
Agmon D (abst) 209
Agodoa L (abst) 178
Agrafiotis A: *see* Rottembourg et al 40
Agus Z (abst) 110
Agus ZS (abst) 239
Ahmad R (abst) 564
Ahmad S (abst) 152
Aimé F (abst) 549
Akmal M (abst) 210
Al-Awqati Q (abst) 232, 237, 252
Al-Bander H (abst) 220
Al Dahhan J: *see* Mak et al 410
Al-Kudsi RR (abst) 168
Albert FW (abst) 550
Albertazzi A (abst) 563
Alberti KGMM (abst) 561
Albini B (abst) 178
Albright PW (abst) 252
Albright R (abst) 141
Alcarez C (abst) 287
Alcazar JM (abst) 555, 560
Alexander EA: *see* Bengele et al 684
Alexander EA (abst) 282
Alexandre GPJ (abst) ..... 552(2)
Alexopoulos J (abst) 298
Alfani D: *see* Cortesini et al S14-66
Alford MF: *see* Cheung et al 866
Alfrey AC (abst) 100, 129
Aljama P (abst) 562
Allaluf D (abst) 216
Allegra SR (abst) 122
Allen C (abst) 193
Allison NL (abst) 271
Alpern RJ (abst) 228
Alpert H (abst) ..... 208(2)
Alterman L (abst) 211
Altmeyer P (abst) 152
Altona BJ (abst) 433
Alveranga D (abst) 225
Alvestrand A (abst) 222
Amemiya H (abst) 115
Amend W (abst) 115
Amplatz K (abst) 119
Anderson CF (abst) 121
Anderson GH (abst) 279
Anderson GH Jr (abst) 170
Anderson GW (abst) 432, 435
Anderson JM (abst) 155
Anderson RJ (abst) 146
Anderson S (abst) 166
Anderson SA (abst) 275
Andrassy K (abst) 200, 554, 556
Andreoli TE (abst) 253
Andres GA (abst) 188
Andress D (abst) 94
Andress DL (abst) 111
Andreu L (abst) 555
Andreucci VE (abst) 555, 658
Andrews PM (abst) 200
Ang KK: *see* Vanrenterghem et al S14-69
Antonacci A (abst) 657
Antonovych T (abst) 192, 196
Antonovych TT (abst) 115
Appel GB (abst) 116, 196
Arant BS Jr (abst) 272
Arbeit LA (abst) 272
Arbus GS (abst) 116
Ardaillou R (abst) 178, 284
Arend LJ (abst) 272
Arieff AI (abst) 121, 206
Armbrecht HJ (abst) 94
Arnaout MA (abst) 178
Arnold P (abst) 209
Arnold PE (abst) 104, 201, 427
Aroldi A (abst) 564, 660
Aronson PS (abst) 256, 266
Arora ML (abst) 274
Arruda JAL: *see* Sabatini et al 102
Arruda JAL (abst) 132, 223, 240
Arteaga J (abst) 560
Arthus MF (abst) 222
Asano Y (abst) 138
Ascer K (abst) 228
Ash S (abst) ..... 142(2)
Ash SR (abst) 144, 152
Ashby M (abst) 114, 215
Atkins C (abst) 289, 295
Atkins RC: *see* Thomson et al 9
Atkins RC (abst) 182, 183, 192, 431
Atkinson J (abst) 899, 900
Aubert J (abst) 899
Aucamp L (abst) 434
Ausiello C (abst) 656
Ausiello DA (abst) 221

Austin H (abst) 192, 196
Austin HA III, Goldin H, Gaydos D, Preuss HG: Polyamine metabolism in compensatory renal growth ... 581
Avasthi PS (abst) 116
Avasthi PS, Greene ER, Scholler C, Fowler CR: Noninvasive diagnosis of renal vein thrombosis by ultrasonic echo-Doppler flowmetry 882
Averdunk R: *see* von Baeyer et al 29
Avilés CS (abst) 138
Avison MJ (abst) 207
Aviv A (abst) 171, 177
Avner ED (abst) 179
Avram MM (abst) 99, 142
Aynedjian HS (abst) 211
Ayus JC (abst) 117
Azar S (abst) 219
Azer M (abst) 123, 134, 136, 142
Azogba U (abst) 550
Azzopardi D: *see* Mak et al 410

Baczynski R (abst) 212
Badylak S (abst) 142
Baecke P (abst) 563
Baehler RW (abst) 192
Bagby SP (abst) 166
Bagnasco S (abst) 227
Bailie MD (abst) 166
Baillod RA: *see* Moorhead et al S14-20
Baines AD (abst) 94
Baird B (abst) 122
Baker JD (abst) 200, 205
Baker LRI (abst) 563
Baker R: *see* Steinhausen et al 794
Bakir AA (abst) 117, 125
Balcke P (abst) 563
Baldamus CA (abst) 152
Balfe JW (abst) 116
Ball J (abst) 552
Ballarín JA (abst) 559
Ballermann BJ (abst) 272
Balow J (abst) 192, 196
Bank N (abst) 211, 297
Bankir L (abst) 249
Baran D (abst) 117
Baranowski RL (abst) ..... 209, 248, 273(2)
Barber KG (abst) ..... 158(2)
Barbiano G (abst) 553, 658
Barbiano do Belgiojoso G (abst) 657
Barbour B (abst) 132
Barceló P (abst) 559
Barg AP (abst) 167
Baricos WH: *see* Shah et al 691
Bariety J: *see* Nochy et al 375
Barlassina C: *see* Bianchi et al 870
Barnard W (abst) 165
Barndt R (abst) 97
Barnes AD (abst) 557
Barnes JL (abst) 179
Barnes T: *see* Rubin et al 51
Barnett CA (abst) 273
Barnicle M (abst) 143, 161
Barone P (abst) 281
Barratt TM (abst) 555
Barres D: *see* Nochy et al 375
Barrientos A (abst) 560
Barril G (abst) 548
Barron W (abst) 249
Barry CR (abst) 168
Barry JM: *see* Wickre et al 731
Barry JM (abst) 293, 298
Barsotti G (abst) 561
Bartlett S (abst) 99
Bartolomeo F (abst) 559
Baseman A (abst) 241
Basgen J (abst) 188
Baskin S (abst) 171
Basolo B (abst) 553, 658
Bassett LW (abst) 145
Bassi S (abst) 564
Bastl CP (abst) 133, 272, 284
Batlle D (abst) 229
Batlle DC (abst) 137, 153
Batsford S (abst) 190, 199
Batuman V (abst) 220
Baud L (abst) 178
Bauer H (abst) 557
Bauer JH (abst) 166, 247
Baum M (abst) 143
Baumal R (abst) 116, 191
Bauman JW Jr (abst) 177
Baumann K: *see* Knauf et al 350
Baumgartner D (abst) 900
Baur GM (abst) 166
Bayer RM: *see* Hoy et al 79
Bayer RM (abst) 126
Bazilinski N (abst) 225
Beahm LS (abst) 97
Beale MG, Nash GS, Bertovich MJ, MacDermott RP: Immunoglobulin synthesis by peripheral blood mononuclear cells in minimal change nephrotic syndrome 380
Beallo R (abst) 111
Beam T (abst) 143
Beam TB (abst) 159
Bear R (abst) 172, 193
Beastall G (abst) 560
Becaus I (abst) 559
Beck N (abst) 94
Beck T (abst) 233
Beck TR (abst) 271, 273
Becker G (abst) 552
Becker K (abst) 563
Becker M (abst) 172
Bedrossian J (abst) 550
Bedrossian J: *see* Niaudet et al S14-50
Behbehani AM (abst) 181
Beierwaltes WH (abst) 274
Beiles B (abst) 429
Beischel L: *see* Marder et al 749
Belfield DC (abst) 430
Beliveau R (abst) 95, 96
Bell A (abst) 246
Bell JD (abst) 287, 293
Bell P (abst) 430
Bell PD (abst) 241
Belledonne M (abst) 118
Bellomo R (abst) 183
Bellorin-Font E (abst) 285
Bellucci A (abst) 274
Benabe JE (abst) 274, 276
Bender WL (abst) 198
Bengele HH (abst) 282

Bengele HH, Mathias R, Perkins JH, McNamara ER, Alexander EA: Impaired renal and extrarenal potassium adaptation in old rats 684
Benjamin M (abst) 229
Bennett CM (abst) 145
Bennett M (abst) 136
Bennett S: *see* Weinman et al 832
Bennett SC (abst) 269
Bennett WM, Kincaid-Smith P: Macroscopic hematuria in mesangial I_gA nephropathy: Correlation with glomerular crescents and renal dysfunction 393
Bennett W (abst) 136
Bennett WM: *see* Wickre et al 514
Bennett WM: *see* also Wickre et al 731
Bennett WM (abst) 200, 203, 207, 293, 298
Bennison A: *see* Wickre et al 731
Bentzel CJ (abst) 159, 264
Berardinelli L (abst) 557
Berardinelli L: *see* Ponticelli et al S14-85
Beretta C (abst) 557
Beretta-Piccoli C: *see* Weidmann et al 320
Berg KJ: *see* Wideroe et al 22
Bergadá E (abst) 562
Bergeron M, Hoang T: Adenosine and compensatory renal growth 588
Bergeron M (abst) 220, 222
Bergman D (abst) 190
Bergrem H (abst) 551
Bergrem H: Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis 876
Berkey CS: *see* Laird et al S13-101
Berl T: *see* Levi et al 489
Berl T (abst) 104, 201
Berloco P: *see* Cortesini et al S14-66
Berlyne GM (abst) 93, 210, 213
Bermudez F (abst) 115
Berndt TJ (abst) 95
Bernstein KN (abst) 167
Berry CA (abst) 238
Berry RE (abst) 122
Bertani T (abst) 192, 211
Berthoux FC (abst) 553
Bertolatus JA (abst) 179, 183
Bertoli S (abst) 558, 657
Bertovitch MJ: *see* Beale et al 380
Besarab A (abst) 241, 291
Beschorner WE (abst) 198
Best CF: *see* Harris et al 616
Better OS, Schrier RW: Disturbed volume homeostasis in patients with cirrhosis of the liver 303
Better OS (abst) 209, 242
Bevan M (abst) 249
Beyenbach KW (abst) 250, 255
Beyer MM (abst) 289
Bhan AK (abst) 179
Bhathena DB (abst) 192
Bia M (abst) 211, 286
Bianchi G, Cusi D, Barlassina C, Lupi GP, Ferrari P, Picotti GB, Gatti M, Polli E: Renal dysfunction as a cause of essential hypertension in predisposed subjects 10
Bichara M (abst) 237
Biasioli S (abst) 660
Bichet BD (abst) 427, 428
Bichsel G (abst) 899
Bidani A (abst) 229
Biemesderfer D: *see* Sterzel et al 480
Bierman M (abst) 143, 161
Bigi G (abst) 564
Bigi L (abst) 564
Biglieri E (abst) 131
Bigos M (abst) 289
Binswanger U (abst) 899, 900, 902, 903
Biollaz J (abst) 900
Birch DF (abst) 122
Birch DF: *see* Fairley et al 862
Birge SJ: *see* Harter et al 465
Birkenhäger WH (abst) 780
Birmingham DJ (abst) 183
Birnbaum J (abst) 115
Biscardi A (abst) 138
Bitter-Suermann D (abst) 199
Bivens CH (abst) 122
Black FO (abst) 135
Blair ML (abst) 274
Blake DE (abst) 144
Blantz RC (abst) 247
Blasco R (abst) 553
Blasucci DJ (abst) 173
Blaufox D (abst) 171
Blecher SR (abst) 180
Bledsoe T: *see* Cooke et al 71
Bliss G (abst) 270
Block FJ (abst) 141
Blohmé I (abst) 550
Bluementhal SS (abst) 177
Blum C (abst) 116
Blumenstein M: *see* Gurland et al S14-82
Blumenthal S (abst) 229
Boatman J (abst) 200, 205
Bockhorn H (abst) 550
Bogden JD (abst) 177
Boen FST: *see* Gahl et al 2
see also Nolph et al 3
Boer P (abst) 123, 216, 780
Bohan L (abst) 196
Boillat N (abst) 899
Boineau F (abst) 275
Boletis J (abst) 298
Bolton WK (abst) 180, 292
Bommer J (abst) 143
Bomsztyk K (abst) 95
Bonduris DN (abst) 232
Bone JM (abst) 554
Bonjour JP (abst) 101, 900, 902
Bonoldi G (abst) 565
Bonomini V (abst) 656
Bonomini V: Introductory remarks S14-1
Bonomini V: *see* Vangelista et al S14-41
Booker BB (abst) 262
Booth BE (abst) 108
Border W (abst) 195
Border WA (abst) 119, 190, 191
Borgonjon DJ: *see* De Backer et al 738
Borhani N (abst) 171
Boron WF (abst) 230
Borowzak R: *see* von Baeyer et al 29
Borra S (abst) 144
Bortz D (abst) 432
Bosch JP (abst) 118
Bosque M: *see* Mak et al 410

Botey A (abst) 562
Botha JR (abst) ..... 429, 430(2), 433, 434
Bouby N (abst) 249
Boue A: *see* Niaudet et al S14-50
Bouillon R: *see* Vanrenterghem et al S14-69
Boulpaep EL (abst) 266
Bourgoignie G (abst) 215
Bourgoignie JJ (abst) 100, 114, 211, 215
Bourke E (abst) 140
Bourla S (abst) 176
Bourne JR: *see* Teschan et al S13-58
Bovio I (abst) 564
Bowen PA (abst) 288
Bower J: *see* Rubin et al 51
Bower J (abst) 159
Bowman RH (abst) 110
Boylan JW (abst) 167, 169
Braden GL (abst) 148
Bradley T (abst) 213
Brancaccio D (abst) 564, 656
Brandi F (abst) 564
Brandis M (abst) 555
Brando B (abst) 558, 656, 657
Brater DC (abst) 275
Braun W (abst) 296
Braun WE (abst) 290
Braun-Werness JL (abst) 222, 250, 261
Braunwald E (abst) 245
Brautbar N (abst) 97, 105, 212
Bravo EL (abst) 138
Brazy PC (abst) 96, 223
Bregman H (abst) 148
Brem AS (abst) 295
Bremer HJ (abst) 555
Brenchley P (abst) 198
Brenner BM: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease .. 647
Brenner BM (abst) 124, 201, 214, 215, 218, 245, 272
Brentjens JB (abst) 188
Bretschneider A (abst) 194
Brewer ED (abst) 190
Breyer D (abst) 561
Brezis M (abst) 221
Bricker NS (abst) 250
Bricker S (abst) 219
Bridges CR (abst) 201, 214
Briefel G (abst) 216
Briganti M (abst) 659
Brigati C (abst) 558
Briggs JD (abst) 560
Briggs JP (abst) 285
Briggs W (abst) 129, 135
Brinck-Johnsen T (abst) 242
Briot M: *see* Gallice et al 764
Brisson E (abst) 550
Britten D (abst) 428
Broccoli AV (abst) 242
Brochier J (abst) 557
Brod-Miller C (abst) 234
Brodde O-E (abst) 562
Brodehl J (abst) 555
Brodsky WA (abst) 240
Broggi M (abst) 656
Brokl DH (abst) 253
Broyer M: *see* Niaudet et al S14-50
Brown DM (abst) 181
Brown G (abst) 275, 277
Brown RS (abst) 295
Brown WS (abst) 156
Browning PJ (abst) 121
Broyer M: *see* Mongeau et al 530
Broyer M (abst) 555
Brunette MG (abst) 95, 96
Brunner FP (abst) 201, 271, 902
Brunner HR (abst) 549, 900, 904
Brunner J-P (abst) 901
Bruns F (abst) 120
Brunswick J (abst) 175
Bryce GF (abst) 145
Brygner H (abst) 550
Buchanan M (abst) 552
Buckalew VM Jr (abst) 118, 170
Buckels JAC (abst) 557
Buerkert J (abst) 230, 239
Bulger RE (abst) 201, 202
Bulla M (abst) 556
Bulova S (abst) 295
Bulzomi MR (abst) 658
Burakoff SJ (abst) 291
Burckhardt P (abst) 901
Burdiel LG (abst) 562
Burg MB (abst) 232
Bürgin D (abst) 900, 904
Burger HR (abst) 900, 902
Burke EJ (abst) 148
Burke J (abst) 291
Burke T (abst) 209
Burke TJ (abst) 104, 201, 427
Burnatowska-Hledin M (abst) 250
Burnatowska-Hledin MA (abst) 105, 152, 215
Burnier M (abst) 900
Burns G (abst) 218
Burns P: *see* Rubin et al 51
Burns WA (abst) 194
Buscaroli A (abst) 656
Bush A: *see* Wickre et al 731
Bushinsky DA (abst) 96, 109
Busnach G (abst) 558, 656, 657
Busson M: *see* Niaudet et al S14-50
Buszta C (abst) 296
Butkowski R (abst) 193
Butt KMH (abst) ..... 289, 293(2)
Bygren P, Wieslander J, Heinegård D: Antiglomerular basement membrane antibody: Antibody specificity in different forms of glomerulonephritis 855
Cabau N: *see* Niaudet et al S14-50
Cable H (abst) 134
Caccamo A (abst) 559
Cadnapaphornchai P (abst) 276
Cagnoli L (abst) 559
Calcagno PL (abst) 243, 280
Calderone P (abst) 137
Caldwell R (abst) 245
Calhoun KA (abst) 96
Callis L (abst) 556
Camargo MJF (abst) 224, 251
Cambi V (abst) 549, 560
Cameron JS: *see* Frampton et al 506
Cameron JS: Effect of the recipient's disease on the results of transplantation (other than diabetes mellitus) S14-24
Camilleri J-P: *see* Nochy et al 375

Campese VM (abst) 97, 176
Camussi G (abst) 658
Canepa A (abst) 660
Cannata JB (abst) 560
Cantaluppi A (abst) 564
Canterburry JM (abst) 100
Cantù P (abst) 549
Capasso G (abst) 251
Cappelli P (abst) 563
Cardella C (abst) 193
Cardella CJ (abst) 292
Cardinal J (abst) 251, 261
Caron CR (abst) 118
Carone F (abst) 193
Carone FA (abst) 184
Carr D (abst) 142
Carr DJ (abst) 144
Carrea A (abst) 659
Carretero OA (abst) 274
Carroll HJ (abst) 225
Carter NW (abst) 233
Caruana RJ (abst) 118
Caruso C (abst) 95
Carvalho JS (abst) 122
Catto GRD (abst) 551
Caversazio J (abst) 101, 900, 902
Carvounis CP (abst) 264
Carvounis G (abst) 264
Casanova C (abst) 554
Casanova S (abst) 657,658
Casati S (abst) 564
Casciani CU (abst) 656
Case DB (abst) 109
Caspersen AH (abst) 565
Cassidy MJD (abst) 431
Castaneda-Zuniga W (abst) 119
Castellani A (abst) 564
Castello R (abst) 658
Castro LA (abst) 558
Catherwood BD (abst) 111
Cattell WR (abst) 563
Cattran D (abst) 147, 193
Caverzasio J (abst) 101
Cécile JP (abst) 555
Cento G (abst) 559
Cervenka J (abst) 167
Chabrades D (abst) 251
Chaimovitz C (abst) 214
Chakrin A (abst) 171
Chamberlin ME (abst) 221
Chami J (abst) 144
Champion J (abst) 283
Chan JCM (abst) 118
Chan L (abst) 202
Chan MK: *see* Moorhead et al S14-20
Chan YL (abst) 230
Chander PN (abst) 180
Chang B (abst) 124
Chang BS: *see* Clark et al 336
Chang E (abst) 127
Chang PC (abst) 145
Chantler C: *see* Mak et al 410
Chantler C (abst) 556
Chappell T (abst) 150
Chaput de Saintonge DM (abst) 563
Charney AN (abst) 230
Charron R (abst) 193
Charytan C (abst) ..... 162(2)
Chase H (abst) 252
Chatelanat F (abst) 899, 902
Chatzilias A (abst) 172
Chaudhari A (abst) 276
Check IJ (abst) 199
Cheigh J (abst) 296
Cheigh JS (abst) 144, 295
Chen DS (abst) 901
Chen S (abst) 167
Chen SM (abst) ..... 158(2)
Chen TC (abst) 97
Chen YH (abst) 274
Cheng JT (abst) 215
Cheng L (abst) ..... 216(2)
Chennavasin P (abst) 275
Chenoweth D (abst) 144
Chesney RW (abst) 252
Cheung A (abst) 144
Cheung AK, Alford MF, Wilson MM, Leypoldt JK, Henderson LW: Urea movement across erythrocyte membrane during artificial kidney treatment 866
Chevalier RL (abst) 242
Chiang R (abst) 170
Chiaramonte S (abst) 660
Chiarini C: *see* Zucchelli et al 46
Chiarini C (abst) 559
Chizzolini C (abst) 558
Chong G (abst) 551
Chopra S (abst) ..... 145(3), 208
Chou SY (abst) 243
Chou Y-N (abst) 262
Chrystal V (abst) 434
Chug D (abst) 197
Chung T (abst) ..... 145(2)
Chung TJ (abst) 145
Churchill BM (abst) 116
Churchill DN (abst) 119
Chvala R (abst) 295
Ciabattoni G (abst) 282
Cianciaruso B (abst) 555
Ciardella F (abst) 561
Ciccone CD (abst) 167
Cilliers GD (abst) 433
Citterro A (abst) 564
Civati G (abst) 656
Clark AS (abst) 202
Clark DD, Chang BS, Garella SG, Cohen JJ, Madias NE: Secondary hypocapnia fails to protect "whole body" intracellular pH during chronic HCl-acidosis in the dog 336
Clark M (abst) 202
Clark WF (abst) 180
Clarke C: *see* Robertson et al 327
Clarke HS Jr (abst) 173
Clarke WTW (abst) 147
Clausen C (abst) 231
Clayman M (abst) 161, 187
Clayman RV (abst) 19
Clayton S (abst) 146
Clive DM (abst) 276
Coburn JW: *see* Kraut et al 725
Coburn JW (abst) ..... 100, 103(2), 104(2), 107, 129, 145
Cochrane CG (abst) 191
Cody RJ (abst) 243

Coe FL (abst) ..... 96(2), 102, 109
Coffey AK (abst) 200
Cogan MG (abst) 231, 235
Cohen AH (abst) 119
Cohen AJ: *see* Madaio et al 498
Cohen AJ (abst) 276
Cohen D (abst) 116
Cohen JJ: *see* Clark et al 336
Cohn DE (abst) 100, 212
Colasanti G (abst) 553, 658
Cole CH (abst) 151
Cole E (abst) 193
Coleman TH: *see* Marder et al 749
Coli L (abst) 656
Colina F (abst) 560
Colindres RE (abst) 130
Collart F (abst) 147, 163
Collins AB (abst) 179
Colombe BW (abst) 289
Colussi G (abst) 657,660
Como G (abst) 656
Conger JD (abst) 207, 252
Conrad KP (abst) 242
Conrad MP (abst) 97
Conte G (abst) 555, 658
Cook DB (abst) 552
Cooke CR, Gann DS, Whelton PK, Hsu TH, Bledsoe T, Moore MA, Walker WG: Hormonal responses to acute volume changes in anephric subjects 71
Cooper JH: *see* Skutches et al 57
Coovadia HM (abst) ..... 431, 434(3)
Coppo R (abst) 553, 658
Cordier G (abst) 557
Cordy PE (abst) 150
Corman B (abst) 237, 252
Cornacoff JB (abst) 183
Cornelio F (abst) 656
Corona S (abst) 226
Corry RJ (abst) 288
Corsones J (abst) 113
Cortes P (abst) 121, 221
Cortesini R, Famulari A, Pasquali B, Alfani D: Potential for international cooperative programs in renal transplantation S14-66
Corvol P: *see* Nochy et al 375
Corwin RL (abst) 221
Cosci P (abst) 660
Cosio FG (abst) 181
Costanzo LS (abst) 97
Costilde P (abst) 217
Cosyns JP (abst) 552
Coulson R (abst) 110, 242, 269
Coulthard MG, Ruddock V: Validation of inulin as a marker for glomerular filtration in preterm babies .. 407
Coupes B (abst) 198
Couser WG: *see* Madaio et al 498
Couser WG (abst) 182
Couser WG: *see* Adler et al 807
Covarsi A (abst) 559
Covit AB (abst) 243
Cowan R (abst) 177
Cowley AW Jr (abst) 283
Crandall E (abst) 229
Crater C (abst) 149
Crawford C (abst) 132
Crevat A: *see* Gallice et al 764
Crissman JD (abst) 199
Crocker C (abst) 165
Crocker JFS (abst) 180
Croker BP (abst) 193
Cruz C (abst) 98, 156
Cruz FC: *see* Shah et al 691
Cruz-Soto M (abst) 274, 276
Cucinotta J (abst) 170
Culpepper RM (abst) 253
Cunningham E (abst) 281
Cunningham EE (abst) 119
Cunningham R (abst) 296
Cunningham RJ (abst) 217
Cuppage FE (abst) 181
Curb D (abst) 171
Currie BL (abst) 273
Curthoys NP (abst) 102
Curtis J (abst) 168
Curtis JR (abst) 548
Curtis RN (abst) 116
Cusi D: *see* Bianchi et al 870
Cuvelier J (abst) 559
Czaczkes W (abst) 111
Czekalski S (abst) 562

D'Amico G (abst) 553, 658
D'Andrea G (abst) 660
D'Occhio MA (abst) 167
Da Rocha JRC (abst) 133
Daikos G (abst) 298
Dalbow M (abst) 140
Dal Canton A (abst) 555, 658
Dall'Aglio P (abst) 558
Dalmasso A (abst) 194
Dana N (abst) 178
Danielson BG (abst) 146
Danovitch G (abst) 120, 128
Dantzler WH (abst) 253, 263
Darnell A (abst) 562
Darrow M (abst) 264
Darwish MO (abst) 176
Dathe G (abst) 289
Daudon M, Protat MF, Reveillaud RJ, Jaeschki-Boyer H: Infrared spectometry and Raman microprobe in the analysis of urinary calculi 842
Daugirdas JT (abst) ..... 151(2), 154, 157, 168
Daul A (abst) 562
Davidman M (abst) 246
Davidson E (abst) 291
Davidson K (abst) 202
Davin JC (abst) 556
Davis BB, Thomasson D, Zenser TV: Renal disease profoundly alters cortical interstitial cell function 458
Davis BB: *see* Zelman et al 594
Davis BB (abst) 94, 287
Davis T (abst) 212
Davis JM (abst) 244
Dawids SG (abst) 565
Dawidson I (abst) 291
Dawson DV (abst) 193
Day JP (abst) 552
Daye M (abst) 210
De Backer WA, Verpooten GA, Borgonjon DJ, Vermeire PA, Lins RR, De Broe ME: Hypoxemia during hemodialysis: Effects of different membranes and dialysate compositions 738

de Bermudez L (abst) 117
De Broe ME: *see* De Backer et al 738
de Francesco D (abst) 549
de Graeff J (abst) 550
de Groc F: *see* Rottembourg et al 40
de Groc F (abst) 553
De Jong PE (abst) 277, 779, 780
De Leeuw PW (abst) 780
de Mendonca M: *see* Mongeau et al 530
De Paepe MBJ (abst) 779
De Paepe MBJ, Schelstraete KHG, Ringoir SMG, Lameire NH: Influence of CAPD on the anemia of end-stage renal disease 744
De Rosos OL (abst) 146, 165
De Rouffignac C (abst) 237, 253
De Santo NG (abst) 251
de Torrenté A (abst) 899
de Vinuesa SG (abst) 548
De Wolf JTM (abst) 120, 124
De Zeeuw D (abst) 277, 780
Deen WM (abst) 201, 214
Deferrari G (abst) 660
DeFronzo R (abst) 211, 222, 258, 262, 286
Deftos L (abst) 111
Degli Esposito E (abst) 559
Degoulet P (abst) 549
Degugman A (abst) 241
Dehnel PJ (abst) 181
Del Greco F (abst) 126, 283
del Rio G (abst) 559
Delahaye BE (abst) 222
Delambre D (abst) 555
Delaney V (abst) 120
Delano BG (abst) 168
Delargy H (abst) 551
Denis G (abst) 222
Dennis VW (abst) 223
Denton J (abst) 552
Depace NL (abst) 120
DePasquale EE (abst) 287
Depner TA (abst) 212
Derauf B (abst) 153
des Combres BJ (abst) 901
De Vecchi AF: *see* Ponticelli et al S14-85
Devia CJ (abst) 153
Devine JP (abst) 181
Dewar J: *see* Gokal et al 15
Dewar J (abst) 137
Di Paolo B (abst) 563
Di Stéphano A (abst) 252
Dibone DR (abst) 259
DiBone GF (abst) 244, 253, 260
DiCianni N (abst) 216
Dickinson C (abst) 163
Dickinson CA: *see* Maher et al S13-50
Didlake R (abst) 288
Didomenico NC (abst) 145
Diederich D (abst) 147
Diekmann L (abst) 556
Diethelm A (abst) 168
Digenis GE (abst) 146, 164
Dillingham G (abst) 149
Dillingham MA (abst) 146
Dillon J (abst) 556
Dipette D (abst) 213
Dirks JH: The kidney and magnesium regulation 771
Dirks JH (abst) 113
Disher B (abst) 149
Disney TA (abst) 251
Dittmer JE: *see* Adler et al 807
Dixon TE (abst) 239
Dobyan DC (abst) 201, 203
Dodd NJ (abst) 564
Doherty CC (abst) 105, 555
Dombrouski J (abst) 163
Dominguez J (abst) 108
Dominguez JH (abst) 97
Donadio JV Jr (abst) 121
Donini U (abst) 554, 559, 657, 658
Donker AB (abst) 281
Donker AJM (abst) 277, 779, 780
Donoso V (abst) 166
Doorenbos H (abst) 845
Dosa S (abst) 197
Dosekun AK (abst) 193, 196
Dossetor JB (abst) 291, 550
Douglas F (abst) 551
Douglas J (abst) 275, 277
Douglas JF (abst) 429, 433
Dousa TP (abst) 114, 222, 250, 261
Douté M (abst) 249
Downer M (abst) 229
Doyle T (abst) 250
Drance SM (abst) 137
Drangova R (abst) 95
Dratwa M (abst) 147, 163
Dreikorn K (abst) 550
Dreslinski GR (abst) 175
Drevyanko T (abst) 288
Drueck C (abst) 129
Drüeke T (abst) 98, 102, 158
Du XH (abst) 181
Du P Heyns A (abst) 432
Duane D (abst) 179
Duback UC (abst) 903
Dubinsky WP (abst) 264
Dubois E (abst) 132
Dubois GD (abst) 121
DuBose T Jr (abst) 236
DuBose TD Jr (abst) 231
Dubost C (abst) 98
Dudek MA (abst) 231
Duffus P: *see* Frampton et al 506
Duffy WB (abst) 98, 261
Dumbauld SL (abst) 254
Dumler F (abst) 121, 128, 221
Duncan K (abst) 147
Dunckel P (abst) 286
Dunea G (abst) 117, 125
Dunn FG (abst) 169, 175
Dunn I (abst) 137
Dunn MJ (abst) ..... 185(2), 283, 284
Dunn SR (abst) 216
Dupont E (abst) 163
Düsing R (abst) 277
Dustan H (abst) 168
Dutta S (abst) 218
Dutto A (abst) 559
Dworzak F (abst) 656
Dyer P (abst) 198
Dytko G (abst) 223, 240

Dzau VJ (abst) 272, 286
Dzua VJ (abst) 121

Eagleton L (abst) 130
Earle D (abst) 132
Eby B (abst) 103, 112, 167, 254, 255
Eddy A (abst) 122
Edelstein S (abst) 100
Edward N (abst) 551
Edwards B: *see* Yanagawa et al 674
Edwards BR (abst) 254
Edwards LC, Helderman JH, Hamm LL, Ludwin D, Gailiunas P Jr, Hull AR: Noninvasive monitoring of renal transplant function by analysis of beta-$_2$-microglobulin 767
Edwards LC (abst) 228
Edwards RM (abst) 243
Egidi FM: *see* Ponticelli et al S14-85
Egido J (abst) 553
Egli F (abst) 556
Ehrich JHH (abst) 556
Eich E (abst) 224
Eisenhauer T (abst) 160, 164, 563
Eisinger RP (abst) 160, 164
Eisner GM (abst) 243
Eknoyan G (abst) 139, 201, 203
El-Belbessi S (abst) 212
El-Malik F: *see* Moorhead et al S14-20
El Shahat Y: *see* Rottembourg et al 40
Elalouf JM (abst) 253
Elema JD (abst) 778
Elfenbein IB (abst) 133
Eliahou HE (abst) 203, 204
Elijovich F (abst) 168
Elliott W (abst) 557
Elliott WC (abst) 200, 203
Ellis D (abst) 179
Ellis HA: *see* Gokal et al 15
Ellis HA (abst) 552
Ellison D (abst) 166
Ellison DH (abst) 169
Elson B (abst) 129
Elstein D (abst) 111
Emiliani G (abst) 659
Endreny RG (abst) 122
Endres W (abst) 556
Engel RH: *see* Frankel R et al S13-31
Epstein EM (abst) 243
Epstein FH (abst) 221
Epstein M (abst) 246, 277
Eraklis AJ (abst) 290
Ercolani L (abst) ..... 288(2)
Ernst W (abst) 551
Esbrit P (abst) 98
Eschbach J (abst) 213
Eslami H (abst) 287
Esparza AR (abst) 122
Esposti ED: *see* Zucchelli et al 46
Essadki A (abst) 900
Estes D (abst) 116
Estes R (abst) 98
Ettenger R (abst) 195
Evan AP: *see* Welling et al 358
Evan AP (abst) 244
Evangelista B (abst) 656
Ewald RW (abst) 550

Exaire E (abst) 139
Ezzibdeh MY (abst) 557

Fabbri A (abst) 659
Fabbri L: *see* Zucchelli et al 46
Fabris A (abst) 660
Faenza A, Spolaore R, Poggioli G, Selleri S, Roversi R, Gozzetti G: Renal artery stenosis after renal transplantation S14-54
Fairley KF (abst) 122
Fairley KF, Birch DF: Unconcentional bacteria in urinary tract disease: *Gardnerella vaginalis* 862
Falardeau P (abst) 276
Falk RJ (abst) 194
Falk SA (abst) 252
Falkinburg N (abst) 122
Famulari A: *see* Cortesini et al S14-66
Fanconi A (abst) 556
Fanti P (abst) 105
Farkas S (abst) 191
Farquhar MG (abst) 185
Farrell PC: *see* Nolph et al 3
Farruggella T (abst) 205
Fassbinder W (abst) 289, 550, 551
Fasth AL (abst) 182
Faubert PF (abst) 243
Faugere MC (abst) 99, 105, 141
Favus MJ (abst) ..... 96(2), 102, 109
Feddergreen W (abst) 189
Feehally J (abst) 194, 198
Feest TG (abst) ..... 560(2)
Feig PU (abst) 167, 169
Fein PA (abst) 99, 142
Feingold KR (abst) 223
Feinstein EI (abst) 123, 127, 132
Fejes-Toth G (abst) 278, 282
Feld L (abst) 297
Feld LG (abst) 147
Felder RA (abst) 280
Feldhoff C (abst) 556
Feldman TE (abst) 128
Feliciangeli G (abst) 656
Fell GS (abst) 560
Felsenfeld A (abst) 94, 113, 157, 219
Felsenfeld AJ: *see* Robertson et al 327
Fenton S (abst) 147
Ferguson CW (abst) 140
Ferguson R (abst) 198
Ferguson RM: *see* Najarian et al S14-10
Ferguson RK (abst) 169
Feriani M (abst) 660
Fernandez-Repollet E (abst) 203
Fernando ON: *see* Moorhead et al S14-20
Ferrari E (abst) 217
Ferrari P: *see* Bianchi et al 870
Ferrario F (abst) 658
Ferris T (abst) 279
Fetta RF (abst) 550
Fidelman ML (abst) 278
Field MJ (abst) 254
Fievet R (abst) 552
Fildes RD (abst) 243, 286
Filippone EF (abst) 213
Fine LG: *see* Yanagawa et al 674
Fine LG (abst) 103, 213, 226, 264
Fine RN (abst) 104, 159, 195

Finkelstein A (abst) 262
Finn WF (abst) 203
Fiorini G (abst) 553, 657
Fischman R (abst) 123
Fisher JW (abst) 217
Fitzgibbons JP (abst) 148
Flamenbaum W (abst) ..... 145(2)
Flanagan P (abst) 172
Flanigan W (abst) 132
Flax S (abst) 147
Fleig G (abst) 155
Flombaum CD (abst) 160
Florman R (abst) 214
Flugel-Link R (abst) 165
Foegh ML: *see* Winchester et al S14-34
Fogazzi T (abst) 661
Foidart JB (abst) 556
Foley R (abst) 229
Foley RJ (abst) 165
Folkert VW (abst) 278
Fong JSC (abst) 427
Fong P (abst) 230
Forbes C (abst) 186
Forbes RDC (abst) 294
Foreman JW (abst) 223
Fornasieri A (abst) 553, 657, 658
Forrest JN (abst) 261
Forrest JN Jr (abst) 255
Forristal J: *see* Marder et al 749
Fortier B: *see* Niaudet et al S14-50
Fouad FM (abst) 138
Foucault C (abst) 550
Foulks CJ (abst) 99
Fournier A (abst) 555, 561
Fournier N: *see* Gallice et al 764
Fowler CR: *see* Avasthi et al 882
Fox L (abst) 165
Fox S (abst) 165
Fragola J (abst) 140
Fragola JA (abst) 148
Fraley DS (abst) 120
Frampton G, Parbtani A, Marchesi D, Duffus P, Livio M, Remuzzi G, Cameron JS: In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients 506
Francis J (abst) 135
Francis RB: *see* Ozanne et al 519
Frankel R, Engel RH, Olivier DC, Halpern EP: Laboratory quality control in the National Cooperative Dialysis Study S13-31
Franki N (abst) 268
Franz HE (abst) 557
Franz KA, Reubi FC: Rate of functional deterioration in polycystic kidney disease 526
Fraser D (abst) 271
Frasca GM: *see* Vangelista et al S14-41
Frayssinet R: *see* Gallice et al 764
Freeland P (abst) 429
Freeman DS (abst) 99
Freeman R (abst) 147
Freeman RB (abst) 126, 157, 553
Frei D (abst) 901
Frei U (abst) 289, 551
Freidler RM (abst) 141
Friedman EA: Clinical imperatives in diabetic nephropathy S14-16
Friedman EA: Ethical aspects in renal transplantation S14-90
Freimer EH (abst) 148
Freundlich M (abst) 100
Frey B (abst) 903
Fried T (abst) 203
Friedland J (abst) 175
Friedman AL (abst) 182, 252
Friedman D (abst) 257
Friedman E (abst) 131
Friedman EA (abst) 168, 427
Friedman JJ (abst) 248
Friedman S (abst) 214
Fries D: *see* Niaudet el al S14-50
Frigon R (abst) 174
Frohlich ED (abst) 169, 175
Frölich JC (abst) 278, 282
From G (abst) 164
Frommer JP (abst) 231
Frömter E (abst) 561
Frösnier G (abst) 558
Fuchinoue S (abst) 130
Fuiano G (abst) 555, 658
Furlanetto RW (abst) 217
Furman KI (abst) ..... 428(2), 429
Fusaroli M (abst) 659
Fuster V (abst) 121

Gafter U (abst) 100, 216
Gahl GM, Boen EST, Nolph KD: Introduction 2
Gahl GM: *see* von Baeyer et al 29
Gailiunas P (abst) 288, 289, 290, 295
Gailiunas P Jr: *see* Edwards et al 767
Galla JH (abst) 232, 254, 262
Gallagher N (abst) 152
Galler M (abst) 162
Galli F (abst) 564
Gallice P, Fournier N, Crevat A, Briot M, Frayssinet R, Murisasco A: Separation of one uremic middle molecules fraction by high performance liquid chromatography 764
Galmozzi C (abst) 656
Gambertoglio J (abst) 115
Gamble CN (abst) 123
Gammaro L (abst) 660
Gan A (abst) 142
Gandhi VC (abst) ..... 151(2), 154, 157
Ganel JA (abst) 123
Ganguli M (abst) 187
Gann DS: *see* Cooke et al 71
Garay R: *see* Mongeau et al 530
Garcia J (abst) 213
Garcia R (abst) 190
Garcia Robles R (abst) 555
Gardenswartz MH (abst) 287
Garella S (abst) 124
Garella SG: *see* Clark et al 336
Garg LC (abst) 255
Garibotto G (abst) 660
Garini G (abst) 549
Garovoy MR (abst) 289
Garrick R (abst) 239
Garstang FM (abst) 552
Gary NE (abst) 194
Gaston T (abst) 188
Gattereau A (abst) 140

Gatti M: *see* Bianchi et al 870
Gattone VH III: *see* Welling et al 358
Gattone VH II (abst) 244
Gauthier VJ (abst) 178
Gavellas G (abst) 144, 211
Gavendo S (abst) 204
Gaydos D: *see* Austin et al 581
Gaydos D (abst) 227
Geerlings W (abst) 778, 779
Geers AB (abst) 123, 216, 780
Geis WP (abst) 154
Geisert J (abst) 556
Gekle D (abst) 556
Gelfand MC (abst) 290
Gelfand MC: *see* Winchester et al S14-34
Gellai M (abst) 242
Gelpi C (abst) 559
Gelzayd B (abst) 255
Gemsa D (abst) 143
Genin C (abst) 553
Gennari FJ (abst) 236
Gephardt G (abst) 131
Gerber A (abst) 901
Gerlag PGG (abst) 562
Germain MJ (abst) 148
Germuth FG (abst) 190
Geschöll-Bauer B (abst) 556
Geus JW (abst) 124
Geus WP (abst) 120, 124
Gewurz H (abst) 194
Ghezzi PM (abst) 559
Giacchino JL (abst) 154
Giangrande A (abst) 549, 563
Giannoni A (abst) 561
Gibelli A (abst) 553
Gibson S (abst) 151
Gibson TP: *see* Hoy et al 79
Gibson TP (abst) 126, 175
Giebisch G (abst) ..... 230, 256(2), 260, 262
Giebisch GH (abst) 254
Gifford RW Jr (abst) 204
Gilbert DN (abst) 200, 203, 207
Gilchrist EP (abst) 179
Gill JR Jr (abst) 170
Gillardin JP (abst) 559
Gillet A (abst) 564
Ginevri F (abst) 659
Ginsberg J (abst) 124
Giordano C (abst) 251
Giovannetti S (abst) 561
Gioventù M (abst) 656
Glabman S (abst) 118
Glänzer K (abst) 277
Glas-Greenwalt P (abst) 193, 196
Glasgow EF (abst) 182, 431
Glassock RJ (abst) 119, 125
Gleim GW (abst) 244, 287
Glick J (abst) 110
Glöckner WM (abst) 548
Gloor F (abst) 900
Gloor HJ: *see* Miller et al 35
Glover D (abst) 110
Gluck S (abst) 232, 237
Glück Z: *see* Weidmann et al 320
Gluckman JC (abst) 550
Gmähle E (abst) 557
Goetz A (abst) 149
Gokal JM (abst) 558
Gokal R, Ramos JM, Ellis HA, Parkinson I, Sweetman V, Dewar J, Ward MK, Kerr DNS: Histological renal osteodystrophy, and 25 hydroxycholecalciferol and aluminum levels in patients on continuous ambulatory dialysis 15
Gokal R (abst) 194
Gokel J (abst) 558
Gold RH (abst) 145
Goldaniga D (abst) 553
Goldberg A (abst) 212
Goldberg AP (abst) 214
Goldberg M (abst) 124
Goldblat MG (abst) 287
Golden RA (abst) 162
Goldfarb D (abst) 203
Goldfarb S (abst) 110
Goldin H: *see* Austin et al 581
see also Preuss et al 635
Goldman M (abst) 298
Goldmann SF (abst) 550
Goldsmith HJ (abst) 564
Goldstein DA (abst) 210
Goldstein DS (abst) 173
Goldszer RC (abst) 124
Goligorsky M (abst) 214
Golper TA (abst) 223
Gomez J (abst) 562
González FM (abst) 153
González N (abst) 166
Gonzáloz C (abst) 548
Good DW (abst) 232
Goodman WG (abst) 100
Goodwin FJ (abst) 563
Goorno WE (abst) 121
Gordon E (abst) 103
Gordon JA (abst) 135, 427
Gorfien P (abst) 154, 214
Gorman H (abst) 100
Gornick CC (abst) 148
Gougoux A (abst) 140
Gould DA (abst) 564
Gower PE (abst) 548
Gozzetti G: *see* Faenaza et al S14-54
Graben N (abst) 562
Gradus D (abst) 125
Grady J (abst) 166
Graff LG (abst) 133
Granger JP (abst) 170, 279
Grantham J (abst) 193, 255
Grassi C (abst) 554
Grasso MA (abst) 287
Graves JW (abst) 290
Gray RW (abst) 102, 105
Graziani G (abst) 564, 660
Green R (abst) 256
Green S (abst) 281, 298
Greenberg A (abst) 108
Greene ER (abst) 116
Greene ER: *See* Avasthi et al 882
Greenwood RN (abst) 563
Grefberg N (abst) 146
Gregoire L (abst) 561
Greifer I (abst) 138, 147, 297
Gretz N (abst) 433, 555

Gretz T (abst) 433
Grillo C (abst) 656
Grivet V (abst) 559
Groggel GC (abst) 182
Grond J (abst) 778
Gross M (abst) 240
Gross ML (abst) 148, 173
Grossman S (abst) 171
Grote K (abst) 556
Gruber KA (abst) 170
Grumbach Y (abst) 555
Grunberger M (abst) 219
Grupe WE (abst) 149
Grüttner R (abst) 556
Gruwez J: *see* Vanrenterghem et al S14-69
Guastoni C (abst) 656, 657
Gueffaf B (abst) 549
Guerrini L (abst) 659
Guggino SE (abst) ..... 256(2)
Guggino WB (abst) 256
Guiducci A (abst) 561
Guignard J-P (abst) 901
Gulati SC (abst) 160
Gullans SR (abst) 96, 223
Güllner HG (abst) 180
Gumbel B (abst) 550
Gurland HJ (abst) 558
Gurland HJ: Plasmaphersis in renal transplantation S14-82
Gurreri G (abst) 660
Gurumurthy K (abst) 125, 137
Gusmano R (abst) 659
Gusowski N (abst) 252
Guth R (abst) 557
Gutierrez S (abst) 139
Gutierrez-Millet V (abst) 555
Gutman C (abst) 147
Gutmann FD (abst) 256
Gutsche HU (abst) 235, 265
Guttmann RD (abst) 294, 901
Gyde OHB (abst) 564

Haas JA (abst) 101
Haase P (abst) 114
Haberle DA (abst) 244
Hagberg J (abst) 214
Hagege J (abst) 178
Hagge W (abst) 556
Haguet M (abst) 550
Hahn G (abst) 548
Hakala TR: *see* Starzl et al S14-60
Hakim RM (abst) 124
Haley RJ (abst) 149, 175
Hall JE (abst) 170, 279
Hall R (abst) 128
Hall-Craggs M (abst) 198
Halloran BP (abst) 108
Halloran P (abst) 191
Halpern EP: *see* Frankel et al S13-31
Hamburger R (abst) ..... 145(2), 160
Hamburger RJ (abst) 145, 208, 259
Hamilton RW (abst) 149
Hamm LL: *see* Edwards et al .....
Hamm LL (abst) 767
Hammeke M (abst) 143, 161
Hammerman MR (abst) 100, 212, 219
Hampl H (abst) 565
Hanchett JE (abst) 149
Hancock W (abst) 431
Hancock WW (abst) 182, 183, 192
Handler JS (abst) 261
Hanefeld F (abst) 565
Hanley MJ (abst) 202
Hann S (abst) 166
Hannafin J (abst) 257
Hano JE (abst) 168
Hansen AP (abst) 561
Hansen B (abst) 550
Hansen HE (abst) 561
Haramati A (abst) 101
Harari R (abst) 209
Harder F (abst) 292
Hardy BE (abst) 116
Hardy MA (abst) 257
Harford A (abst) 161
Harmon WE (abst) 149
Harrington WW (abst) 173
Harris FH Jr (abst) 125
Harris RH, Hise MK, Best CF: Renotrophic factors in urine 616
Harris RH (abst) 224
Hart JI (abst) 232
Harter H (abst) 162, 212, 214
Harter HR, Birge SJ, Martin KJ, Klahr S, Karl IE: Effects of vitamin D metabolites on protein catabolism of muscle from uremic rats 465
Harter HR: *see* Teehan et al S13-66
Harter HR, Laird NM, Teehan BP: Effects of dialysis prescription on bone and mineral metabolism: The National Cooperative Dialysis Study S13-73
Harter HR: Review of significant findings from the National Cooperative Dialysis Study and recommendations S13-107
Hartnett A (abst) 136
Hartwig JH (abst) 221
Haschemeyer R (abst) 295
Haskell LP (abst) 230
Hately W (abst) 563
Hausen M (abst) 150
Hawthorne VM (abst) 140
Haycock GB: *see* Mak et al 410
Haycock GB (abst) 556
Hayek T (abst) 108
Haygood CC: *see* Robertson et al 327
Hays R (abst) 268
Hayslett JP: Effect of age on compensatory renal growth 599
Hayslett JP (abst) 257, 279
Heaton A (abst) 557
Hebert LA (abst) 183
Heck P: *see* Riedasch et al 759
Heinegard D: *see* Bygren et al 855
Helderman JH: *see* Edwards et al 767
Helderman JH (abst) 288, 289, 290, 295
Helfrich GB (abst) 290, 294
Helfrich GB: *see* Winchester et al S14-34
Hellems E: *see* Rubin et al 51
Henderson L (abst) 144
Henderson LW: *see* Cheung et al 866
Hennemann H (abst) 556
Hennessy JF (abst) 170
Henrich W (abst) 150

Henrich WL (abst) ... 150
Henry DA (abst) ... 100
Henry RR: *see* Lowrie et al ... S13-11
Henry RR: *see* Schoenfeld et al ... S13-80
Herbert D (abst) ... 108
Hermle M (abst) ... 271
Hernando L (abst) ... 553
Herrera O (abst) ... 232
Hessl SM (abst) ... 125
Heyns A du P (abst) ... 432
Higashino H (abst) ... 177
Higgins J (abst) ... 240
Higgins JT (abst) ... 148, 173
Hill C (abst) ... 432
Hill CM (abst) ... 433
Hill CMB (abst) ... 555
Hill K (abst) ... 552
Hillebrand G (abst) ... 558
Hirayama P (abst) ... 265
Hirsch D (abst) ... 257
Hise MK: *see* Harris et al ... 616
Hise MK (abst) ... 224, 616
Hishida A (abst) ... 203
Ho P (abst) ... 94
Hoang T: *see* Bergeron et al ... 588
Hoang T (abst) ... 220
Hoda P (abst) ... 161
Hodge KC (abst) ... 552
Hodler J (abst) ... 903
Hodsman AB (abst) ... 150
Hoedemaeker PH (abst) ... 778
Hoefle D (abst) ... 206
Hoefnagels C (abst) ... 136
Hoenderdos-Blom P (abst) ... 120
Hoffman D (abst) ... 125
Hofman D (abst) ... 143, 161
Hogg R (abst) ... 249
Hogg RJ (abst) ... 233
Holdaas H (abst) ... 244
Holdsworth S (abst) ... 183
Holford N (abst) ... 115
Holland NH (abst) ... 141
Holley KE: *see* Wagoner et al ... 368
Holley KE (abst) ... 121
Holliday M (abst) ... 218
Holliger C (abst) ... 245
Hollis B (abst) ... 101
Holman R (abst) ... 560
Holt K: *see* Zerwekh et al ... 838
Holt W (abst) ... 245
Honda N: Acute renal failure and rhabdomyolysis ... 888
Hong JH (abst) ... 293
Honrath U: *see* Wilson et al ... 711
Hood SA (abst) ... 150
Hook JB (abst) ... 206, 225
Hooke DH (abst) ... 192
Hoots K (abst) ... 190
Hoover WJ (abst) ... 226
Hopp M (abst) ... 430
Horner E (abst) ... 259
Horst M (abst) ... 128
Horst RL (abst) ... 103, 104
Horster M (abst) ... 286
Horton C (abst) ... 246
Hosoda S (abst) ... 138
Hosokawa S (abst) ... 204
Hostetter TH (abst) ... 215, 218, 245
Houck JC: *see* Patt et al ... 603
Houghton DC (abst) ... 194, 200, 203, 207
Houser MT (abst) ... 224
Houston IB (abst) ... 194
Howland T (abst) ... 170
Hoy WE, Gibson TP, Rivero AJ, Jain VK, Talley TT, Bayer RM, Montondo DF: XAD-4 hemoperfusion for digitoxic patients with renal failure ... 79
Hoy WE (abst) ... 126
Hoyer JR (abst) ... 182, 184
Hricik DE (abst) ... 121
Hruska K (abst) ... 98, 101, 104
Hsu C (abst) ... 245
Hsu TH: *see* Cooke et al ... 71
Huang CM (abst) ... 126
Huang W-C, Navar LG: Effects of unclipping and converting enzyme inhibition on bilateral renal function in Goldblatt hypertensive rats ... 816
Hudson B (abst) ... 193
Hueber P (abst) ... 284
Hüfler M (abst) ... 160
Hughes ML (abst) ... 260
Hull AR: *see* Edwards et al ... 767
Hull AR (abst) ... 289
Humair L (abst) ... 899
Humayun HM (abst) ... 151
Humes C (abst) ... 197
Humes HD (abst) ... 202, 204, 205, 206, 207, 209, 222
Humphery TJ: *see* Thomson et al ... 9
Humphreys MH (abst) ... 220, 262
Hunsicker L (abst) ... 131
Hunsicker LG (abst) ... 179, 183
Hunt J (abst) ... 151
Hunter S (abst) ... 241
Hunter-Baines J (abst) ... 203
Hurwich D (abst) ... 129
Hutchinson TA (abst) ... 117, 151
Hwang ER (abst) ... 160, 164
Hwang KH (abst) ... 215
Hyman A (abst) ... 275
Hymes LC (abst) ... 199

Iaina A (abst) ... 203, 204
Iancu M (abst) ... 99, 142
Ichikawa I (abst) ... 245, 260
Igarashi P (abst) ... 212
Ihle B (abst) ... 552
Ilstrup DM (abst) ... 121
Imai M (abst) ... 263
Imbasciati E (abst) ... 554
Imhoof B (abst) ... 552
Imbert-Teboul M (abst) ... 251
Ince A (abst) ... 190
Ing TS (abst) ... 151(2), 154, 157, 168
Ingelfinger JR (abst) ... 290
Ingenito E (abst) ... 244
Isaacs M (abst) ... 160
Isaacson LC (abst) ... 432
Ish-Shalom N (abst) ... 242
Ishidate T (abst) ... 184
Ishigami M (abst) ... 204
Ishikawa S (abst) ... 427
Israelit SJ (abst) ... 136
Issad B (abst) ... 549
Itskovitz HD (abst) ... 225

Iurino N (abst) 660
Ives HE (abst) 233, 240
Iwai J (abst) 177, 187, 279, 280
Iwanami S (abst) 155
Iwatsuki S: *see* Starzl et al S14-60
Izui S (abst) 189
Izzo JL Jr (abst) 267, 274

Jackson AM (abst) 133
Jackson B (abst) 171
Jacob AI (abst) 100, 101
Jacobs C: *see* Rottembourg et al 40
Jacobs JB (abst) 133
Jacobs MG (abst) 155
Jacobson HR (abst) 226, 238, 239
Jacobson MP (abst) 151
Jacoby M (abst) 262
Jacquet AF (abst) 901
Jaeger P (abst) 126
Jaeschke-Boyer H: *see* Daudon et al 842
Jahjah F (abst) 564
Jain VK: *see* Hoy et al 79
Jain VK (abst) 126
James H (abst) 94
Jamison RL (abst) 245, 268
Jankovíc N (abst) 561
Janzen A (abst) 267
Jarrell B (abst) 291
Jaudon MC (abst) 561
Jeekel J (abst) 78, 779
Jenkins P (abst) 126
Jennette JC (abst) 130
Jobin J (abst) 101, 902
Joe O (abst) 114
Johnson JP (abst) 196, 282
Johnson M (abst) 257, 281, 298
Johnson MA (abst) 177, 187, 279, 280
Johnson PC: *see* Steinhausen et al 794
Johnson RJ (abst) 152
Johnston CI (abst) 171, 258
Johnston JL (abst) 279
Johnston PA (abst) 205
Joles JA (abst) 779
Jones D (abst) 289
Jones ER (abst) ..... 229, 233(2)
Jones G (abst) 276
Jones LB (abst) 166
Jones MR (abst) 165
Jones P (abst) 168
Jones Q (abst) 159
Jones W (abst) 258
Jones WJ (abst) 279
Jordan SC (abst) 104, 125, 195
Jorgetti V (abst) 98, 158
Jörstad S: *see* Wideroe et al 22
Jose PA (abst) 243, 280
Josepovitz C (abst) 205
Joshi KK (abst) 127
Joshi SJ (abst) 127
Joyce K (abst) 192
Julian BA (abst) ..... 141(2), 192
Junco E (abst) 548
Jung CY (abst) 262
Junor BJR (abst) 560

Kachadorian WA (abst) 258, 263
Kachel HG (abst) 152
Kadir S (abst) 176
Kadowitz P (abst) 275
Kahn AM (abst) 258, 269
Kahn AM: *see* Weinman et al 832
Kahn T (abst) 215, 234
Kaiser L (abst) 152
Kaji D (abst) 215
Kalbfleisch JH (abst) 171
Kalff MW (abst) 550
Kallenberg CGM (abst) 779
Kallmeyer JC (abst) 433
Kaloyanides GJ (abst) 205
Kamdar A (abst) 132
Kamm DE (abst) 127
Kanetake H: *see* Yamamoto et al 624
see also Yamada et al 632
Kant KS (abst) 196
Kant SK (abst) 193
Kanwar YS (abst) 184
Kao-Lo G (abst) 244
Kaojarern S (abst) 275
Kaplan BS (abst) 431
Kaplan DS (abst) 186
Kapoor S (abst) 233
Kapoor V (abst) 284
Kaptein EM (abst) 127
Kapuler S (abst) 204
Karl I (abst) 212
Karl IE: *see* Harter et al 465
Karnovsky MJ: *see* Kreisberg et al 439
Karsch R (abst) 291
Karsenty G (abst) 102
Kashgarian M: *see* Lovett et al 342
see also Sterzel et al 480
Kashgarian M (abst) 168, 189
Kathpalia SC (abst) 96, 102
Katsilabros N (abst) 298
Katz A (abst) 140
Katz LD (abst) 258
Katz T (abst) 233
Kaufman AM (abst) 234
Kaufman GM (abst) 152
Kaufman J (abst) 208
Kaufman JS (abst) 259
Kaup J (abst) 213
Kawala K (abst) 197
Kaye M (abst) 151
Kaye WA (abst) 296
Kaylor G (abst) 213
Kaysen G (abst) 153
Kaysen GA, Kropp J: Dietary tryptophan supplementation prevents proteinuria in the seven-eighths nephrectomized rat 473
Kazimierczak J (abst) 902
Keane WF (abst) 184, 219, 246
Keehoe B (abst) 432
Keeton GR (abst) ..... 432(2)
Keiser HR (abst) 173
Kelepouris E (abst) 239
Kelley VE (abst) 184, 189
Kelly R (abst) 128
Kelly S (abst) 232
Kem DC (abst) 218
Kempson SA (abst) 102, 109
Kentera D (abst) 172
Kenyon CJ (abst) 275

Kerjaschki D (abst) 185
Kerr DNS: *see* Gokal et al 15
Kerr DNS (abst) 548, 552
Kesler PA (abst) 248
Kessel M: *see* von Baeyer et al 29
Kessel M (abst) 565
Keusch G: *see* Weidmann et al 320
Keusch G (abst) 899, 900, 902
Khairallah PA (abst) 204
Khalifa S (abst) 101
Khanna R (abst) 146, 164
Kheirbek AO (abst) 157
Kher KK (abst) 185
Kienstra R (abst) 130
Kiepiela P (abst) 431
Kim Y (abst) 122, 194, 195
Kimball P (abst) 105
Kimmel P (abst) 161
Kincaid-Smith P: *see* Bennett et al 393
Kincaid-Smith P (abst) 552
Kindler J (abst) 548
Kinnaert P (abst) 552
Kinne R (abst) 251, 257, 262
Kinne-Saffran E (abst) 257
Kinter LB (abst) 259
Kirchberger M (abst) 168
Kirchner KA (abst) 280, 288
Kirk KL (abst) 259
Kirkendol PL (abst) 159
Kirkman RL (abst) 297
Kirschenbaum MA (abst) 276
Kishimoto T (abst) 562
Kjellstrand CM (abst) 148
Klahr S: Pathophysiology of obstructive nephropathy 414
Klahr S: *see* Harter et al 465
Klahr S (abst) 107, 212, 219
Klare B (abst) 556
Klatzmann H (abst) 550
Kleerekopoer M (abst) 156
Klein AM (abst) 215
Klein DJ (abst) 181
Klein-Robbenhar T (abst) 262
Kleinert HD (abst) 251
Kleinfeld M (abst) 144
Kleinman J (abst) 229
Kleinman LI (abst) 259
Klinkmann H (abst) 558
Klintmalm GBG: *see* Starzl et al S14-60
Klippel J (abst) 192
Kloberdanz N (abst) 165
Klopp J (abst) 565
Klotman PE (abst) 200, 205
Kluge R (abst) 141
Knauf H, Lübcke R, Röttger P, Baumann K, Richet G: Relation of dark cells to the transport of H^+/HCO^-_3 and K^+ ions. A microperfusion study in the rat submaxillary duct 350
Knauss TC (abst) 205
Knepper MA (abst) 260
Knickelbein R (abst) 266
Knox FG (abst) 95, 101
Knutson DW (abst) 145
Kobayashi N (abst) 558
Koch DM (abst) 152
Koch MH (abst) 122
Kochar MS (abst) 171
Koelz AM (abst) 902
Koene RAP (abst) 562
Koep LJ (abst) 297
Koeppen B (abst) 260
Koett JW (abst) 156
Kohira S (abst) 204
Kokko J (abst) 249
Kokko JP (abst) 233, 238, 239
Kon V (abst) 260
Kondo A: *see* Yamada et al 632
Koomans HA (abst) 123, 216, 780
Kopelman RI (abst) 121
Kopin IJ (abst) 170
Kopp UC (abst) 244, 260
Koppera S: *see* Sabatini et al 705
Kopple JD (abst) 123, 159, 165
Kopsa H (abst) 563
Kopyt N (abst) 229
Korb E (abst) 433
Korkor A (abst) 102
Kornandakieti C (abst) 234
Korngold R (abst) 187
Kosanovich JM (abst) 128
Kotchen T (abst) 286
Köthe U (abst) 563
Kotter M (abst) 120
Kovan J (abst) 215
Kovithavongs T (abst) 291, 550
Kowalski JC (abst) 109
Kraft N (abst) 182
Krakauer R (abst) 131
Krakoff LR (abst) 168
Kram B (abst) 141
Kramer HJ (abst) 277
Kramer MS (abst) ..... 158(2)
Krasne S (abst) 241
Kraus E (abst) 216
Kraut EH (abst) 183
Kraut JA, Shinaberger JH, Singer FR, Sherrard DJ, Saxton J, Miller JH, Kurokawa K, Coburn JW: Parathyroid gland responsiveness to acute hypocalcemia in dialysis osteomalacia 725
Kraut JA (abst) 103, 106
Kreger C (abst) 206
Kreis H: *see* Niaudet el al S14-50
Kreisberg JI, Karnovsky MJ: Glomerular cells in culture 439
Kreisberg JI (abst) 247
Krensky AM (abst) 291
Krishna G (abst) 120
Krishna GG (abst) 128, 250
Krok K (abst) 179
Kropp DL (abst) 171
Kropp J: *see* Kaysen et al 473
Krothapalli R (abst) 98, 117, 261
Krous HF (abst) 195
Kuchibhotla J (abst) 102
Kuehn KW (abst) 152
Kullick M (abst) 192
Kumar V (abst) 121
Kunau RT (abst) 232, 268
Kunis C (abst) 116
Kuo CH (abst) 206
Kurokawa K (abst) 103, 104, 106, 114
Kurokawa K: *see* Kraut et al 725
Kurtzman NA: *see* Sabatini et al 705
Kurtzman NA (abst) 110, 137, 153, 165, 231, 234, 235, 273

Kusano E (abst) 222, 250, 261
Kuusi T (abst) 214
Kuznetsky K (abst) 128

L'Abbate A (abst) 559
La Greca G (abst) 660
Lacour B (abst) 98, 102, 158
Lafontaine JJ (abst) 552
Laidley L (abst) 433
Laird NM, Berkey CS, Lowrie EG: Modeling success or failure of dialysis therapy: The National Cooperative Dialysis Study S13-101
Laird NM: *see* Lowrie et al S13-11
Laird NM: *see* Parker et al S13-42
Laird NM: *see* Teehan et al S13-66
Laird NM: *see* Harter et al S13-73
Laird NM: *see* Henry et al S13-80
Laird NM: *see* Rao et al S13-89
Laird NM: *see* Santiago et al S13-95
Lal SM (abst) 564
Lallenberg CGM (abst) 779
Lam M (abst) 129, 219
Lameijer LDF (abst) 778, 779
Lameire NH: *see* De Paepe et al 744
Lamping DL: *see* Maher et al S13-50
Lampton LM: *see* Twardowski et al 64
Land W (abst) 558
Landsberg DN (abst) 292
Landy P (abst) 140
Lane B (abst) 205
Lang G (abst) 153
Lang MA (abst) 261
Lang RP (abst) 103
Langan S (abst) 182
Lange J (abst) 280
Lange K (abst) 195, 197
Lange PH (abst) 119
Langford HG (abst) 171
LaNoue KF (abst) 226
Lapointe J-Y (abst) 251, 261
Laprade R (abst) 251, 261
Laragh JH (abst) ..... 109, 172, 174(2), 243, 251
Largiadèr F (abst) 900
Larios O (abst) 277
LaRochelle FT (abst) 254
Larson T (abst) 234
Laski ME (abst) 231, 235
Lau A (abst) 153
Lau K (abst) 103, 112, 162, 245, 255, 291
Lauer A (abst) 118
Laurent B (abst) 553
Laurent P (abst) 553
Lauria F (abst) 659
Lavagni MG (abst) 657
Lavelle KJ (abst) 185
Laveri LA (abst) 206
Laville M (abst) 557
Laville M: *see* Traeger et al S14-74
Lawton W (abst) 280
Lazar I (abst) 225
Lazar IL (abst) 185
Lazaridis A: *see* Tourkantonis et al S14-46
Le Hir M (abst) 903
Le Petit JC (abst) 553
Leach W (abst) 121
Lebien TW (abst) 188
Leblanc A (abst) 139
Lechene C (abst) 266
Leclerc M (abst) 158
Lee DBN (abst) 94, 103, 112, 114
Lee TH (abst) 151
Leehey DJ (abst) 154
Lees P (abst) 163
Lefebvre R (abst) 557
Lefevre J-J: *see* Niaudet et al S14-50
LeFurgey A (abst) 221
Léger C (abst) 118
Legrain M: *see* Rottembourg et al 40
Legrain M (abst) 549, 550, 553
Leithner C (abst) 551
Lele PS (abst) 216
Lemann J Jr (abst) 105
Lemire J (abst) 95
Lemire JM (abst) 104
Lemley KV (abst) 245
Lenfesty BS (abst) 292
Lenhard V (abst) 550, 554, 556
Lennox G (abst) 161
Leohapand T (abst) 548
Lerut T: *see* Vanrenterghem et al S14-69
Leschke M (abst) 563
Leslie BR (abst) 172
Leung FY (abst) 150
Leupold D (abst) 556
Levendoglu-Tugal O (abst) 220
Levey MJ (abst) ..... 432(2)
Levey RH (abst) 290
Levi J (abst) 100, 216
Levi M, Peterson L, Berl T: Mechanism of concentrating defect in hypercalcemia. Role of polydipsia and prostaglandins 489
Levi M (abst) 104, 201
Levien LJ (abst) 429
Levin NW (abst) 98, 121, 128, 155, 156, 221
Levine BS (abst) 104
Levine DZ (abst) 235, 265
Levine R (abst) 205
Levine SD (abst) 262
Levinsky H (abst) 216
Levinsky NG (abst) 205
Levy SR: *see* Shapiro et al 536
Lewis EJ (abst) 131, 197
Lewis GP (abst) 173
Lewis J (abst) 104
Lewis S (abst) 295
Lewy J (abst) 275
Leypoldt JK: *see* Cheung et al 866
Lianos E (abst) 186
Lianos EA (abst) 186
Licht JH (abst) 175, 235
Licina M (abst) 120
Lief P (abst) 228
Lifschitz M (abst) 207, 277
Lim VS (abst) 217
Limido A (abst) 554
Limido D (abst) 549, 565
Lin J-T (abst) 262
Lin S-Y (abst) 262
Linas S (abst) 174, 281
Lindheimer MD (abst) 249
Lindner A (abst) 246
Lindquist J (abst) 129

Lindsay RM (abst) ... 164
Link L (abst) ... 901
Lins RR: *see* De Backer et al ... 738
Linshaw MA (abst) ... 270
Linton AL (abst) ... 144
Lipkow T (abst) ... 556
Lipner H (abst) ... 144
Lipner NI (abst) ... 154, 214
Lippton H (abst) ... 275
Little JR (abst) ... 135
Litwack G (abst) ... 273
Liu FY (abst) ... 235
Livio M: *see* Frampton et al ... 506
Lizak P (abst) ... 115
Llach F: *see* Robertson et al ... 327
Llach F (abst) ... 94, 113, 146, 154, 157, 158, 165, 200, 219
Lobo PI (abst) ... 292
Locatelli F (abst) ... 554
Lock A (abst) ... 154, 214
Lodish J (abst) ... 126
Loertscher R (abst) ... 292
Loewenstein I (abst) ... 228
Logan A (abst) ... 172
Logan AG (abst) ... 279
Löhr H (abst) ... 556
Lombardi R (abst) ... 132
Lonati F (abst) ... 564
Lopez-Majano V (abst) ... 117
Lopez-Predet J (abst) ... 555, 562
Lornoy W (abst) ... 559
Lortan J (abst) ... 431
Loschavio C (abst) ... 660
Lotan D (abst) ... 186
Lotter MG (abst) ... 432
Louis BM (abst) ... 154, 214
Loutzenhiser R (abst) ... 246
Lovett DH, Sterzel RB, Kashgarian M, Ryan JL: Neutral proteinase activity produced in vitro by cells of glomerular mesangium ... 342
Low MG (abst) ... 114
Lowenstein J (abst) ... 176
Lowrie EG: History and organization of the National Cooperative Dialysis Study ... S13-1
Lowrie EG, Laird NM, Henry RR: Protocol for the National Cooperative Dialysis Study ... S13-11
Lowrie EG: *see* Parker et al ... S13-37
Lowrie EG: *see* Parker et al ... S13-42
Lowrie EG: *see* Laird et al ... S13-101
Lowrie EG, Teehan BP: Principles of prescribing dialysis therapy: Implementing recommendations from the National Cooperative Dialysis Study ... S13-113
Lowry RP (abst) ... 186
Lübcke R: *see* Knauf et al ... 350
Lucci M (abst) ... 236
Lucci MS (abst) ... 231, 233
Luciano JM (abst) ... 293
Ludgin JR (abst) ... 154
Ludwin D: *see* Edwards et al ... 767
Luft FC (abst) ... 244
Luger A (abst) ... 163
Luger A: *see* Verger et al ... 823
Luke R (abst) ... 168
Luke RG (abst) ... 232, 254, 262
Luño J (abst) ... 548
Lupi GP; *see* Bianchi et al ... 870
Lupo A (abst) ... 660
Lupo F (abst) ... 559
Lupus Nephritis Collaborative Study Group (abst) ... 129, 131
Lusheng S (abst) ... 198
Lüthi P (abst) ... 899
Lüthy E (abst) ... 899
Lyman N (abst) ... 155
Lymangrover JR (abst) ... 170
Lynch RE (abst) ... 217
Lyons P (abst) ... 295
Lysaght MJ: *see* Gurland et al ... S14-82

Maack T (abst) ... 224, 251, 265
MacDermott RP: *see* Beale et al ... 380
Mackenzie T (abst) ... 281
MacLeod A (abst) ... 551
Macneill D (abst) ... 187
Macsai M (abst) ... 128
Madaio MP, Salant DJ, Cohen AJ, Adler S, Couser WG: A comparative study of in situ immune deposit formation in active and passive Heymann nephritis ... 498
Madaio MP: *see* Adler et al ... 807
Madden MA (abst) ... 217
Maddox DA (abst) ... 236
Madias NE: *see* Clark et al ... 336
Madias NE (abst) ... 121, 228, 236
Madsen KM (abst) ... 236
Maekawa M (abst) ... 562
Maesaka JK (abst) ... 189
Maggiore Q (abst) ... 559
Magni E (abst) ... 659
Magrinat G (abst) ... 139
Mahajan S (abst) ... 129, 135
Mahan J (abst) ... 187
Mahany D (abst) ... 267
Maher BA, Lamping DL, Dickinson CA, Murawski BJ, Olivier DC, Santiago GC: Psychosocial aspects of chronic hemodialysis: The National Cooperative Dialysis Study ... S13-50
Maher C Jr (abst) ... 130
Mahida BH (abst) ... 155
Mahieu P (abst) ... 556
Mahoney CA (abst) ... 206
Maia MDN (abst) ... 133
Maierhofer WJ (abst) ... 105, 171
Majeed HA (abst) ... 195, 197
Mak RHK, Al Dahhan J, Azzopardi D, Bosque M, Chantler C, Haycock GB: Measurement of glomerular filtration rate in children after renal transplantation ... 410
Malacrida V (abst) ... 549
Malberti F (abst) ... 657, 660
Maletta G (abst) ... 554, 658
Malik MC: *see* Traeger et al ... S14-74
Malik S: *see* Moorhead et al ... S14-20
Mallick NP (abst) ... 194, 197, 198
Mallon JP (abst) ... 145
Malluche HH (abst) ... 98, 105, 141(2)
Malnic G (abst) ... 230
Maloney NA (abst) ... 111
Malt RA: Humoral factors in regulation of compensatory renal hypertrophy ... 611
Mampaso FM, Wilson CB: Characterization of inflammatory cells in autoimmune tubulointerstitial nephritis in rats ... 448
Mamunes P (abst) ... 118

Manaligod J: *see* Sabatini et al 705
Mancilla R (abst) 139
Mandal AK (abst) 172, 281
Mandel LJ (abst) 221, 223, 263, 267
Mandin J (abst) 551
Mandreoli M (abst) 659
Manganella G (abst) 659
Manis T (abst) 131, 293
Mann JFE (abst) 150, 172
Mannik M (abst) 178
Mannucci PM (abst) 132
Manohar NL (abst) 154, 214
Manolagas S (abst) 111
Mansbach M (abst) 224
Manz F (abst) 555
Manzi M (abst) 282
Marchant KK (abst) 155
Marchesi D: *see* Frampton et al 506
Marder HK, Coleman TH, Forristal J, Beischel L, West CD: An inherited defect in the C3 convertase, C_3b,Bb, associated with glomerulonephritis 749
Marhoffer W (abst) 565
Marks ES (abst) 173
Marni A (abst) 660
Marrink J (abst) 779
Marsh FF (abst) 563
Marsh JT (abst) 156
Marshall DG (abst) 287, 293
Martin D (abst) 230, 239
Martin G (abst) 162
Martin J (abst) 161
Martin K (abst) 104, 162
Martin KJ: *see* Harter et al 465
Martin KJ (abst) 100, 285
Martin RS (abst) 279
Martin-Malo A (abst) 562
Martineau A (abst) 278
Martinez AJ: *see* Twardowski et al 64
Martinez Maldonado M (abst) 274, 275
Martinez-Vea A (abst) 555
Martorano C (abst) 559
Marumo F (abst) 155, 558
Maschio G (abst) 660
Mascia F (abst) 565
Mason RJ (abst) 551
Massazza M (abst) 132
Massry SG (abst) 97, 105, 123, 127, 132, 176, 210, 212
Matarese R (abst) 124
Matarese RA (abst) 122
Mathews R (abst) 146
Mathias R: *see* Bengele et al 684
Mattammal MB (abst) 287
Matter B (abst) 217
Matter L (abst) 904
Mattern WD (abst) 130
Matthews PG (abst) 171
Matthys E, Patton MK, Osgood RW, Venkatachalam MA, Stein JH: Alterations in vascular function and morphology in acute ischemia renal failure 717
Maude DL (abst) 244
Mauer SM (abst) 217
Maynard J (abst) 156
Mayor G: *see* Morrissey et al 699
Mayor GH (abst) 105, 152, 115, 250
Mazur AT (abst) 106
Mazzucco G (abst) 553, 658
Mbakop A (abst) 902
McCafferty E (abst) 187, 191
McCarron D (abst) 130, 166
McCarron DA (abst) 106, 113, 169, 207, 292
McCarthy DM (abst) 276
McClure HM (abst) 294
McCluskey RT (abst) 179
McConnell CA (abst) 564
McConnell M (abst) 554
McConnell J (abst) 295
McCrae K (abst) 182
McCready W (abst) 147
McCreary JT (abst) 110
McCurdy P (abst) 290
McDonald F (abst) 129
McDonald FD (abst) 276
McElligott T (abst) 291
McGeown MG (abst) 427, 429, 433, 551
McGonigle RJ (abst) 217
McGrath BP (abst) 171
McHenry K (abst) 143
McKendall G (abst) 225
McKenna BA (abst) 131, 157, 553
McKeown JW (abst) 106
McMorrow RG (abst) 192
McMullen-Laird M (abst) 275
McNamara D (abst) 275
McNamara ER: *see* Bengele et al 684
McNamara PD (abst) 223
McNeal R (abst) 156
McNeaney H (abst) 161
McPhaul JJ Jr: *see* Zerwekh et al 401
McSherry NR (abst) 270
McVicker K (abst) 235
Mecca G (abst) 132, 192, 211
Medina A (abst) 903
Meeks LA (abst) 173
Mees EJD (abst) 123, 216, 780
Mehls O (abst) 556
Mehta P (abst) 130
Meier A: *see* Weidmann et al 320
Meier W (abst) 903
Meiselman HJ: *see* Ozanne et al 519
Meister J (abst) 156
Meiteles L (abst) 268
Mejia G (abst) 156
Melamed J (abst) 178
Meltzer J (abst) 116
Melvin T (abst) 195
Menard J: *see* Nochy et al 375
Mendoza E (abst) 120, 219
Mendoza SA (abst) 265
Mendrick DL (abst) 187, 189
Merkel FK (abst) 151
Messa M (abst) 659
Messa P (abst) 659
Messerli FH (abst) 169, 175
Messina M (abst) 553, 658
Metcalfe P (abst) 552
Metcoff J (abst) 218
Meuwly M (abst) 904
Meyer B (abst) 150
Meyer P: *see* Mongeau et al 530
Meyer R Jr (abst) 102

Meyer T (abst) 128
Meyer TW (abst) 215, 218
Meyers AM (abst) ..... 429, 430(2), 433(2), 434
Michael AF (abst) 181, 188, 194, 195, 198
Michalk D (abst) 556
Michelis MF (abst) 287
Michels LD (abst) 246
Michielson P: *see* Vanrenterghem et al S14-69
Middleton DTC (abst) 555
Migdal S (abst) 129
Migone L (abst) 560
Mihatsch M (abst) 199, 292
Militano L (abst) 557
Millan N (abst) 139
Miller FN, Nolph KD, Sorkin MI, Gloor HJ: The influence of solution composition on protein loss during peritoneal dialysis 35
Miller JH: *see* Kraut et al 725
Miller ON (abst) 145
Miller RB (abst) 145
Miller TE: *see* Nelson et al 312
Millet VG (abst) 560
Mills S (abst) 101
Milne FJ (abst) ..... 429, 430(2), 434
Milne J (abst) 428
Milner LS (abst) ..... 430(2)
Milutinovíc C (abst) 561
Min I (abst) 281
Minari M (abst) 564
Minetti AE (abst) 656
Minetti L (abst) 558, 656, 657, 660
Mintz GS (abst) 120
Mion C (abst) 549, 551
Mioni G (abst) 659
Mir AR (abst) 151
Misefari V (abst) 559
Mishler DR (abst) 106
Misler S (abst) 107
Mitas JA II (abst) 156
Mitch WE (abst) 128, 202
Mitchell JC (abst) 121
Mitchell PP (abst) 167, 169
Mitha AS (abst) 434
Mitra S (abst) 130
Mitsuno K (abst) 130
Mittelsteadt CA (abst) 130
Mladenovic J (abst) 213
Moake J (abst) 160
Mock D (abst) 220
Moethilalh R (abst) 434
Mohos SC (abst) 180
Moller MB (abst) 135
Molnar V (abst) ..... 561(2)
Molteni A (abst) 283
Monaco AP (abst) 295
Mongeau J-G, Garay R, de Mendonca M, Broyer M, Meyer P: Erythrocyte Na^+ and K^+ transport systems in children with Bartter syndrome: Increase in passive sodium permeability 530
Montali G (abst) 563
Montanari A (abst) 659
Montanaro D (abst) 659
Montegut M (abst) 251
Monteón F (abst) 139
Montfort I (abst) 189
Monti G (abst) 659
Montiliu J (abst) 555, 562
Montondo DF: *see* Hoy et al 79
Montondo DF (abst) 126
Mookerjee BK (abst) 159
Moore H (abst) 163
Moore HL: *see* Verger et al 823
Moore J (abst) 196
Moore MA: *see* Cooke et al 71
Moorhead JF, Chan MK, El-Malik S, Raftery M, Baillod RA, Fernando ON, Varghese Z: Blood transfusion from renal transplantation: Benefits and risks ... S14-20
Mora-Palma F (abst) 552
Morales J: *see* Rivera et al 387
Morales JM (abst) 560
Morandi L (abst) 656
Morel F (abst) 251
Morelli E (abst) 561
Moreno E (abst) 562
Morgan AG (abst) 563
Morgan VE (abst) 235
Mori PG (abst) 659
Morinière P (abst) 561
Morley AR (abst) 548
Morrill L (abst) 247
Morris C (abst) 130
Morris CD (abst) 292
Morris CR (abst) 130
Morris DJ (abst) 275
Morris RC Jr (abst) 108, 220
Morrison G (abst) 161
Morrissey J, Rothstein M, Mayor G, Slatopolsky E: Suppression of parathyroid hormone secretion by aluminum 699
Morrissey J (abst) 107
Morrow CE: *see* Najarian et al S14-10
Mosconi G (abst) 656
Mosley CA Jr (abst) 156
Moss NG (abst) 173
Mossey R (abst) 162
Moulin B (abst) 140
Mourad G (abst) 551
Moyer D (abst) 105
Mueller P (abst) 288
Mukherjee SK (abst) 173, 263
Mulgaonkar S (abst) 155
Muir JW (abst) 563
Müller C (abst) 556
Müller G (abst) 556
Muller J (abst) 263
Multani S (abst) 210
Murisasco A: *see* Gallice et al 764
Murata Y (abst) 217
Murawski BJ: *see* Maher et al S13-50
Murphy E (abst) 263
Mutz B (abst) 228
Myburgh JA (abst) 429
Myers BD (abst) 214

Naff GB (abst) 154
Nagami G (abst) 114
Naicker S (abst) 428, 433
Najarian JS, Sutherland DER, Morrow CE, Ferguson RM, Simmons RL: Kidney transplants for high-risk patients S14-10
Nakamura M (abst) 155
Nakatani T (abst) 562

Nally J (abst) 240
Nally JV (abst) 148, 173
Napier J (abst) 112
Naray-Fejes-Toth A (abst) 278, 282
Narins RG (abst) ..... 133, 229, 233(2)
Nascimento L (abst) 237
Nash BA: *see* Olivier et al S13-26
Nash GS: *see* Beale et al 380
Nava S (abst) 658
Navar LG (abst) 247, 283
Navar LG: *see* Huang et al 816
Nawab S (abst) 151
Neilson EG (abst) 187, 191
Nel M (abst) 428
Nelson J, Ormrod DJ, Miller TE: Host immune status in uremia. IV. Phagocytosis and inflammatory response in vivo 312
Nelson P (abst) 159
Nelson WE (abst) 429
Nemhauser G (abst) 136
Nestico PF (abst) 120
Neufeld T (abst) 255
Neusy AJ (abst) 176
Nevins TE (abst) 188
Newrick P (abst) 560
Newton JF (abst) 206, 225
Nghiem DD (abst) 288
Niarchos AP (abst) 174
Niaudet P, Raguin G, Lefevre J-J, Busson M, Cabau N, Fortier B, Boue A, Broyer M, Bedrossian J, Fries D, Kreis H, Sraer J-D: Serological status of cytomegalovirus and outcome of renal transplantation S14-50
Nicastri AD (abst) 125, 131, 137
Nicholas JA (abst) 287
Nicholson JP (abst) 174
Nicoloff JT (abst) 127
Nikkila E (abst) 214
Nilsson P (abst) 146
Nisengard RJ (abst) 178
Nishimura H (abst) 263
Nissenblatt MJ (abst) 164
Nissenson AR (abst) 156
Nissenson RA: *see* Yanagawa et al 674
Nissenson RA (abst) 107
Nixon JV (abst) 150
Noble B (abst) 188
Noble D (abst) 226
Nochy D, Barres D, Camilleri J-P, Bariety J, Corvol P, Menard J: Abnormalities of renin- containing cells in human glomerular and vascular renal diseases 375
Noddin JL (abst) 218
Nolph K (abst) 163
Nolph KD, Boen FST, Farrell PC, Pyle KW: Continuous ambulatory dialysis in Australia, Europe, and the United States: 1981 3
Nolph KD: *see* Gahl et al 1
see also Miller et al 35
see also Twardowski et al 64
Nolph KD (abst) 163
Nolph KD: *see* Verger et al 823
Nooyen WJ (abst) 134, 136
Nord E (abst) 103
Nord EP (abst) 213, 264
Norman B (abst) 177
Norman DJ: *see* Wickre et al 731
Norman DJ (abst) 293, 298
Norman ME (abst) 106
Norris A (abst) 284
Nova ML (abst) 558
Novara P (abst) 559
Novick A (abst) 296
Novick AC (abst) 290
Novogrodsky A (abst) 197, 296
Noya M (abst) 264
Nubé MJ (abst) 550
Nudelman RA (abst) 100

O'Connor DT (abst) 167, 174
O'Driscoll JB (abst) 548
O'Neil R (abst) 264
O'Neil T (abst) 208
O'Neil TJ (abst) 294
O'Neill D (abst) 143, 161
O'Neill WW Jr (abst) 217
O'Riordan J (abst) 563
Oberleithner H (abst) 256
Ochs T (abst) 270
Occhialini L (abst) 549
Oegema TR (abst) 181
Oertel PJ (abst) 556
Ogawa M (abst) 263
Oh JH (abst) 294
Oh MS (abst) 139, 225
Oigman W (abst) 169, 175
Oken DE (abst) 206, 246
Okubo M (abst) 558
Oldrizzi L (abst) 660
Olivier DC, Nash BA: Data management, data analysis, and statistical methods in the National Cooperative Dialysis Study S13-26
Olivier DC: *see* Frankel et al S13-31
Olivier DC: *see* Maher et al S13-50
Oliver J (abst) 170
Olmer M (abst) 564
Onesti G (abst) 295
Ono K (abst) 157
Ooi BS (abst) 188, 196
Ooi BS: *see* Ooi et al 851
Ooi YM (abst) 188, 196
Ooi YM, Ooi BS: Identification of monocyte phagocytic defect in a subpopulation of patients with nephritis 4, 851
Oosthuizen OJ (abst) 433
Oparil S (abst) 283
Opelz G (abst) 556
Oreopoulos DG (abst) 146, 164
Ormrod DJ: *see* Nelson et al 312
Orskov H (abst) 561
Ortalda V (abst) 660
Osgood RW: *see* Matthys et al 717
Oster JR (abst) 139, 218
Ota K (abst) 115, 130, 241
Otrakji J (abst) 151
Ott C (abst) 286
Ott F (abst) 556
Ott SM (abst) 107, 111
Ouellette AJ: Messenger RNA regulation during compensatory renal growth 575
Owens B (abst) ..... 208(2)
Ozanne P, Francis RB, Meiselman HJ: Red blood cell aggregation in nephrotic syndrome 519

Pabico RC (abst) 131, 553
Pace E (abst) 117
Pacholski M (abst) 275
Pahilan A (abst) 142
Paillard M (abst) 237
Pajel PA (abst) 196
Pak CYC: *see* Zerwekh et al 401, 838
Pak CYC (abst) 226
Palanca R (abst) 559
Palant CE (abst) 264
Paller M (abst) 174, 281
Panzetta G (abst) 660
Paone RP (abst) 173
Papapoulos SE (abst) 563
Papadopoulou ZL (abst) 294
Papin JM (abst) 118
Paradinas FJ (abst) 548
Paravicini M (abst) ..... 285(2)
Parbtani A: *see* Frampton et al 506
Pardo V (abst) ..... 208(2), 211
Parekh N: *see* Steinhausen et al 794
Parfitt AM (abst) 98
Parfrey PS (abst) 548
Parisen P (abst) 660
Park CH (abst) 265
Park MH (abst) 196
Park R (abst) 237
Parker TF: *see* Zerwekh et al 401
Parker TF, Reed RB, Lowrie EG: Description of the participating centers and the patient population in the National Cooperative Dialysis Study S13-37
Parker TF, Laird NM, Lowrie EG: Comparison of the study groups in the National Cooperative Dialysis Study and a description of morbidity, mortality, and patient withdrawal S13-42
Parkinson I: *see* Gokal et al 15
Parsoo I (abst) 433
Parsons V (abst) 564
Pasalodos J (abst) 562
Pascoe MD (abst) 429, 430, 431
Pasko KA (abst) 224
Pasquali S (abst) 559
Passo C (abst) 217
Pasternak RE (abst) 247
Patrono C (abst) 282
Patt LM, Houck JC: Role of polypeptide growth factors in normal and abnormal growth 603
Patton MK: *see* Matthys et al 717
Paukert T (abst) 220
Paul LC (abst) 778
Paunier L (abst) 104
Pauw FH (abst) 432, 435
Pauw W (abst) 136
Pearson JE (abst) 153
Pecorara M (abst) 659
Pederson J (abst) 146, 154, 157, 158, 165, 218
Pelayo JC (abst) 247, 280
Pelleya R (abst) 218
Pelzer R (abst) 548
Penhos JC: Dedication to Eduardo Braun Menendez: 1903 to 1959 569
Pépin JM (abst) 118
Peraino RA (abst) 108
Perego A (abst) 656
Pérez A (abst) 139
Perez GO (abst) 139, 218
Perez R (abst) 562
Perfetto M: *see* Sterzel et al 480
Perfumo F (abst) 659
Perkins H (abst) 289
Perkins JH: *see* Bengele et al 684
Perrone RD (abst) 282
Persijn GG (abst) 550
Peter S (abst) 899
Peters J (abst) 903
Peters P (abst) 295
Peters PC (abst) 289, 290
Peters S (abst) 164
Peters W (abst) 131
Peterson L: *see* Levi et al 489
Peterson LN (abst) 265
Petrella E (abst) 564
Petruzzi MJ (abst) 185
Pezzagno C (abst) 564
Pfeffer JM (abst) 245
Pfeffer MA (abst) 245
Phillips T (abst) 290
Phillips TM (abst) 197
Piazza A (abst) 656
Piazza V (abst) 564
Picardi L (abst) 564
Picotti GB: *see* Bianchi et al 870
Piccoli G (abst) 553, 658
Pickering TG (abst) 109, 172
Pierandrei E (abst) 102
Pierratos A (abst) 146
Pierucci A (abst) 282
Piesco NP (abst) 179
Pinnick R (abst) 147
Pinnick RV (abst) 248
Piraino B (abst) 108
Pirani CL (abst) 116, 196
Pirson Y (abst) ..... 552(2)
Pisani E (abst) 660
Pisegna J (abst) 208
Pistor K (abst) 556
Pitts TO (abst) 97
Planch A (abst) 159
Plant SB (abst) 113
Platt JL (abst) 188, 198
Ploos van Amstel SLB (abst) 556
Ploth DW (abst) 247
Poggio F (abst) 564
Poggioli G: *see* Faenza et al S14-54
Pohanka E (abst) 551
Pohl MA (abst) 131
Poiatti P (abst) 564
Poignet JL (abst) 553
Poirier A (abst) 98
Pola P (abst) 563
Poletti I (abst) 656
Pollak VE (abst) 193, 195
Polli E: *see* Bianchi et al 870
Pollock AS (abst) 237
Ponticelli C (abst) 554, 564
Ponticelli C, De Vecchi Af, Tarantino A, Rivolta E, Egidi FM, Berardinelli L, Vegeto A: A search for optimizing corticosteroid administration to renal transplant patients S14-85
Pontoriero G (abst) 657, 660
Poon-King T (abst) 132
Popli S (abst) 157

Popovtzer MM (abst) 108
Porchet M (abst) 901
Portale AA (abst) 108
Portman L (abst) 126
Portmann L (abst) 901
Porush JG: *see* Shapiro et al 536
Porush JG (abst) 243
Posborg V (abst) 561
Potter D (abst) 143
Potter E (abst) 132
Potvin WJ (abst) 173
Poucell S (abst) 191
Pouliquen M (abst) 551
Powell D (abst) 143, 218
Power DA (abst) 551
Prandini R (abst) 656
Prasad A (abst) 129
Pratt RD (abst) 282
Preston AS (abst) 261
Preuss H (abst) 165, 227
Preuss HG: Compensatory renal growth symposium: An introduction 571
Preuss HG, Goldin H: Serum renotropic activity and renal growth in spontaneously hypertensive rats 635
Preuss HG: *see* Austin et al 581
Price PA (abst) 105
Prieto C (abst) 555
Primera MI (abst) 175, 283
Protat MF: *see* Daudon et al 842
Protiva D (abst) 290
Prowant BF: *see* Twardowski et al 64
Prowant BF (abst) 163
Pucacco L (abst) 233
Pugh B (abst) 175
Pugliese F (abst) 282
Pumphrey R (abst) 198
Puschett J (abst) 108
Puschett JB (abst) ..... 97(2), 109, 135
Pusineri F (abst) 132
Pustelnik A (abst) 565
Pyle KW: *see* Nolph et al 3

Quamme GA (abst) 109, 113, 227
Quandt C (abst) 128
Quarum M (abst) 207
Quebbemann AJ (abst) 227
Quillen EW Jr (abst) 283
Quintanilla A (abst) 126, 283
Quintanilla AP (abst) 175
Quismorio F (abst) 132

Raab T (abst) 143
Rabkin R (abst) 265
Radda G (abst) 99
Radda GK (abst) 228
Radnik RA (abst) 179
Raftery M: *see* Moorhead et al S14-20
Raguin G: *see* Niaudet et al S14-50
Rahman A (abst) 162
Rahman M (abst) 175, 283
Raichura N (abst) 564
Raij L (abst) 184, 219
Raja RM (abst) ..... 158(2)
Raju S (abst) 288
Ralston AJ (abst) 552
Rambausek M (abst) 554
Rambauser M (abst) 561
Ramirez-Gonzalez R: *see* Rivera et al 387
Ramos JM: *see* Gokal et al 15
Ramsey PG (abst) 152
Rance CP (abst) 116
Rance P (abst) 193
Randall P (abst) 170
Rankin L (abst) 146, 165
Ransil BJ (abst) 295
Ransom JC (abst) 103, 403
Ransome OJ (abst) 430
Rao BPCS (abst) 248
Rao L (abst) 271
Rao TKS (abst) 175
Rapoport J (abst) 214
Rapp N (abst) 287
Rascoff JH (abst) 162
Rastogi SP (abst) 132
Rastorfer M (abst) 903
Ratner M (abst) 558
Rau J (abst) 566
Rault R (abst) 108
Rauterberg E: *see* Riedasch et al 759
Ravetto C (abst) 563
Rawat R (abst) 428, 434
Ray R: *see* Rubin et al 51
Rayment C (abst) 128
Read DJ (abst) ..... 560(2)
Reams G (abst) 247
Recker RR (abst) 107
Rector FC Jr (abst) 228
Redaelli B (abst) 565
Reddington M (abst) 241
Reed RB: *see* Parker et al S13-37
Reed RB: *see* Teschan et al S13-58
Reeves W (abst) 237
Refetoff S (abst) 217
Refvem OK (abst) 551
Reich L (abst) 160
Reichard GA: *see* Skutches et al 57
Reid BD (abst) 180
Reid RW (abst) 151
Reilly H (abst) 207
Reineck HJ (abst) 247
Reinitz R (abst) 298
Reisin E (abst) 175
Reitz R (abst) 111
Rémond A (abst) 555
Remussi G (abst) 132
Remuzzi G: *see* Frampton et al 506
Remuzzi G (abst) 192, 211
Rennert O (abst) 218
Rennke G (abst) 182
Rennke H (abst) 205
Rennke HG (abst) 187, 189, 201, 215, 218
Rennke HG: *see* Adler et al 807
Resano M (abst) 548
Resnick L (abst) 174
Resnick LM (abst) 109, 174
Reubi FC: *see* Franz et al 526
Reutter FW (abst) 904
Reveillaud RJ: *see* Daudon et al 842
Revell P (abst) 563
Revert L (abst) 555, 562
Revillar JP: *see* Traeger et al S14-74
Revillard JP (abst) 557

Reznik VM (abst) ... 265
Rheinschmidt MA (abst) ... 289
Rhoads M (abst) ... 125
Ribeiro LC (abst) ... 133
Ribot S (abst) ... 287
Ricanati ES (abst) ... 129
Rich [illegible] (abst) ... 111
Richardson RMA (abst) ... 238
Richardson WP (abst) ... 248
Richet G: *see* Knauf et al ... 350
Richet G: Renal transplantation: A community affair . S14-3
Ridgeway D (abst) ... 194
Riedasch G, Heck P, Rauterberg E, Ritz E: Does low urinary sIgA predispose to urinary tract infection? ... 759
Riedinger H: *see* von Baeyer et al ... 29
Riera GS (abst) ... 109
Rigaud M (abst) ... 284
Riggio R (abst) ... 296
Riggio RR (abst) ... 295
Riley L (abst) ... 110
Rinder D (abst) ... 283
Ringoir SMG: *see* De Paepe et al ... 744
Ringoir SMG (abst) ... 779
Ritchie S (abst) ... 193
Ritter L (abst) ... 285(2)
Ritz E: *see* Riedasch et al ... 759
Ritz E (abst) ... 143, 150, 172, 200, 554, 556
Rivera JV, Ramírez-González R, Morales J: Altered anion handling by choroid plexus in renal insufficiency 387
Rivero AJ: *see* Hoy et al ... 79
Rivero AJ (abst) ... 126, 157, 553
Rivolta E: *see* Ponticelli et al ... S14-85
Robaudo C (abst) ... 660
Robert A (abst) ... 564
Robert D (abst) ... 158
Roberts JL (abst) ... 128, 131, 197
Robertson CR (abst) ... 245
Robertson JA, Felsenfeld AJ, Haygood CC, Wilson P, Clarke C, Llach F: Animal model of aluminum-induced osteomalacia: Role of chronic renal failure .. 327
Robinette JB (abst) ... 207, 252
Robson JS (abst) ... 554
Rocchi G (abst) ... 192, 211
Roch-Ramel F (abst) ... 903
Rocha AM (abst) ... 133(2)
Rocha JRC (abst) ... 133(2)
Rodicio JL (abst) ... 550, 560
Rodríguez E (abst) ... 190
Rodríguez JL (abst) ... 559
Rodríguez M (abst) ... 146, 154, 158, 165
Rodríguez-Iturbe B (abst) ... 190
Roelcke D (abst) ... 550
Rogers C (abst) ... 103
Roman RJ (abst) ... 266
Romani T (abst) ... 103
Rombolà G (abst) ... 657, 660
Ronan WV (abst) ... 156
Ronco C (abst) ... 660
Roos JC (abst) ... 216
Rosansky SJ (abst) ... 136, 159
Roscoe J (abst) ... 193
Roscoe JM (abst) ... 133
Rose BD (abst) ... 133
Rosen S (abst) ... 221, 290
Rosendorff C (abst) ... 428
Rosenfeld BA (abst) ... 96
Rosenfeld BI (abst) ... 558
Rosenfeld J: Hypertension in the elderly ... 540
Rosenfeld R (abst) ... 171
Rosenfeld SI (abst) ... 185
Rosenthal JT: *see* Starzl et al ... S14-60
Rosenzweig P (abst) ... 159
Rosivall L (abst) ... 283
Ross B (abst) ... 99
Rostand SG (abst) ... 225
Rothberg AD (abst) ... 430
Rothmann SA (abst) ... 290
Roths JB (abst) ... 189
Rothstein M: *see* Morrissey et al ... 699
Rotmensch HH (abst) ... 169
Rottembourg J, El Shahat Y, Agrafiotis A, Thuillier Y, de Groc F, Jacobs C, Legrain M: Continuous ambulatory peritoneal dialysis in insulin-dependent diabetic patients: A 40-month experience ... 40
Rottembourg J (abst) ... 549, 553
Röttger P: *see* Knauf et al ... 350
Rouse D (abst) ... 110
Roussel A (abst) ... 561
Rovere A (abst) ... 559
Roversi R: *see* Faenza et al ... S14-54
Rowe P (abst) ... 111
Roxe D (abst) ... 129
Roxe DM: *see* Schoenfeld et al ... S13-80
Roxe DM: *see* Streepada Rao et al ... S13-89
Rubenstein J (abst) ... 176
Rubin A (abst) ... 296
Rubin AL (abst) ... 144, 197, 295, 296(3)
Rubin J, Barnes T, Burns P, Ray R, Teal N, Hellems E, Bower J: Comparison of home hemodialysis to continuous ambulatory peritoneal dialysis ... 51
Rubin L (abst) ... 150
Rubin M (abst) ... 140
Rubin R (abst) ... 145(2)
Rubin J (abst) ... 159
Ruddy MC (abst) ... 197
Ruddock V: *see* Coulthard et al ... 407
Ruder H (abst) ... 556
Rudhardt M (abst) ... 903
Rudnick MR (abst) ... 133
Rugiu C (abst) ... 660
Ruilope LM (abst) ... 555, 560
Ruiz G (abst) ... 551
Rumpf KW (abst) ... 563
Runne O (abst) ... 152
Rush GF (abst) ... 225
Russell RP (abst) ... 176
Ryan JL: *see* Lovett et al ... 342

Sabatini S, Koppera S, Manaligod J, Arruda JAL, Kurtzman NA: Role of urinary concentrating ability in the generation of toxic papillary necrosis ... 705
Sabatini S (abst) ... 110, 153(2), 165, 234
Sabbatini M (abst) ... 555, 659
Sabnis SG (abst) ... 115
Saccagi A (abst) ... 118
Sacchi G (abst) ... 192, 211
Sacchi V (abst) ... 143
Sacchi VA (abst) ... 159
Sackett D (abst) ... 161
Sackin H (abst) ... 266
Sacktor B (abst) ... 216
Safirstein R (abst) ... 210

Sagalowsky A (abst) 295
Sagalowsky AI (abst) 290
Saglikes Y (abst) 97, 176
Sahhar I (abst) 281
Saito Y: *see* Yamada et al 632
Sakai R (abst) 195
Sakhaee K (abst) 226
Sakhrani L (abst) 226
Salant DJ: *see* Madaio et al 498
Salant DJ (abst) 182
Salant DJ: *see* Adler et al 807
Saleh AW (abst) 277, 780
Sallman AL (abst) 101
Salusky IB (abst) 159
Salvadeo A (abst) 564
Salvatierra O (abst) 289
Salvidio G (abst) 660
Samarzija I (abst) 561
Sampohl J (abst) 564
Samtleben W: *see* Gurland et al S14-82
transplantation S14-82
Samuelsson B (abst) 550
Sanaka T (abst) 241
Sanchez-Madrid F (abst) 291
Sancho J (abst) 553
Sancho M (abst) 562
Sandberg L (abst) 550
Sanders K (abst) 165
Sanders M (abst) 779
Sanfilippo F (abst) 193
Sankarapandian P (abst) 162
Sansom SC: *see* Weinman et al 832
Santiago GC, Streepada Rao TK, Laird NM: Effect of dialysis therapy on the hematopoietic system: The National Cooperative Dialysis Study S13-95
Santiago GC: *see* Maher et al S13-50
Santiago GC: *see* Streepada Rao et al S13-89
Santiz Z (abst) 101
Santoro A: *see* Zucchelli et al 46
Santoro A (abst) 559
Sanz R (abst) 562
Sapir DG (abst) 176
Sargent JA (abst) 128
Sargent JA: Control of dialysis by a single-pool urea model: The National Cooperative Dialysis Study S13-19
Sarnacki P (abst) 206
Sasaki J (abst) 268
Sasaki S (abst) 238
Sasaki T (abst) 157
Sastrasinh M (abst) 204, 207
Sato M (abst) 283
Savazzi GM (abst) 560
Savin VJ (abst) 248
Sawin LL (abst) 253
Saxton J: *see* Kraut et al 725
Saylor RP (abst) ..... 134(2)
Schaefer K (abst) 160
Schafer JA (abst) 259, 271
Schainuck L (abst) 134
Schambelan M (abst) 131
Schandene L (abst) 163
Schardijn GHC (abst) 134, 136
Schärer K (abst) ..... 556(2)
Scharschmidt LA (abst) 284
Schecter L (abst) 162
Scheiner E (abst) 160
Scheinman JI (abst) 194
Scheinman SJ (abst) 110
Scheler F (abst) 563
Schell RE (abst) 241
Schelstraete KHG: *see* De Paepe et al 744
Schelstraete KHG (abst) 779
Scherhag R (abst) 277
Schettino MA (abst) 189
Scheuermann E (abst) 551
Schiaffino E (abst) 658
Schilb TP: *see* Shapiro et al 536
Schild L (abst) 903
Schiller R (abst) 565
Schindera F (abst) 556
Schindler B (abst) 565
Schoenfeld PY, Henry RR, Laird NM, Roxe DM: Assessment of nutritional status of the National Cooperative Dialysis Study population S13-80
Schlondorff D (abst) 278
Schmicker R (abst) 558
Schmidt H (abst) 556
Schmidt M (abst) 900
Schmidt P (abst) 563
Schmidt TJ (abst) 284
Schmidtlein JM (abst) 151
Schmitt GW (abst) 160
Schmitt SL (abst) 245
Schmitz O (abst) 561
Schneeberger EE (abst) 179
Schnermann J (abst) 285
Schoeneman MJ (abst) 135
Schoenfeld P (abst) 153
Schoeppe W (abst) 289, 551
Scholler C: *see* Avasthi et al 882
Schollmeyer P (abst) ..... 285(2)
Schoolwerth AC (abst) 135, 226
Schrager M (abst) 126
Schreiner GE (abst) 290
Schreiner GE: Past, present, and future of transplantation S14-4
Schreiner GE: *see* Winchester et al S14-34
Schrier RW: *see* Better et al 303
Schrier RW (abst) ..... 104, 201, 209, 427(2), 428
Schroeder ET (abst) 284
Schulte-Wissermann H (abst) 556
Schurig R: *see* von Baeyer et al 29
Schuster V (abst) 238
Schütterle G (abst) 549
Schwartz E (abst) 111
Schwartz GJ (abst) 238
Schwartz JH (abst) 133, 239, 282
Schwartz JS (abst) 120
Schwartz KA (abst) 152
Schwartz M (abst) 551
Schwartz MM (abst) 131, 197
Schwartzberg G (abst) 113
Schwartzman M (abst) 228
Schweitzer C (abst) 779
Scicli AG (abst) 274
Scolari MP (abst) 656
Scott EC (abst) 141
Sealey JE (abst) 251
Searle BM (abst) 177
Seaton R (abst) 147
Sebastian A (abst) 131

Sebert J (abst) 561
Seedat YK (abst) 428, 431, 433, 434
Seelig W (abst) 554
Segagni S (abst) 565
Segal S (abst) 223
Segel DP (abst) 120
Seggie J (abst) 434
Seifter J (abst) 266
Seiler A (abst) 903
Seiler MW (abst) 182, 183
Seldin DW (abst) 239
Seligson G (abst) 197
Selleri S: *see* Faenza et al S14-54
Sen D (abst) 131
Sen SB (abst) 901
Senekjian HO (abst) 98, 117, 203, 261
Serban I (abst) 204
Serov VV (abst) 558
Servadio C (abst) 557
Seyer-Hansen K: Renal hypertrophy in experimental diabetes mellitus 643
Sforzini S (abst) 565
Shadduck RK (abst) 217
Shaffer SJ (abst) 183
Shah J (abst) 237
Shah SV, Cruz FC, Baricos WH: NADPH-induced chemiluminescence and lipid peroxidation in kidney microsomes 691
Shah SV (abst) 226
Shankel SW (abst) 111
Shany S (abst) 214
Shapira Z (abst) 557
Shapiro MS (abst) 219
Shapiro WB, Schilb TP, Waltrous CL, Levy SR, Porush JG: Aluminum leakage from REDY sorbent cartridge 536
Sharda D (abst) 195
Sharf B (abst) 430
Sharif J (abst) 220
Sharma HM (abst) 210
Sharman VL (abst) 563
Shaw BA (abst) 287, 293
Shaw, Jr. BW: *see* Starzl et al S14-60
Sheinman JI (abst) 194
Sherman RA (abst) 160, 164
Sherrard DJ: *see* Kraut et al 725
Sherrard DJ (abst) 104, 107, 111
Shewan G (abst) 551
Shih Y (abst) 176
Shimamura T (abst) 189
Shimizu A (abst) 161
Shinaberger JH: *see* Kraut et al 725
Shiuan D (abst) 266
Shohat B (abst) 557
Short C (abst) 197
Short CD (abst) 198
Shoubridge E (abst) 228
Shulman RG (abst) 207
Shupien SA (abst) 145
Shusterman N (abst) 161
Shyh TP (abst) 289
Sibbald W (abst) 164
Sibley R (abst) 122, 198
Sica D (abst) 298
Sica DA (abst) 161
Sieberth HG (abst) 548
Siegel NJ (abst) 207
Sigler MH: *see* Skutches et al 57
Silberman H (abst) 123
Sillix D (abst) 135
Silva P (abst) 221
Silver J (abst) 111
Silver MR (abst) 135
Silverman M (abst) 249, 271
Silverstein E (abst) 175
Simenhoff ML (abst) 216
Simmons M (abst) 143, 161
Simmons RL: *see* Najarian et al S14-10
Simon E (abst) 239
Simon N (abst) 129
Simonetti BM (abst) 282
Simonian S (abst) 295
Simpson DP (abst) 156
Simpson DP: Mitochondrial transport functions and renal metabolism 785
Simpson K (abst) 213
Singer FR: *see* Kraut et al 725
Sinico R (abst) 553, 658
Sinicrope RA (abst) 135
Sinn W (abst) 558
Sinsteden T (abst) 208
Sinzinger H (abst) 551
Siperstein MD (abst) 223
Sirota RA (abst) 141
Sisson S (abst) 187
Skorecki K (abst) 128
Skorecki KL (abst) 272
Skurla C (abst) 226
Skutches CL, Sigler MH, Teehan BP, Cooper JH, Reichard GA: Contribution of dialysate acetate to energy metabolism: Metabolic implications 57
Slatopolsky E: *see* Morrissey et al 699
Slatopolsky E (abst) 103, 104, 110, 162
Slingeneyer A (abst) 549
Sloof MJH (abst) 559
Small R (abst) 161
Smead WL (abst) 183
Smeby LC: *see* Wideroe et al 22
Smit JA (abst) 429
Smith A (abst) 141
Smith BH (abst) 136
Smith CL (abst) 112, 115
Smith D (abst) 222
Smith L (abst) 144
Smith MC (abst) 155
Smith PB (abst) 149
Smits PJH (abst) 559
Snoei H: *see* Steinhausen et al 794
Solbiati L (abst) 563
Solez K (abst) 198
Soltoff SP (abst) 96, 267
Somani P (abst) 148
Soncuya LF (abst) 99
Sondheimer J (abst) 162
Song MK (abst) 112
Sonnenberg H: *see* Wilson et al 711
Sorkin M (abst) 108
Sorkin MI: *see* Miller et al 35
Sosnowski G (abst) 245
Souffriau G (abst) 559
Souney P (abst) 128
Sowers J (abst) 120, 128

Spagnuolo P (abst) 154
Spar B (abst) 110, 239
Speck J (abst) 129
Spector D (abst) 216
Spielman WS (abst) 272
Spinowitz BS (abst) ..... 162(2)
Spinozzi NS (abst) 149
Spirnak J (abst) 112, 254
Spital A (abst) 127
Spohn B (abst) 557
Spolaore R: *see* Faenza et al S14-54
Sprenger-Klasen I (abst) 550
Springer T (abst) 291
Squifflet JP (abst) 552
Sraer J-D (abst) 178, 284
Sraer J-D: *see* Niaudet et al S14-50
Sreenivasan C (abst) 154, 214
Stachura I (abst) 140, 198
Stahl RAK (abst) ..... 285(2)
Stamoutsos B (abst) 249
Stanchina J (abst) 293
Stanson AW: *see* Wagoner et al 368
Stanton B (abst) 262
Stanton BA (abst) 254
Stanton J (abst) 130
Stanton R (abst) 113
Starkman MT (abst) 176
Starzl TE, Rosenthal JT, Hakala TR, Iwatsuki S, Shaw Jr. BW, Klintmalm GBG: Steps in immunosupression for renal transplantation S14-60
Stassen F (abst) 259
Stastny P (abst) 289
Stathakis C (abst) 298
Steele BT (abst) 116
Stefoni S: *see* Vangelista et al S14-41
Streepada-Rao TK, Roxe DM, Laird NM, Santiago GC: Hemodynamic and cardiac correlates of different hemodialysis regimes: The National Cooperative Dialysis Study S13-89
Streepada Rao: *see* Santiago et al S13-95
Stefoni S (abst) 656
Stein HD (abst) 189
Stein JH: *see* Matthys et al 717
Stein JH (abst) 203, 207
Steingart A (abst) 172
Steinhausen M, Snoei H, Parekh N, Baker R, Johnson PC: Postischemic hydronephrosis: A new method to visualize vas afferens and efferens in vivo 794
Steinman TI (abst) 295
Steinmuller D (abst) 296
Steinmuller DR (abst) 290
Steipe B (abst) 285
Stenzel K (abst) 296
Stenzel KH (abst) ..... 144, 197, 225, 296(2)
Stern K (abst) 127
Sterns R (abst) 127
Sterns RH (abst) 267
Sterzel RB, Perfetto M, Biemesderfer D, Kashgarian M: Disposal of ferritin in glomerular mesangium of rats 480
Sterzel RB: *see* Lovett et al 342
Sterzel RB (abst) 189
Stevens B (abst) 552
Stevens BJ: *see* Thomson et al 9
Stevens ME (abst) 554
Stevenson JA (abst) 190
Stewart LM (abst) 551
Stier CT Jr (abst) 225
Stinson MW (abst) 178
Stoffner D: *see* Gurland et al S14-82
Stokes JB (abst) 267
Stone D (abst) 163
Stone DK (abst) 239
Stothart MN (abst) ..... 430(2)
Stow JL (abst) 431
Stowe N (abst) 204
Strandhoy JW (abst) 248
Strauch M (abst) 433, 565
Strauss GM (abst) 133
Strauss J (abst) 100
Streeten DHP (abst) 170
Strewler GJ (abst) 107
Striegel S (abst) 240
Strom TB (abst) 297
Strezelecka G (abst) 562
Stubenbord WT (abst) 295
Sturani A: *see* Zucchelli et al 46
Sturani A (abst) 559
Sturgill BC (abst) 180, 292
Stutte HJ (abst) 551
Sufit CR (abst) 268
Sugarman M (abst) 132
Sugimoto T (abst) 136
Sugimura K (abst) 562
Sugino N (abst) 115
Suki WN (abst) 110, 139, 261
Sulima D (abst) 562
Sullivan J (abst) 144
Sullivan L (abst) 270
Surian M (abst) 657, 660
Surya V (abst) 118
Susic D (abst) 172
Suthanthiran M (abst) ..... 295, 296(2)
Sutherland DER: *see* Najarian et al S14-10
Sutton J (abst) 136
Sutton RAL: Disorders of renal calcium excretion 665
Sutton RAL (abst) 137
Svartås TM: *see* Wideroe et al 22
Swainson CP (abst) 554
Swanepoel CR (abst) 429, 430
Swanson BN (abst) 169
Swartz C (abst) 120, 137
Swartz R (abst) 163
Swartz S (abst) 286
Sweeney WE (abst) 179
Sweet SJ (abst) 113
Sweetman V: *see* Gokal et al 15
Szabadi RR (abst) 173
Szwed JJ (abst) 248

Tagliavini D (abst) 549
Tahiri Y (abst) 561
Takahashi M (abst) 130
Takamitsu Y (abst) 268
Talley TT: *see* Hoy et al 79
Talwalker Y (abst) 190
Tamayo J (abst) 100, 285
Tanaka A (abst) 286
Tannen RL (abst) 234
Tapia L (abst) 296
Tarantino A: *see* Ponticelli et al S14-85
Tarazi RC (abst) 138
Tarka J (abst) 137

Tarver SD (abst) 181
Taub M (abst) 226
Taufield PA (abst) 296
Taylor C (abst) 101, 902
Taylor G (abst) 428
Taylor RMR (abst) 557
Taylor W (abst) 161
Tchang P (abst) 780
Teal N: *see* Rubin et al 51
Teehan BP: *see* Skutches et al 57
Teehan BP, Laird NM, Harter HR: Influences of dialysis prescription on electrolyte and acid-base metabolism: The National Cooperative Dialysis Study S13-66
Teehan BP: *see* Harter et al S13-73
Teehan BP: *see* Lourie et al S13-113
Teele RL (abst) 290
Tegtmeyer E (abst) 212
Tejani A (abst) 125, 131, 137
Temple D (abst) 551
Tennant J (abst) 158
Terao N (abst) 138
Teraoka S (abst) 241
Terreros D (abst) 255
Terreros DA (abst) 268
Terribile M (abst) 555, 659
Teschan PE, Bourne JR, Reed RB, Ward JW: Electrophysiological and neurobehavioral responses to therapy: The National Cooperative Dialysis Study .. S13-58
Tessitore N (abst) 660
Tevaarwerk GJM (abst) 180
Textor SC (abst) 138
Thaiss F (abst) 199
Thames MD (abst) 260
Thévenin M (abst) 98
Thiel G (abst) 201, 271, 292
Thiel GT (abst) 902
Thielan J (abst) 162
Thoenes G (abst) 558
Thomas FC (abst) 245
Thomasson D: *see* Davis et al 458
Thompson AM (abst) 197
Thomson NM, Stevens BJ, Humphery TJ, Atkins RC: Comparison of trace elements in peritoneal dialysis, hemodialysis, and uremia 9
Thomson PD (abst) ..... 429, 430(2), 434
Thornhill JD (abst) 152
Thuillier Y: *see* Rottembourg et al 40
Thurau K (abst) 204
Thysen B (abst) 147
Tiedemann K (abst) 268
Tielemans C (abst) 147, 163
Tilles S (abst) 268
Tilney NL (abst) 297
Tinker J (abst) 236
Tisher CC (abst) 236, 255
Tizianello A (abst) 660
Toback FG (abst) 227
Tobian L (abst) 177, 187, 279, 280
Todd RA (abst) 178
Todt MJ (abst) 180
Tokushige A (abst) 177
Tomoyoski T (abst) 204
Tonini GP (abst) 659
Toronto Glomerulonephritis Group (abst) 193
Torras A (abst) 555, 562
Torres RG (abst) 139
Touraine F (abst) 553
Touraine JL (abst) 553
Touraine JL: *see* Traeger et al S14-74
Tourkantonis A, Lazaridis A: Interaction between cytomegalovirus infection and renal transplant rejection S14-46
Toussaint C (abst) 552
Trachtman H (abst) 138, 297
Traeger J (abst) 557
Traeger J, Touranine JL, Malik MC, Revillar JP, Laville M: Antilymphocyte globulin and thoracic duct drainage in renal transplantation S14-74
Travis LB (abst) 217
Tremaine LM (abst) 227
Tresguerres JF (abst) 555
Treviño A (abst) 138, 139
Trigg D (abst) 230
Trimble ME (abst) 269
Trinh MM (abst) 249
Tripolone M (abst) 239
Trizna W: *see* Yanagawa et al 674
Trizna W (abst) 226
Troy JL (abst) 201
Tsai CH (abst) 194
Tsukamoto Y (abst) 155
Tucker AK (abst) 563
Tucker BJ (abst) 247
Tuma J (abst) 904
Tuma SN (abst) 139
Turini GA (abst) 901
Turgeon K (abst) 267
Turner D (abst) 659
Turner ME (abst) 294
Turner ST (abst) 114
Turney JH (abst) 564
Tuttle EP (abst) 294
Twardowski ZJ, Prowant BF, Nolph KD, Martinez AJ, Lampton LM: High volume, low frequency continuous ambulatory peritoneal dialysis 64
Twardowski ZJ (abst) 163
Tyler K (abst) 211, 286
Tyler P (abst) 428

Ulmann A (abst) 102
Umezu R (abst) 130
Uribarri J (abst) 138, 225

Vaamonde CA (abst) ..... 139, 208(2), 218
Vaamonde CM (abst) 208
Valade D (abst) 156
Valderábano F (abst) 548
Valdes AJ (abst) 190
Valeri M (abst) 656
Valle G (abs) 559
Valsecchi C (abst) 132
Valtin H (abst) 242
Valvo E (abst) 660
Van Agthoven A (abst) 178
VanAman MA (abst) 183
van Ballegooie (abst) 779
van den Ende A (abst) 120, 134
van der Hem GK (abst) 277, 779, 780
van der Schueren E: *see* Vanrenterghem et al S14-69
Van Eps LWS (abst) 120, 124, 134, 136, 271
Van Eps LW (abst) 550, 780
van Eyl O (abst) 565

Van Geertruyden H (abst) 552
van Liebergen FHJM (abst) 562
Van Liew JB (abst) 188
van Malderen P (abst) 559
van Rood JJ (abst) 550
Van Soesbergen RM (abst) 134
van Soest GAW (abst) 780
Van Strien S (abst) 160
van Ypersele de Strihou C (abst) ..... 552(2)
Van Zyl-Smit R (abst) 431
Vanamee P (abst) 160
Vandenberg SN (abst) 122
Vandenbroucke JM (abst) 552
Vandeputte I: *see* Vanrenterghem et al S14-69
Vandeputte M: *see* Vantrenterghem et al S14-69
VanderWerf BA (abst) 297
Vangelista A, Frasca GM, Stefoni S, Bonomini V: Graft biopsy in renal transplantation; Correlation with clinical, immunological, and virological investigations S14-41
Vanrenterghem Y, Waer M, Ang KK, Lerut T, Bouillon R, Vandeputte I, Vandeputte M, van der Schueren E, Gruwez J, Michielsen P: Renal cadaveric transplantation after total lymphoid irradiation in patients with diabetes S14-69
Varghese G (abst) 129
Varghese Z: *see* Moorhead et al S14-20
Vas SI: Microbiologic aspects of chronic ambulatory dialysis 83
Vaughan-Norton M (abst) 106
Vegeto A (abst) 557
Vegeto A: *see* Ponticelli et al S14-85
Velazquez H (abst) 269
Vendemia F (abst) 553
Venkatachalam MA: *see* Matthys et al 717
Venkatachalam MA (abst) 179
Ventura HU (abst) 169, 175
Venuto R (abst) 281
Venuto RC (abst) 119
Verani R (abst) 190
Vereerstraeten P (abst) 552
Verger C (abst) 163
Verger C, Luger A, Moore HL, Nolph KD: Acute changes in peritoneal morphology and transport properties with infectious peritonitis and mechanical injury 823
Vermaak WJ (abst) 433
Vermaut M (abst) 559
Vermeire PA: *see* De Backer et al 738
Vernier RL (abst) 187
Verpooten GA: *see* De Backer et al 738
Verrier-Jones K (abst) 556
Versura P (abst) 657
Vertuno L (abst) 227
Vicks S (abst) ..... 145(2), 160, 208
Vicks SL (abst) 145
Vigano MR (abst) 565
Vilbar RM (abst) 157
Villa G (abst) 564
Vinay P (abst) 140
Viol GW (abst) 157
Virani G (abst) 133
Viscuso R (abst) 155
Vlaho M (abst) 548
Vlasses PH (abst) 168
Vogel R (abst) 296
Vogt A (abst) 190, 199
Voigts A (abst) 94, 113, 157
Volpini T (abst) 554
von Baeyer H, Gahl GM, Riedinger H, Borowzak R, Averdunk R, Schurig R, Kessel M: Adaptation of CAPD patients to the continuous peritoneal energy uptake 29
Von Felten A (abst) 902
Von Herrath D (abst) 160
Von Riotte A (abst) 153
Vonwiller HM (abst) 902
Voyles WF (abst) 116
Vyvial TM (abst) 297

Wade J (abst) 267
Wadgymar A (abst) 191
Waeber B (abst) 904
Waer M: *see* Vanrenterghem et al S14-69
Wagner L (abst) 565
Wagner M (abst) 149
Wagoner RD, Stanson AW, Holley KE, Winter CS: Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance 368
Waki Y (abst) 157
Walcer R (abst) 155
Wald H (abst) 108
Waldherr R (abst) 143
Walker BR (abst) 177
Walker F (abst) 164
Walker JA (abst) 160, 164
Walker JF (abst) 140, 164
Walker VR (abst) 137
Walker WG: *see* Cooke et al 71
Wall C III (abst) 135
Wallimann C (abst) 901
Wallin JD (abst) 217
Walling MW (abst) 103
Walsh-Reitz MM (abst) 227
Walter L (abst) 297
Waltrous CL: *see* Shapiro et al 536
Wang F (abst) 255
Wang H (abst) 119, 191
Wang SH (abst) 181
Ward D (abst) 144
Ward DM (abst) 149
Ward JW: *see* Teschan et al S13-58
Ward MK: *see* Gokal et al 15
Ward MK (abst) 548, 552
Ward RA (abst) 164
Ware R (abst) 229
Warnock DG (abst) 233, 240
Warshaw BL (abst) 199
Wathen RL (abst) 164
Watlington CO (abst) 278
Watson A (abst) 140, 213
Watson RM (abst) 140
Wauters JP (abst) 549, 904
Wauthier M (abst) 551
Waxman FJ (abst) 183
Weaver J (abst) 111
Weber HP (abst) 556
Wedeen RP (abst) 220
Weening JJ (abst) 778
Weerts C (abst) 162

Weinman EJ, Sansom SC, Bennett S, Kahn AM: Effect of anion exchange inhibitors and para-amminohippurate on the transport of urate in the rat proximal tubule 832
Weidmann P, Beretta-Piccoli C, Meier A, Keusch G, Glück Z, Ziegler WH: Antihypertensive mechanism of diuretic treatment with chlorthalidone. Complementary roles of sympathetic axis and sodium 320
Weidmann P (abst) 901
Weimar W (abst) 778, 779
Weinberg JM (abst) 202, 204, 205, 206, 207, 208, 222
Weiner I (abst) 236
Weinman EJ (abst) 258, 269
Weinstein S (abst) 266
Weinstein SW (abst) 269
Weir MR (abst) 297
Weiser H (abst) 903
Weiss L (abst) 146
Weiss MA (abst) 188, 193, 199
Weiss R (abst) 138, 147
Weiss RA (abst) 297
Welbourne TC (abst) 234
Welch W (abst) 286
Weller JM (abst) 140
Welling DJ: *see* Welling et al 358
Welling DJ (abst) 270
Welling LW, Evan AP, Welling DJ, Gattone VH III: Morphometric comparison of rabbit cortical connecting tubules and collecting ducts 358
Welling LW (abst) 268, 270
Welling P (abst) 270
Wells DE (abst) 151
Wen SF (abst) 270
Wenzl JE (abst) 195
Werner M (abst) 147
Wernet P (abst) 550, 556
Wesson D (abst) 231
Wesson DE (abst) 165
West CD: *see* Marder et al 749
Westenfelder C (abst) ..... 209, 248, 273(2)
Weston MJ (abst) 564
Wheeler R (abst) 132, 223, 240
Whelchel J (abst) 168
Whelton A (abst) 198
Whelton PK: *see* Cooke et al 71
White C (abst) 277
White RP (abst) 141
Whiteside C (abst) 249
Whiteside TL (abst) 198
Whiting SJ (abst) 109, 227
Wickre CG, Bennett WM: Renal cyst epithelial transport in non-uremic polycystic kidney disease 514
Wickre CG, Norman DJ, Bush A, Barry JM, Bennett WM: Postrenal transplant erythrocytosis: A review of 53 patients 731
Wickre CG (abst) 298
Wideröe T-E, Smeby LC, Berg KJ, Jorstad S, Svartas TM: Intraperitoneal (^{125}I) insulin absorption during intermittent and continuous peritoneal dialysis 22
Widmer C (abst) 904
Wiebelhaus V (abst) 245, 259
Wiedemann E (abst) 262
Wiegmann T (abst) 147
Wieslander J: *see* Bygren et al 855
Wiggins RC (abst) 191
Wilcox CS (abst) 128, 286
Wiley MH (abst) 223
Wilkes B (abst) 162
Wilkes BM (abst) 274
Wilkinson R (abst) 557
Willenbach KD (abst) 433
Willenbockel LL (abst) 556
Williams A (abst) 269
Williams C (abst) 154, 165
Williams CC (abst) 133
Williams G (abst) 286
Williams HH (abst) 199
Williams RD (abst) 107
Williams TE (abst) 164
Willie G (abst) 98
Wilms H (abst) 550
Wilson A (abst) 137
Wilson C (abst) 196
Wilson CB: *see* Mampaso et al 448
Wilson DJ (abst) 177
Wilson DR, Honrath U, Sonnenberg H: Thiazide diuretic effect on medullary collecting duct function in the rat 711
Wilson DR (abst) 209, 427
Wilson FS (abst) 177
Wilson L (abst) 219
Wilson MM: *see* Cheung et al .....
Wilson P: *see* Robertson et al 327
Wilson P (abst) 113
Wilson PD (abst) 286
Winaver J (abst) 209
Winchester JF (abst) 165
Winchester JF, Gelfand MC, Foegh ML, Helfrich GB, Schreiner GE: Early indicators of renal allograft rejection S14-34
Windham JP (abst) 173
Windus D (abst) 219
Wineman RJ: Rationale of the National Cooperative Dialysis Study S13-8
Wingen AM (abst) 556
Wingo CS (abst) 270
Winston J (abst) 210
Winter CS: *see* Wagoner et al 368
Wise D (abst) 177
Wish JB (abst) 154, 155
Withers L (abst) 223
Wizemann V (abst) 549
Wolcott D (abst) 156
Wolf H (abst) 556
Wolf RE (abst) 142
Wolff DW (abst) 248
Wolfgruber M (abst) 565
Wolfson M (abst) 165
Womack A (abst) 233
Wombolt DG (abst) 125
Wong E (abst) 145
Wong MA (abst) 112
Wong NL (abst) 109
Wong NLM (abst) 113
Wong-Garcia RM (abst) 232
Wongsurawat N (abst) 94
Woodard T (abst) 150
Work J (abst) 225, 271
Worman HJ (abst) 240
Wright EM (abst) 241, 264
Wright FS (abst) 95, 269

Wright LF (abst) ..... 99, 134(2)
Wu SC (abst) 140
Wunderlich P (abst) 271, 902
Wyatt RJ (abst) 141
Wybran J (abst) 163

Xefterie 298

Yager HM (abst) 295
Yamada J, Kanetake H, Saito Y, Kondo A, Yamamoto Y: Renotropic growth factor found in cancer patient sera after removal of cancer-bearing kidney 632
Yamada J: *see* Yamamoto et al 624
Yamagami S (abst) 562
Yamamoto N, Kanetake H, Yamada J: In vitro evidence from tissue cultures to prove existence of rabbit and human renotropic growth factor 624
Yamamoto N: *see* Yamada et al 632
Yanagawa N, Nissenson RA, Edwards B, Yeung P, Trizna W, Fine LG: Functional profile of the isolated uremic nephron: Intrinsic adaptation of phosphate transport in the rabbit proximal tubule 674
Yanagawa N (abst) 103, 114
Yang JPS (abst) 133
Yang S (abst) 295
Yarger WE (abst) 200, 205
Yau C (abst) 271
Yee VJ (abst) 233, 240
Yeung P: *see* Yanagawa et al 674
Yim N (abst) 259
Yokel R (abst) 141
Yoo TJ (abst) 199
Yoomans SJ (abst) 240
Young RB (abst) 118
Yourist JE (abst) 114
Yu VL (abst) 149
Yudis M (abst) 141
Yusufi ANK (abst) 114, 222

Zabetakis PM (abst) 287
Zager RA (abst) 210
Zakheim B (abst) 191
Zalups RK (abst) 114
Zambraski EJ (abst) 167, 194
Zäruba K (abst) 903
Zasuwa G (abst) 98, 155, 156
Zawada ET Jr (abst) 257, 281, 298
Zazgornik J (abst) 563
Zelman S (abst) 287
Zelman SJ, Zenser TV, Davis BB: Renal growth in response to unilateral ureteral obstruction 594
Zenser TV: *see* Davis et al 458
see also Zelman et al 594
Zenser TV (abst) 94, 287
Zerefos NS (abst) 298
Zerwekh JE, McPhaul JJ Jr, Parker TF, Pak CYC: Extrarenal production of 24, 25 dihydroxyvitamin D in chronic renal failure during 25 hydroxyvitamin D_3 therapy 401
Zerwekh JE, Holt K, Pak CYC: Natural urinary macromolecular inhibitors: Attenuation of inhibitory activity by urate salts 838
Zhang YK (abst) 181
Zhou WZ (abst) 181
Ziegler WH: *see* Weidmann et al 320
Zielezny MA (abst) 119
Zielinski N (abst) 172
Zilleruelo G (abst) 100
Zimmerman CE (abst) 295
Zimmerman SW (abst) 156, 217, 298
Zonozi S (abst) 165
Zuccalà A: *see* Zucchelli et al 46
Zuccalà A (abst) 559
Zucchelli P, Chiarini C, Esposti ED, Fabbri L, Santoro A, Sturani A, Zuccalà A: Influence of continuous ambulatory peritoneal dialysis on the autonomic nervous system 46
Zucchelli P (abst) ..... 554(2), 559, 657, 658

Subject Index For Volume 23

Abdominal girth
in high volume, low frequency CAPD 64
Acetaminophen
mechanism of *a.*-induced renal cortical necrosis (abst) 206
Acetate
role of dialysate *a.* in energy metabolism..... 57
Acetazolamide
effects on calcium and phosphate metabolism in nephrotic syndrome (abst)..... 659
Acid handling
by deep and surface nephrons of remnant kidney (abst) 230
Acid-base and electrolyte metabolism
influenced by dialysis prescription..... S13-66
Acid-base disorders
in idiopathic hypercalciuria (abst) 660
Acidification
evidence for voltage-dependent *a.* in cortical collecting tubule (abst) 235
Acidosis
affected by potassium removal during dialysis (abst)... 565
and chronic alkalosis, uniform ventilatory response to (abst) 236
hydrogen chloride-induced, effects on net acidification rate in proximal convoluted tubule (abst)..... 232
in primary hyperparathyroidism (abst) 433
substrate metabolism and ammoniagenesis during *a.* (abst) 227
Acute tubular necrosis
renin and renal dysfunction in (abst)..... 432
Adenosine
and adenosine analog hemodynamic responses to *a.* in isolated perfused rat kidney (abst)..... 242
and compensatory renal growth..... 588
effects on cyclic AMP and sodium transport in epithelia formed by A6 cells in culture (abst) 261
renal hemodynamic and renin release effects dissociated by verapamil (abst) 272
renal transport of (abst)..... 269
ADH
increases urinary prostaglandin excretion (abst)..... 278
influence on potassium handling by distal nephron (abst) 254
studied with scanning electron microscope in toad bladder luminal membrane (abst)..... 268
Adrenal response
affected by prednisolone therapy in renal transplantation (abst) 429
α-Adrenergic agonist
inhibits vasopressin-induced cyclic AMP accumulation in collecting tubule (abst)..... 251
Adrenergic nervous system
role in hyperkalemia (abst) 267
Adrenoceptors
α-1 and α-2, *a.* in renal blood flow alterations in dogs (abst) 248
α-Adrenoceptor blockade
effects on renal hemodynamics during maturation (abst) 243
β-Adrenoceptor blockade
pre- and postsynaptic responses to graded renal nerve stimulation before and during β-*a.* (abst)..... 274
Adriamycin nephrosis
immune and protamine-heparin aggregates in (abst) ... 778
mesangial function and focal sclerosis in (abst) 778
Age
as factor in renal transplantation S14-10
effects on compensatory renal growth 599
impaired renal and extrarenal potassium adaptation in old rats 684
Aggregates
immune and protamine-heparin *a.* in Adriamycin nephrosis (abst) 778
Albumin
labeled *a.* method used to survey plasma volume measurements in nephrotic syndrome (abst)..... 780
tubular absorption of *a.* in isolated perfused proximal convoluted tubule of rabbit (abst) 265
Albuminuria
in intact and splenectomized dogs after exercise (abst) 779
Aldosterone
effects on urinary prostaglandin and kallikrein excretion (abst) 282
response of plasma *a.* and cortisol concentration to acute volume depletion 71
role in
regulation of distal tubule morphology and potassium transport (abst) 267
renal potassium adaptation (abst)..... 257
Aldosterone metabolites
effects of reduced *a. m.* in toad bladder (abst) 275
Alfa-interferon
effects on natural killer cells (abst) 656
Alkalosis
segmental nephron chloride handling during chloride depletion *a.* (abst)..... 232
Allograft, renal
acute cortical ruptures in (abst) 557
adverse pretransplant sensitization detected by ADCC (abst) 288
analysis of lymphocyte activation in *r. a.* recipients at production/response level of interleukin-2 (abst) 296
cadaveric *r. a.* survival improved by thoracic duct drainage (abst) 557
cytomegalovirus infection in 50 *r. a.* recipients (abst) . 551
early indicators of *r. a.* rejection S14-34
evaluation of cellular infiltrates in human *r.a.* with monoclonal antibodies and heteroantisera (abst) 288
failure due to dense intramembranous deposit disease (abst) 122
genetic study of graft survival in (abst) 901
in vivo platelet activation with in vitro hyperaggregability to arachidonic acid in 506
incidence and cause of death in *r. a.* recipients (abst). 434
interstitial fibrosis of *r. a.* in urinary tract obstruction (abst) 900
late ureteral obstruction in pediatric *r. a.* patients related to ureteral fibrosis and stricture (abst) 290
minor histocompatibility antigens in HLA identical *r. a.* (abst)..... 550
monoclonal OKT3 antibody therapy of acute *r. a.* rejection (abst)..... 288
myocardial infarction effects on (abst) 430

natural killer cell activity in *r. a.* recipients (abst) 296
natural killer cells versus malignant cells (abst) 656
papillary necrosis observed by sonography in *r. a.* (abst) 904
plasmapheresis associated with *r. a.* rejection S14-82
rehabilitation in recipients of long-term *r. a.* (abst) 297
rejection of MHC-identical *r. a.* in rat (abst)..... 778
reversal of
acute cadaveric *r. a.* rejection with adjunctive horse antithymocyte globulin treatment (abst)..... 295
steroid-resistant *r. a.* rejection by plasmaleukapheresis (abst) 290
study of patient with recurrent focal glomerular sclerosis in two *r. a.* (abst) 298
survival in patients transfused perioperatively only (abst) 289
urine cytology versus fine needle aspiration cytology in monitoring *r. a.* (abst) 557
Aluminum
bone and serum *a.* removal in hemodialysis (abst) 431
effects of *a.* loading on specific tissue calcium and magnesium concentration (abst) 105
histological renal osteodystrophy, 25 hydroxycholecalciferol, and *a.* levels in CAPD 15
in peritoneal dialysis, hemodialysis, and uremia..... 9
leakage from REDY sorbent cartridge 536
parathyroid hormone or bile duct ligation effects on fecal excretion of *a.* (abst) 215
plasma, affected by aluminum-containing antacids (abst) 129
renal clearance of *a.* in normal rats (abst)..... 250
suppressive effects on parathyroid hormone secretion 699
treatment of *a.*-associated bone disease (abst) 552
used to induce osteomalacia in animal model 327
Aluminum hydroxide
oral, effects on serum 1,25-$(OH)_2$-vitamin D in healthy male humans (abst)..... 105
Amiloride
effects on
calcium transport by distal convoluted tubule (abst) 97
distal tubular carbonic-anhydrase independent bicarbonate reabsorption in rat (abst) 231
kaliuresis in Liddle syndrome (abst)..... 176
inhibits
potassium secretion in cortical collecting tubule and is influenced by mineralocorticoid status (abst) ... 270
sodium, potassium-ATPase of rabbit proximal tubule (abst) 267
uptake into rabbit renal epithelial cells (abst) 264
Aminophylline
suppressor factor in plasma of *a.*-treated renal transplanted patients (abst) 557
Ammonia
metabolism, in renal disease (abst) 233
production
by individual segments of rat nephron (abst)..... 232
modulated by prostaglandins (abst)..... 233
transport by turtle bladder (abst)..... 223
Ammonium
enhanced urinary *a.* excretion with L-DOPA (abst) ... 240
production, affected by acute metabolic acidosis in proximal tubule (abst)..... 239
Amyloidosis
complication in long-term renal failure (abst) 152
Analgesic nephropathy
effects on renal transplantation..... S14-24
focal segmental glomerulosclerosis in (abst) 900
Anemia
effects of CAPD on *a.* of endstage renal disease 744
effects of CAPD on *a.* of endstage renal disease (abst) 779
hemolytic, chloramine-induced despite carbon filtration (abst) 151
microcytic, secondary to intraperitoneal aluminum in rat (abst) 152
Anephric
hormonal responses to acute volume changes in *a.* subjects 71
Angiographic technique
in renal vein thrombosis..... 368
Angiotensin I
intrarenal conversion to *a.* II at normal and reduced renal blood flow in anesthetized dog (abst)..... 283
Angiotensin II
altered glomerular *a.* II receptor modulation in untreated diabetic rats (abst)..... 272
difference in *a.* II binding sites in rat renal tubular basolateral and brushborder membranes (abst)..... 275
effects on
prazosin (abst) 904
vas afferens and efferens of glomerulus 794
modulates mesangial afferent and efferent limb (abst) . 184
renal function changes induced by *a.* II in mesangial deposition of ferritin (abst) 189
renal vascular response to *a.* II in rats with streptozotocin-induced diabetes mellitus (abst)..... 247
role in regulation of papillary plasma flow and sodium excretion (abst) 243
stimulates prostaglandin production by isolated human glomeruli (abst) 285
Angiotensin converting enzyme inhibitor
CGS 13945 in normal volunteers (abst)..... 901
Anion exchange inhibitors
effects on urate transport in rat proximal tubule 832
Anion handling
by choroid plexus in renal insufficiency 387
Antibodies
B lymphocyte *a.* associated with successful renal transplantation and pregnancy (abst) 551
Antibody binding
in experimental nephrotoxic nephritis injury (abst) 431
Antigens
bovine tubular basement membrane used to develop tubuloiterstitial nephritis 448
effects of planted glomerular *a.* on proteinuria..... 807
endothelial *a.* in rejection of MHC-identical renal allografts (abst)..... 778
multivalent, essential for in situ subepithelial glomerular immune deposit formation (abst) 178
proximal tubule brushborder *a.* characterized by monoclonal antibodies (abst)..... 187
three lymphocyte function-associated *a.* (LFA-l,2,3) (abst) 291
Antigen charge
effects on
immune complex binding to cultured glomerular epithelial cells (abst)..... 185
isoelectric point and biologic properties of preformed immune complexes (abst) 191
Antiglomerular basement membrane
antibody, in different forms of glomerulonephritis 855
antibody disease, therapy of (abst) 196
Antilymphocyte globulin
in renal transplantation..... S14-74

Antithyroid drugs
inhibit prostaglandin production and renal cooxidative drug metabolism (abst) ... 287
Arachidonate metabolism
via lipoxygenase in human and murine glomeruli (abst) ... 284
Arachidonic acid
in vivo platelet activation with in vitro hyperaggregability to *a. a.* in renal allograft recipients ... 506
Arginine vasopressin
role in support of blood pressure in potassium deficient conscious rats (abst) ... 281
Arteriolar resistance
afferent and efferent, mechanism that provides concomitant changes in (abst) ... 246
Arterioles
afferent and efferent *a.* of the rabbit (abst) ... 244
Arteriosclerosis
caused by dialysis (abst) ... 548
Artifacts
in compensatory renal growth ... 611
Artifical Kidney Chronic Uremia Program
1972 workshop on evaluation of dialysis therapy ... S13-8
Atrial natriuretic substance
site of (abst) ... 285
Assay systems
primary human kidney culture *a. s.* used in cancer patient sera ... 632
Auto-infusion
manual, used to correct functional hepato-renal failure and ascites (abst) ... 136
Autonomic nervous system
affected by CAPD ... 46
Azotemia
in chronic glomerulonephritis (abst) ... 555
nonoliguric prerenal *a.* (abst) ... 127

Barium
effects on cell volume regulation in hypotonic medium (abst) ... 270
Berger glomerulonephritis
IgA subclasses in (abst) ... 658
Beta blockade
and potassium secretion in isolated perfused rat kidney (abst) ... 258
Beta-cell, artificial
used to study hemodialysis effects on insulin requirements in uremic diabetic patients (abst) ... 561
Bicarbonate
influence on salicylate reabsorption (abst) ... 903
Bicarbonate ion
exit across basolateral membrane of rabbit proximal convoluted tubules (abst) ... 238
Bicarbonate reabsorption
effects of acute respiratory alkalosis on proximal *b. r.* (abst) ... 231
Bicarbonate transport
in juxtamedullary proximal convoluted tubules (abst) . 238
passive and active components of proximal tubular *b. t.* (abst) ... 230
Blood kinin secretion
in response to reduced renal perfusion in dog (abst) ... 274
Blood pressure
in dehydrated rats (abst) ... 900
Blood transfusions
effects on
cadaver transplants (abst) ... 429
lymphocyte reactivity in humans (abst) ... 550
for renal transplantation ... S14-20
BUN
influence on osmotic-vasopressin relationships in dogs (abst) ... 283
Bone and mineral metabolism
affected by dialysis prescription ... S13-73
Bordetella pertussis
in experimental uremia ... 312
Bradykinin
increases prostaglandin E_2 production in hydronephrotic kidney ... 458
unaffected by renal angiotensin converting enzyme (abst) ... 273
2-Bromoethylamine hydrobromide
used to induce papillary necrosis ... 705
Brushborder membranes
proximal tubular *b. m.*, adaptive response in remnant kidney (abst) ... 213
radiation inactivation of *b. m.* transport functions (abst) ... 262

C3 convertase
associated with glomerulonephritis ... 749
Cadaver kidneys
in renal transplantation ... S14-10
Cadaveric retransplantation
graft survival rate in ... S14-60
Calcitonin
effects on renal concentrating mechanism (abst) ... 253
Calcitriol
in prophylaxis of bone disease in dialysis patients (abst) ... 145
Calcium
absorption by proximal tubule (abst) ... 95
and lanthanum effects on PAH transport by isolated, perfused snake renal tubules (abst) ... 253
and renal phosphate handling and parathyroid activity in pregnancy (abst) ... 660
dependence of hemodynamic and naturiuretic effects of atrial extract in isolated perfused rat kidney (abst) ... 251
disorders of renal *c.* excretion ... 665
effects on
gentamicin and renal membranes in gentamicin nephrotoxicity (abst) ... 204
idiopathic urolithiasis (abst) ... 901
renal compensatory hypertrophy (abst) ... 902
exchange in control of cytosolic free calcium in proximal renal tubules (abst) ... 263
influence on phosphate transport in nephron proximal convoluted and straight tubule segments (abst) ... 110
ionophore A23187 effects on fluid and phosphate reabsorption in proximal convoluted tubules (abst) ... 106
mechanism of intestinal absorption of *c.* (abst) ... 96
metabolism affected by acetazolamide in nephrotic syndrome (abst) ... 659
mobilized by metabolic acidosis (abst) ... 106
reabsorption, distal tubular, in renal hypercalciuria and primary hypoparathyroidism (abst) ... 657
renal handling by spontaneous hypertension (abst) ... 112
role in regulation of intracellular volume of isolated proximal S_2 renal tubules in hypotonic medium (abst) ... 255

role of extracellular *c.* in vanadate-induced vasoconstriction in dog (abst) 274
transport by renal cortical mitochondria (abst) 202
Calcium-ATPase
characterized in parathyroid cell membranes (abst) 107
Calcium influx blockers
effects on renal function, hemodynamics, and response to angiotensin II (abst) 246
Calcium oxalate
adherence of *c. o.* crystals to rat uroepithelium (abst) 112
nucleation of *c. o.* affected by urinary macromolecule inhibitors 838
variations of urinary *c. o.* and brushite saturation (abst) 115
Calcium regulating hormones
effects on renal compensatory hypertrophy (abst) 902
Calcium urolithiasis
treated with thiazides (abst) 119
Cancer
renotropic growth factor in *c.* patient sera 632
Captopril
treatment in bilateral renal-artery stenoses and renal-artery stenosis with "solitary" kidney (abst) 121
Carbon dioxide
concentration, comparison of deep loop of Henle and vasa recta total *c. d. c.* (abst) 231
production
in early proximal tubule of Munich-Wistar rat (abst) 236
role of *c. d. p.* and diffusive gas transfer in elevated renal cortical P_{CO_2} (abst) 229
reabsorption,
in distal convoluted tubule (abst) 235
Carbonic anhydrase inhibitor
effects of dextran-bound and unbound *c. a. i.* on proximal tubule acidification (abst) 236
effects on basolateral HCO_3 transport in salamander proximal tubules (abst) 230
Cardiac and hemodynamic correlates
of different hemodialysis regimes in National Cooperative Dialysis Study S13-89
Cardiac function
in hemofiltration and hemodynamics (abst) 562
Carnitine
loss during hemodialysis and hemofiltration (abst) 563
L-carnitine
endocrine-metabolic effects of *L.-c.* during dialysis (abst) 563
Catecholamines
effects on water absorption in rabbit cortical collecting tubule (abst) 261
Catheter tunnel infection
in CAPD (abst) 903
Cefoperazone
treatment for peritonitis in CAPD (abst) 903
Cell types
in culture 439
Cell volume
and ion transport, relationship in diluting segment of Amphiuma kidney (abst) 256
Ceftizoxime
treatment in CAPD (abst) 148
Cerebrospinal fluid
c. f. changes induced by dialysis (abst) 660
CGS 13945
a new angiotensin converting enzyme inhibitor (abst) . 901
Chalones
in compensatory renal growth 603
Chemiluminescence
NADPH-induced *c.* and lipid peroxidation in kidney microsomes 691
Chloride
and parathyroidectomy effects on Na^+-H^+ exchange in isolated renal brushborder membrane vesicles (abst) 212
renal, in adrenalectomized rat (abst) 254
c. dependence of medullary collecting duct acidification (abst) 239
transport
in rabbit renal microvillus membrane vesicles (abst) 266
Chloriuresis
in medullary collecting duct function in rat 711
Chlorpropamide
effects on
cyclic AMP metabolism in medullary tubules (abst) . 250
urinary concentrating system (abst) 261
Chlorthalidone
as diuretic therapy in essential hypertension 320
Choroid plexus
effects on anions in renal insufficiency 387
Chromatography
high performance liquid *c.* used to separate middle molecules 764
Cimetidine
effects on secondary hyperparathyroidism (abst) 99
Cirrhosis
dissociation of renin from prostaglandins in *c.* (abst) .. 277
of liver, disturbed volume homeostasis in 303
Citrate metabolism
homeostatic role in furosemide-induced metabolic alkalosis in rat (abst) 234
Clearances
in polycystic kidney disease 526
Clinical studies
correlated with graft biopsy in renal transplantation S14-41
Clonidine
effects on acute renal failure (abst) 203
Coformycin
effects on adenosine deaminase in compensatory renal growth 588
Colchicine
treatment in diabetic glomerulosclerosis (abst) 138
Collecting ducts
morphometric comparison of rabbit cortical collecting tubules and *c. d.* 358
Complement
activation of *c.* and factor VIII abnormalities in hemolytic-uremic syndrome in childhood (abst) 659
associated with glomerulonephritis 749
C3bi receptor with monoclonal antibodies, identification of in humans (abst) 178
depletion, in acceleration of clearance of immune complexes from circulation of primates (abst) 183
Connecting tubules
morphometric comparison of rabbit cortical *c. t.* and collecting ducts 358
Converting enzyme inhibitor (CEI)
effects of MK 421 CEI on ischemic acute renal failure (abst) 902

in Goldblatt hypertensive rats 816
Corticosteroid
in renal transplantation S14-85
Cortisol
response of plasma aldosterone and *c.* concentration to acute volume depletion 71
Cuprophan membrane
compared to polycrylonitryl *m.* in hemodialysis 738
Cyclic AMP
effects on hydrogen ion secretion and sodium transport in turtle bladder (abst) 234
inhibition of renal brushborder phosphate transport and stimulation of renal gluconeogenesis by (abst) 109
response
in spontaneous hypertension (abst) 106
induced by parathyroid hormone in vascular smooth muscle cells (abst) 113
Cyclosporine
in renal transplantation S14-60
Cyclosporin A
effects on liver function and renal tissue in kidney transplant recipients (abst) 292
in renal transplantation S14-4
Cystic disease
DPT-induced, reversible cellular and tubular basement membrane changes (abst) 184
effects on renal transplantation S14-24
Cystic metanephric development
in serum-free organ culture (abst) 179
Cystine calculi
studied with x-ray diffraction and scanning electronmicroscopy (abst) 124
Cystinosis
survival time in (abst) 555
Cystinuria
anticystinuric effect of glutamine and of low sodium diet in (abst) 126
effects of cystine on (abst) 120
Cytomegalovirus infection
associated with acute rejection in renal transplantation S14-41, 46
renal changes in (abst) 558
serological status of *c.* and renal transplantation outcome S14-50
Cytotoxic antibodies
in renal transplantation S14-20
Cytotoxicity
natural killing and antibody dependent cell-medicated *c.* in uremia (abst) 199

Dark cells
role in transport of H^+/HCO_3 and K^+ ions in rat submaxillary duct 350
Data management
analysis and methods of *d. m.* in National Cooperative Dialysis Study S13-26
Dedication
of compensatory renal growth symposium to Eduardo Braun Menendez 569
Dehydration
blood pressure in (abst) 900
DNA
role in renotrophic factors in urine 616
Desferrioxamine
and low aluminum water on dialysis encephalopathy (abst) 430
treatment in fracturing renal osteodystrophy (abst) 552
Dexamethasone
effects on renal potassium excretion and potassium tolerance (abst) 286
Diabetes
alteration of transport properties in isolated renal brushborder membranes of *d.* rats (abst) 227
as risk factor in erythrocytosis 731
cadaveric renal transplantation after total lymphoid irradiation in S14-69
CAPD in 40-month experience in insulin-dependent *d.* patients 40
early experimental, glomerular hypertrophy in (abst) . 221
effects of CAPD on autonomic nervous system of *d.* patients 46
experimental, altered renal brushborder membrane alanine transport in (abst) 265
increased resources for renal transplants (abst) 289
influence of strict control of *d.* on intrarenal hemodynamics (abst) 215
(^{125}I) insulin absorption in intraperitoneal dialysis and CAPD in *d.* 22
interstitial nephritis as risk factor for acute renal failure in (abst) 117
protection to *d.* rats against gentamicin-induced acute renal failure (abst) 208
renal effect of radiographic contrast media in old dehydrated *d.* rats (abst) 208
renal transplantation in S14-10
spontaneous, hyporesponsive renin secretion in *s. d.* rat (abst) 276
streptozotocin-induced, effects on gentamicin nephrotoxicity (abst) 203
Diabetes insipidus
function of ADH-induced thick ascending limb hypertrophy in (abst) 249
Diabetes mellitus
experimental, renal hypertrophy in 643
improving prognosis of renal-retinal syndrome in (abst) 427
isolated nephron segments in rabbit model of (abst) ... 202
type I, effects of continuous subcutaneous insulin on renal function in (abst) 779
type II, clinicopathologic study of renal involvement in (abst) 121
Diabetic nephropathy
clinical imperatives in S14-16
Dialysate
compositions
effects of different *d. c.* compared in hypoxemia in hemodialysis 738
concentration
effects on protein in *d. c.* during peritoneal dialysis. 35
formulae
four combinations of *d. f.* (abst) 161
new possibilities from mixtures of succinate and acetate (abst) 153
Dialysis (*also see* Hemodialysis)
acetate and bicarbonate
comparative EEG investigation during (abst) 565
respiratory response of (abst) 564

acetate and hypotension in (abst) 564
aluminum intoxication in *d.* in renal failure (abst) 141
bicarbonate *d.*, side effects in *b. d.* due to low dialysate pH (abst) 565
colloid osmotic pressure in *d.* compared to isolated ultrafiltration (abst) 154
control of *d.* by single-pool urea model S13-19
effects of
  increasing dialysate sodium with sodium bicarbonate in (abst) 158
  regular *d.* and isolated ultrafiltration on colloid osmotic pressure and plasma refilling rate (abst) 158
effects on
  bone and mineral metabolism S13-73
  electrolyte and acid-base metabolism S13-66
  hematopoietic system S13-95
evaluated in 1972 by Artificial Kidney Chronic Uremia Program S13-8
free amino acid loss during *d.* (abst) 157
hematoliquoral changes induced by (abst) 660
hemodialysis
  ambulatory chronic *h.* in elderly (abst) 144
  bicarbonate *h.*, potassium and phosphate removal with (abst) 141
  blood pressure response to changes in serum calcium during *h.* (abst) 156
  blood viscosity, systemic vascular resistance and blood pressure changes during (abst) 165
  bone and serum aluminum removal in (abst) 431
  bone mineral content in *h.* diabetic patients (abst) ... 98
  changes in platelet numbers, β-thromboglobulin, and factor VIII antigen during *h.* (abst) 160
  chronic
    erythrocyte sedimentation rate determination in (abst) 161
    psychosocial aspects of *c. h.* in National Cooperative Dialysis Study S13-50
    unexplained red blood cell microcytosis in (abst) . 164
  clearance of metronidazole in (abst) 153
  compared to CAPD 51
  cooled dialysate in (abst) 155
  copper removal by *h.* with penicillamine (abst) 156
  drug clearances in (abst) 152
  effects of
    calcium infusion on vascular stability during (abst) 160
    dialysate acetate oxidation on energy metabolism in 57
  eosinophilia and suppressive T-cell function in (abst) 163
  fall in PaO_2 with exercise in (abst) 148
  gas exchange during (abst) 430
  hemodynamic and cardiac correlates of different *h.* regimes in National Cooperative Dialysis Study S13-89
  hormonal response to acute volume changes in anephric subjects on *h.* 71
  hypoxemia during *h.* 738
  in interstitial fibrosis (abst) 900
  inverse correlation between mean arterial blood pressure and serum angiotensin converting enzyme levels in (abst) 175
  ionized calcium and bicarbonate on left ventricular contractibility in (abst) 150
  listerosis in *h.* treated with vancomycin (abst) 162
  myocardial performance in (abst) 146
  non-A non-B hepatitis in large *h.* population (abst) . 162
  occupational therapy crafts program for *h.* patients (abst) 159
  potassium removal during (abst) 164
  regional citrate anticoagulation for active bleeding in (abst) 147
  side effects of bicarbonate versus acetate in *h.* (abst) 150
  simultaneous with plasmapheresis (abst) 160
  sodium bath in diabetic patients on (abst) 154
  subclavian vein stenosis as complication of catheterization in *h.* (abst) 162
  3-year study of antibiotic prophylaxis for *Staphylococcus aureus* colonization/infection in (abst) 149
  trace elements in intermittent peritoneal dialysis, *h.*, and uremia 9
  24-hr blood pressure monitoring in hypertension in (abst) 153
  use in cyanide intoxication (abst) 165
  use of Doppler ultrasonic detection in (abst) 142
  variations in dialysate sodium (abst) 158
  vascular and soft tissue calcifications in (abst) 158
hemoglobin concentration and renal cyst formation in (abst) 564
hyperalimentation
  analysis of morbidity of *d. h.* (abst) 142
membranes
  comparison of platelet activation by polyacrylonitrile and cuprophan (abst) 155
  effects of polyacrylonitrile and cuprophan *d. m.* on white blood cell and complement component activation (abst) 154
modeling success or failure of *d.* therapy in National Cooperative Dialysis Study S13-101
peritoneal 903
  bicarbonate-containing dialysate produced by an on-line method in (abst) 151
  blood eosinophilia in maintenance *p. d.* (abst) 151
  changes in peritoneal morphology and transport properties with infectious peritonitis versus mesothelial drying (abst) 163
  chronic ambulatory *p. d.*
    and peritonitis, rabbit model of (abst) 143
    change to and short-term survival (abst) 151
    procainamide in (abst) 161
  chronic intermittent *p. d.*
    early detection of peritonitis in (abst) 148
  complications with temporary catheter in (abst) 154
  continuous ambulatory *p. d.* (CAPD)
    abdominal hernias in (abst) 146
    adaptation to continuous peritoneal energy uptake and cellular immunity (abst) 29, 549
    and intraperitoneal dialysis, (^{125}I) insulin absorption during 22
    compared to home hemodialysis 51, 428
    complications of *CAPD* requiring surgery (abst) .. 903
    determined as "adequate" (abst) 156
    double-bag system in Zurich (abst) 899
    effects on
      anemia of endstage renal disease 744
      anemia of endstage renal disease (abst) 779
      autonomic nervous system 46
      renal osteodystrophy over 1-year study (abst) .. 157

40-month experience in insulin-dependent diabetic patients ... 40
fungal peritonitis in (abst) ... 152
high volume, low frequency *CAPD* ... 64
high volume, low frequency *CAPD* (abst) ... 163
histological renal osteodystrophy, 25 hydroxycholecalciferol, and aluminum levels ... 15
in Australia, Europe, and USA: 1981-1983 ... 3
in diabetes mellitus (abst) ... 156
inter-racial study of *CAPD* in South Africa (abst) 433
introduction to symposium on ... 2
microbiologic aspects of *CAPD*, forum on ... 83
peritonitis in (abst) ... 147
peritonitis in *CAPD* in Johannesburg Hospital (abst) ... 429
quality of patient life in (abst) ... 143
role of lactate in (abst) ... 429
spouse acceptance and attitudes toward *CAPD* patients (abst) ... 161
sterile connection device in (abst) ... 149
3-year study of experience at a university center (abst) ... 163
thyroid function in (abst) ... 164
trace elements in patients on (abst) ... 146
treatment for insulin-dependent diabetic patients (abst) ... 553
treatment for peritonitis in (abst) ... 903
upright posture and exercise lower peritoneal transport rates in (abst) ... 165
influence of solution composition on protein loss during *p. d.* ... 35
intermittent *p. d.*
trace elements in *i. p. d.*, hemodialysis, and uremia ... 9
and *CAPD*, (^{125}I)insulin absorption during ... 22
with polymer solution (abst) ... 159
predicative results of *d.* in uremic pericarditis by discriminant analysis (abst) ... 120
principles of *d.* therapy from National Cooperative Dialysis Study ... S13-113
renal artery stenosis in ... S14-54
review of methodology for dialysis prescription to mid-1970's ... S13-8
serum aluminum in (abst) ... 150
serum levels of bone GLA-protein predict bone histology in (abst) ... 105
sleep apnea in *d.* patients with diabetes mellitus (abst) 130
supplement on National Cooperative Dialysis Study . S13-1
time on *d.* affected by hemodiafiltration (abst) ... 904
transferrin blood level as indicator of protein malnutrition in (abst) ... 123
tubing, macrophage activation by particles released from (abst) ... 143
vibration sensory threshold used in (abst) ... 560
zirconium phosphate and zeolite as sorbent compared in (abst) ... 144

Dialysis encephalopathy
affected by low aluminum water and desferrioxamine (abst) ... 430
approach to evaluate *d. e.* syndrome (abst) ... 660

Dialysis osteomalacia
parathyroid gland responsiveness to acute hypocalcemia in ... 725

Dialyzers
anaphylation formation during cuprophane *d.* re-use (abst) ... 144
cuprophane capillary, severe reactions to (abst) ... 157
effects of *d.* membranes on blood gases and white blood cell count (abst) ... 145
membrane and design, effects on β-thromboglobulin during hemodialysis (abst) ... 145
model to study cardiopulmonary effects of blood-*d.* interactions (abst) ... 164

Dietary sulphur amino acid intake
fasting blunts renal adaptation to (abst) ... 252

Digoxin toxicity
course of XAD-4 resin hemoperfusion in renal failure and *d. t.* ... 79

Diphenylhydantoin
effects on renal renin release (abst) ... 276

Disequilibrium syndrome
computer modeling of hemodialysis/ultrafiltration used to explain pathogenesis of (abst) ... 565

Distal tubular calcium reabsorption
in renal hypercalciuria and primary hypoparathyroidism (abst) ... 657

Diuresis
alcohol-induced, water *d.* (abst) ... 257
osmotic, after radio contrast agents (abst) ... 125

Diuretics
chlorthalidone in essential hypertension ... 320
therapy in congestive heart failure (abst) ... 138
used to alter urinary calcium excretion ... 665
used to assess renal distal tubule pathways for sodium, chloride, and potassium (abst) ... 269

Dopamine
agonists, effects on spontaneous focal glomerular sclerosis in aging rats (abst) ... 180
endogenous *d.* activity in chronic heart failure (abst) . 243
in essential hypertension ... *870*
tyrosine-stimulated, uneffective to urinary aldosterone and sodium in normal weight and obese women (abst) ... 279

Dopamine$_1$ receptors
renal role in salt loading (abst) ... 280

DR-matching
role in predicting renal allograft outcome ... S14-34

Dysplasia, fibrous
renal, splenic, and coeliac arterial lesions in (abst) ... 118

Dyscrasia, plasma cell
manifested by k-IgA nephropathy (abst) ... 123
polymorphic ultrastructural renal findings in (abst) ... 115

Echo-Doppler flowmetry
used for noninvasive diagnosis of renal vein thrombosis 882

Echothomography
in arterio-venous fistulas (abst) ... 559

Elderly
renal transplantation in (abst) ... 430
hypertension in, forum on ... 540

Electrical resistances
of rabbit proximal convoluted tubule perfused in vitro (abst) ... 261

Electroencephalogram
used in National Cooperative Dialysis Study ... S13-58

Electrolyte and acid-base metabolism influenced by dialysis prescription ... S13-66

Electron microscopy
in morphometric comparison of rabbit cortical connecting tubules and collecting ducts ... 358

Electrophysiological response
and neurobehavioral *r.* in dialysis ... S13-58

Encephalins
in human pheochromocytoma (abst) ... 174

Endocarditis
acute infective, renal problems in children with (abst) 434

infective, value of renal biopsy in (abst) 434
Endocytosis
role in hydrogen ion secretion regulation by turtle bladder (abst) 237
Enzyme-linked immunosorbent assay (ELISA)
used to detect cytomegalovirus antibodies S14-50
used to study antibody specificity in different forms of glomerulonephritis 855
Epithelial cell line
cation fluxes and growth regulation in (abst) 265
Epithelial polyanionic coat
and foot processes in nephrotic syndrome (abst) 657
Epithelial transport
in nonuremic polycystic kidney disease 514
Erythrocytes
aggregation of *e.* in nephrotic syndrome 519
effect of salt intake on Na^+, K^+-ATPase activity and cation transport in (abst) 175
e. Na^+ and K^+ transport systems in children with Bartter syndrome 530
normal and rigid, effects on isolated perfused rat kidney (abst) 241
urea movement across *e.* membrane during hemodialysis 866
Erythrocytosis
in renal transplantation (abst) 290
review of 53 patients with post-renal transplant *e.* 731
Escherichia coli
in uremia 312
phagocytosis of *E. c.* by renal tubular epithelia of rats (abst) 189
Ethics
discussion on *e.* in renal transplantation S14-90

Fabry disease
associated with renal transplantation S14-10
Factor VIII
and complement abnormalities in hemolytic-uremic syndrome in childhood (abst) 659
Fat deposits
in nephrons of starved rodents (abst) 903
Ferritin
disposal of *f.* in glomerular mesangium 480
Fibrinogen
red blood cell aggregation induced by 519
Fibrinolysis
blocked by renal vein thrombosis plasma (abst) 196
Filtration fraction
used as indicator in active proliferative lupus nephritis (abst) 779
Flow cytometry analysis
role in improving graft survival (abst) 289
Foot processes
and epithelial polyanionic coat in nephrotic syndrome (abst) 657
Forum on
acute renal failure and rhabdomyolysis 888
hemodynamically mediated glomerular injury and progressive nature of kidney disease 647
hypertension in elderly 540
kidney and magnesium regulation 771
microbiological aspects of CAPD 83
pathophysiology of obstructive nephropathy 414
Furosemide
affected by increased urine flow and aldosterone (abst) 128
and bumetanide, effects on auditory and vestibular function in normal volunteers (abst) 135
effects on
urinary calcium excretion and total body calcium (abst) 139
in toxic papillary necrosis 705
oral, clinical assessment of urinary acidification made with (abst) 137
stimulates urinary acidification in distal renal tubular acidosis (abst) 132

Gardnerella vaginalis
in urinary tract disease 862
Gas exchange
during hemodialysis (abst) 430
Gentamicin
effects on
subcellular distribution of alterations in renal cortex acidic phospholipid content (abst) 205
vasopressin-stimulated water flow (abst) 264
not localized to lysosomes in renal tubular cells (abst) 206
Genetic study
of PHA- and MLC-response in rat (abst) 901
Glandular kallikrein
antigen similar to *g. k.* in plasma increased in dialysis patients (abst) 280
effects of acute and chronic intrarenal infusion on (abst) 279
Glomerular angiotensin II receptors
affected by *a.* II infusion (abst) 277
Glomerular antigen
characterized by use of hybridoma-derived antibodies (abst) 189
Glomerular basement membrane
affected by neutral proteinase activity 342
size and charge selective permeability defects induced by a polycation in (abst) 179
Glomerular capillary wall
effects on antigens in Heymann nephritis (abst) 778
Glomerular cells
in culture 439
Glomerular contractility
new in vitro method to measure *g. c.* (abst) 248
Glomerular crescents
and renal dysfunction, correlated with macroscopic hematuria in mesangial IgA nephropathy 393
Glomerular diseases
renin-containing cells in renal vascular and *g. d.* 375
Glomerular hemodynamics
effects of methoxamine and isoproterenol on (abst) 247
Glomerular immune complex
localization, mechanism of (abst) 180
Glomerular injury
hemodynamically mediated, and progressive nature of kidney disease, forum on 647
Glomerular mesangial cells
disposal of ferritin in 480
neutral proteinase activity produced by 342
reactive oxygen production during phagocytosis in (abst) 178
Glomerular PGE receptors
in rats (abst) 276
Glomerular response
to severe congestive heart failure in rat (abst) 245
Glomerular ultrafiltration coefficient
in human renal disease (abst) 248

Glomerulonephritis
acute
as cause of acute renal failure in angioimmunoblastic lymphadenopathy (abst) ... 126
antiglomerular basement membrane antibody in different forms of ... 855
cellular composition of crescents in human rapidly progressive *g.* (abst) ... 183
chronic
morphologic functional tubular changes in (abst) ... 558
reduced prostacyclin production associated with cyclooxygenase-dependent renal function in (abst) ... 282
effects of steroids on leucocyte-mediated *g.* in rabbit (abst) ... 183
endostreptosin antibody determinations in diagnosis of *g.* (abst) ... 197
experimental immune complex
effects of human and rabbit rheumatoid factors on (abst) ... 190
extracapillary
role of monocytes in (abst) ... 658
filtration dynamics and barrier dysfunction in (abst) ... 214
focal segmental
in analgesic nephropathy (abst) ... 900
glomerular culture outgrowth in *g.* analyzed (abst) ... 431
glomerular deposits of rheumatoid factor in (abst) ... 559
Henoch-Schönlein
IgA subclasses in (abst) ... 658
hereditary
of non-Alport type in three families (abst) ... 555
human idiopathic crescentic, mononuclear cell subsets in (abst) ... 198
idiopathic, arteriolar pathology in (abst) ... 659
idiopathic membranous, monoclonal antibody-defined T cell subsets in *i. m. g.* (abst) ... 198
immune complex
cationic extracellular strepococcal antigens in (abst) 190
in Charcot-Marie-Tooth disease (abst) ... 141
mediator systems in in situ *i. c. g.* (abst) ... 199
IgM-associated mesangial proliferative
in progression to focal and segmental hyalinosis (abst) ... 899
inherited defect of C3 convertase, C3b,Bb, associated with g ... 749
membranoproliferative
treated with
isoniazid (abst) ... 435
platelet inhibitor drugs (abst) ... 121
type I *m. g.*, defective T-suppressor activity in (abst) 657
membranous
human *m.*, immunogenetics and immunopathology of (abst) ... 553
prognostic factors of *m. g.* in systemic lupus erythematosus (abst) ... 197
mesangial IgA
clinical features of (abst) ... 554
minimal change
g. and focal glomerulosclerosis, peripheral mononuclear cells in (abst) ... 558
poststreptococcal
and nephrotic syndrome in Zimbabwe (abst) ... 434
in Trinidad (abst) ... 132
primary and secondary
T-lymphocyte subsets in (abst) ... 553
rapidly progressive crescentic
treated with pulse methyl prednisolone or plasma exchange (abst) ... 554
sclerosing
associated with Wilms tumor (abst) ... 194
segmental necrotizing
pathological features and clinical significance of (abst) ... 199
severe
plasma exchange in (abst) ... 554
Glomerulopathy
idiopathic membranous and nephrotic syndrome, renal vein thrombosis in ... 368
Glomerulosclerosis
familial focal segmental
in hispanic families (abst) ... 137
focal
study of glomerular size related to *f. g.* (abst) ... 192
Glomerulus
filtration rate
affected by
diet (abst) ... 118
7.7 years of lithium therapy (abst) ... 139
comparison of methods of GFR measurement in children after kidney transplantation ... 410
determinants of diminished GFR in early cisplatin-induced renal failure (abst) ... 210
glucocorticoids and mineralocorticoids in potassium adaptation after decreased GFR (abst) ... 211
in renal and extrarenal potassium adaptation in old rats ... 684
inulin as marker for *g. f.* in preterm babies ... 407
methods used to assess GFR in Johannesburg Hospital (abst) ... 433
Glucocorticoids
effects on
electrolyte transport (abst) ... 279
Glucocorticoid receptors
distinction of cation transport from metabolic receptor (abst) ... 273
Gluconeogenesis
interaction with sodium transport in proximal tubule (abst) ... 223
Glucose absorption
during intraperitoneal dialysis and CAPD ... 22
D-glucose
effects of continuous uptake of *D-g.* on metabolism 29
Glucose metabolism
increased splanchnic production of *g.* in chronic renal insufficiency (abst) ... 660
role of apical glucose transport to (abst) ... 226
Glucose uptake
by rat renal brushborder membrane vesicles (abst) ... 182
Glutamate transport
in rat kidney mitochondria (abst) ... 226
Goodpasture syndrome
plasmapheresis in *G. s.* and systemic lupus erythematosus (abst) ... 433
Graft, allogenic
development of metanephros in (abst) ... 902
Graft biopsy
in renal transplantation ... S14-41
Guanyl nucleotides
regulators of rat renal cortical prostaglandin E receptors (abst) ... 273

Hemagglutination assay
used to detect cytomegalovirus antibodies ... S14-50

Hematopoietic system
effects of dialysis therapy on ... S13-95
Hematuria
macroscopic, in mesangial IgA nephropathy ... 393
microscopic, urinary erythrocyte morphology in (abst) 122
primary, isolated C3 in "vascular pole" in (abst) ... 559
Hemodiafiltration
effects on dialysis (abst) ... 904
study of ultrashort *h.* (abst) ... 549
Hemodialysis
acute 25-hydroxyvitamin D_3 therapy in ... 401
β-adrenergic receptors in platelets of patients on *h.* (abst) ... 562
ambulatory chronic *h.* in elderly (abst) ... 144
and peritoneal dialysis, integrated program of (abst) ... 549
autogenous saphenous vein AV fistulas in (abst) ... 559
bicarbonate *h.*, potassium and phosphate removal with (abst) ... 141
blood pressure response to changes in serum calcium during *h.* (abst) ... 156
blood viscosity, systemic vascular resistance and blood pressure changes during (abst) ... 165
bone and serum aluminum removal in (abst) ... 431
bone mineral content in *h.* diabetic patients (abst) ... 98
changes in platelet numbers, β-thromboglobulin, and factor VIII antigen during *h.* (abst) ... 160
chronic
affected by control of arterial hypertension (abst) ... 549
erythrocyte sedimentation rate determination in (abst) ... 161
psychosocial aspects of *c. h.* ... S13-50
unexplained red blood cell microcytosis in (abst) ... 164
clearance of metronidazole in (abst) ... 153
compared to CAPD ... 46
compared to CAPD (abst) ... 549
control of hyperparathyroidism, hyperphosphatemia, and hyperaluminemia in (abst) ... 561
cooled dialysate in (abst) ... 155
copper removal by *h.* with pencillamine (abst) ... 156
drug clearances in (abst) ... 152
effects of
calcium infusion on vascular stability during (abst) ... 160
dialysate acetate oxidation on energy metabolism in *h.* ... 57
eosinophila and suppressive T-cell function in (abst) ... 163
fall in PaO_2 with exercise in (abst) ... 148
gas exchange during (abst) ... 430
hemodynamic and cardiac correlates of different *h.* regimes ... S13-89
home *h.* compared with CAPD (abst) ... 428
hormonal response to acute volume changes in anephric subjects on *h* ... 71
hypoxemia during *h.* ... 738
inverse correlation between mean arterial blood pressure and serum angiotensin converting enzyme in (abst) ... 175
ionized calcium and bicarbonate on left ventricular contractility in (abst) ... 150
leucopenia, hypoxemia, and complement activation in (abst) ... 548
listerosis in *h.* treated with vancomycin (abst) ... 162
myocardial performance in (abst) ... 146
non-A non-B hepatitis in large *h.* population (abst) ... 162
nonthrombotic complications of PTFE grafts for (abst) ... 559
occupational therapy crafts program for *h.* patients (abst) ... 159
1,25 dihydroxycholecalciferol used to prevent bone disease in (abst) ... 563
pharmacokinetics and protein binding of prednisolone in ... 876
potassium removal during (abst) ... 164
refractile particles in liver of *h.* patients (abst) ... 560
regional citrate anticoagulation for active bleeding in (abst) ... 147
results of exercise training in (abst) ... 214
side effects of bicarbonate versus acetate in *h.* (abst) ... 150
simultaneous with plasmapheresis (abst) ... 160
sodium bath in diabetic patients on (abst) ... 154
subclavian vein stenosis as complication of catheterization in *h.* (abst) ... 162
3-year study of antibiotic prophylaxis for *Staphylococcus aureus* colonization/infection in (abst) ... 149
trace elements in intraperitoneal dialysis, *h.*, and uremia ... 9
24-hr blood pressure monitoring in hypertension in (abst) ... 153
urea movement across erythrocyte membrane during *h.* ... 866
use in cyanide intoxication (abst) ... 165
use of Dopple ultrasonic detection in (abst) ... 142
variations in dialysate sodium (abst) ... 158
vascular and soft tissue calcifications in (abst) ... 158
Hemodynamic and cardiac correlates
of different hemodialysis regimes ... S13-89
Hemofiltration
sorbent recycling of ultrafiltrate system in ... 536
Hemolytic-uremic syndrome
and deafness induced by potassium bromate (abst) ... 125
complement activation and factor VIII abnormalities in *h.-u. s.* in childhood (abst) ... 659
development of animal model of (abst) ... 190
platelet aggregation in (abst) ... 431
Hemoperfusion, charcoal
5-year application in chronic uremia (abst) ... 656
Henoch-Schönlein glomerulonephritis
IgA subclasses in (abst) ... 658
Hepatitis B virus
in dialysis center, 1982 study of (abst) ... 146
Hernias
in CAPD (abst) ... 903
High-risk patients
renal transplantation for ... S14-10
Homeostasis
albumin, during CAPD (abst) ... 153
Humoral factors
in regulation of compensatory renal growth ... 611
Hyalinosis, focal and segmental
progression of IgM-associated mesangial proliferative glomerulonephritis to (abst) ... 899
HCl-acidosis, chronic
role of secondary hypocapnia in ... 336
Hydrochlorothiazide
effects on medullary collecting duct function ... 711
H^+ATPase
characteristics of, from mammalian papilla (abst) ... 232
role in electrogenic proton translocation in turtle bladder epithelial cell plasma membrane vesicles (abst) ... 240
H^+/HCO_3
and K^+ ions, transport of related to dark cells in rat

submaxillary duct ... 350
Hydrogen ion
secretion
in rat outer medullary collecting duct (abst) ... 236
stimulated by isoproterenol and cyclic AMP in toad bladder (abst) ... 239
transport
alterations in membrane area associated with H^+ in turtle bladder (abst) ... 231
Hydronephrosis
cortical interstitial cell function in ... 458
Hydroosmosis
morphologic events in ADH-induced *h.* across rabbit cortical collecting tubule (abst) ... 259
Hyperaggregability
in vivo platelet activation with in vitro *h.* to arachidonic acid in renal allograft recipients ... 506
Hypercalcemia
acute
effects on renal HCO_3 handling in rat (abst) ... 238
affected by human cancer cells (abst) ... 107
associated with immunodeficiency (abst) ... 104
chronic
effects on renal cortical mitochondrial calcium and oxidative phosphorylation (abst) ... 104
mechanism of concentrating defect in ... 489
idiopathic
of chronic dialysis (abst) ... 560
in CAPD (abst) ... 147
Hypercalciuria
dietary phosphate and parathyroid hormone in (abst) . 103
idiopathic, acid-base disorders in (abst) ... 660
renal *h.* and primary hypoparathyroidism, distal tubular calcium reabsorption in (abst) ... 657
Hypercapnia, chronic
distal acidification and urinary P_{CO_2} during (abst) ... 229
Hyperkalemia
aldosterone ameliorable, induced by angiotensin-converting enzyme inhibition (abst) ... 131
Hyperlipidemia
in adults with nephrotic syndrome (abst) ... 116
Hyperparathyroidism
as cofactor of uremic myopathy (abst) ... 656
asymptomatic primary, effects on renal concentration and acidfication (abst) ... 99
primary, acidosis in (abst) ... 433
primary/secondary, lipid metabolism in (abst) ... 98
secondary, parathyroid ultrasonography and fine-needle aspiration biopsy in diagnosis of (abst) ... 563
Hyperplasia
in compensatory renal growth ... 599
Hypertension
acute II kidney I clip, renal catecholamines in (abst) . 173
and mesangial injury in progressive glomerular damage (abst) ... 219
angiotensin I converting enzyme activity in (abst) ... 174
bilateral atherosclerotic renovascular *h.*, reversal of renal failure in (abst) ... 176
coarctation
role of renin angiotensin system in (abst) ... 166
vascular reactivity to angiotensin II in canine neonatally induced *c. h.* (abst) ... 166
comparative cost of antihypertensive drugs (abst). ... 177
comparison of diuretic regimens in (abst) ... 175
compensatory renal growth in ... 635
diuretic-treated, combined alpha and beta blocker therapy in (abst) ... 171
DOCA-treated, effects of acute renal denervation on kidney function in (abst) ... 167
effects of
captopril on blood pressure response in (abst) ... 169
dietary sodium loading on divalent ions in (abst) ... 109
enalapril versus hydrochlorothiazide on renal function in (abst) ... 166
oral indapamide on renal function and plasma volume in (abst) ... 173
propranolol in anephric human in regard to (abst) ... 172
essential
abnormalities of cellular sodium transport in (abst) . 167
affected by chlorthalidone ... 320
calcium balance and parathyroid hormone-induced vasodilation in (abst) ... 166
cure of *e. h.* by renal transplantation in black patients (abst) ... 168
effects of heparin on (abst) ... 172
effects of parathyroidectomy on blood pressure, body fluid, and electrolyte homeostasis in (abst) . 172
greater renal vasoconstriction in black patients (abst) 169
mechanism for salutary effects of high diet calcium on blood pressure in (abst) ... 167
membrane protein content, surface area and sodium flux in red blood cells of rats with *e. h.* (abst) ... 169
possibly caused by renal dysfunction ... 870
salt intake and renin-angiotensin system related to first-dose prazosin response in (abst) ... 174
ethnic difference in red blood cell Na^+-K^+ ATPase in (abst) ... 171
identification of heptapeptide with digitalis and natriuretic hormone-like properties in (abst) ... 170
in diabetic nephropathy ... S14-16
in elderly, forum on ... 540
in long-term surviving transplant patients (abst) ... 552
plasma factors which affect sodium efflux in *h.* (abst) . 177
plasma volume in treated *h.* patients (abst) ... 177
primary
effects on renal transplantation ... S14-24
refractory, diagnostic tests in (abst) ... 901
renal
acute plasma renin response to angiotensin-converting enzyme inhibition by captopril as test for (abst) 171
and cardiovascular response to Ca^{2+} infusion at varying Na^+ intakes in *h.* humans (abst) ... 169
and systemic hemodynamics in *h.* obese- and lean-matched patients (abst) ... 175
renal humoral response to isometric exercise in (abst) 780
renovascular
diagnosis and treatment of (abst) ... 555
digital renal angiography as screening test in (abst) . 170
effects of unclipping and converting enzyme inhibition on bilateral renal function in ... 816
role
in kidney donation (abst) ... 168
of increased renal arterial pressure in (abst) ... 170
sodium-lithium countertransport and passive cation permeability abnormalities in erythrocytes of pregnant women with (abst) ... 172
spontaneous
renal handling of potassium in *s. h.* with intrinsic tubular defects (abst) ... 254
selective JM nephron hyperfiltration in *s. h.* rats with reduced renal mass (abst) ... 211
sympatholytic effect of non-CNS penetrating blocker in (abst) ... 167
thiazide-produced uric acid elevations in (abst) ... 171

United States survey of dietary calcium and human *h.* (abst) 130
urinary norepinephrine metabolites in salt-sensitive *h.* (abst) 170
Hypertonic fluid
reabsorption by rat renal proximal tubule (abst)..... 256
Hypertrophy
in compensatory renal growth 599
renal compensatory, affected by calcium and parathyroid hormone (abst)..... 101
Hypocalcemia
acute, parathyroid gland responsiveness to *a. h.* in dialysis osteomalacia..... 725
and parathyroid hormone release affected by WR2721 (abst) 110
Hypocalciuria
$24,25(OH)_2D_3$ in (abst) 108
Hypocapnia, secondary
protective effect in chronic HCl-acidosis 336
Hypocitraturia
in renal stone formers (abst)..... 139
Hypoglycemia
uremic nondiabetic, increase in number of patients with (abst) 142
Hyponatremia
cause of central pontine myelinolysis (abst) 121
clinical spectrum of (abst)..... 428
outcome in general hospital population (abst)..... 117
severe
rapid correction of *s. h.* in rats (abst)..... 117
Hypoparathyroidism
primary *h.* and hypercalciuria, distal tubular calcium reabsorption in (abst) 657
Hypophosphatemia
severe
during hyperalimentation in renal failure and hyperphosphatemia (abst) 113
Hypotension
as effect of prazosin (abst)..... 904
mechanism of *h.* action of intact and aminoterminal fragment of parathyroid hormone (abst)..... 176
postural, in CAPD..... 46
role of pressor hormones in maintenance of peripheral vascular resistance and mean arterial pressure in (abst) 174
Hypouricemia
familial renal, urate transport in erythrocytes in (abst) 140
Hypoxemia
during hemodialysis 738
renal pathophysiology of *h.* defined using manganese (abst) 901

Idiopathic urolithiasis
developments in treatment of (abst) 901
Ileal calcium
and phosphate secretion in uremic rats (abst)..... 903
Ileal ion transport
affected by systemic pH, P_{CO_2}, and HCO_3 concentration (abst) 230
Immune complex
circulating
IgA subclasses in *c. i. c.* of Berger and Henoch-Schönlein glomerulonephritis (abst)..... 658
IgA1 and IgA2 in *c. i. c.* and in renal deposits of Berger and Henoch-Schönlein glomerulonephritis (abst) 553
in Heymann nephritis..... 498
measurements of *c. i. c.* before and after renal transplantation (abst)..... 902
isolated circulating, charges of in glomerular diseases (abst) 197
Immunobiology
of renal allograft rejection S14-34
Immunoglobulins
IgA subclasses in *i.* of Berger and Henoch-Schönlein glomerulonephritis (abst) 658
Immunoglobulin A nephropathy
J chain in mesangial immune deposits of (abst) 658
rapidly progressive (abst)..... 122
study of progression of (abst)..... 141
Immunoglobulin A subclasses
in circulating immune complexes, immunoglobulins, and renal deposits of Berger and Henoch-Schönlein glomerulonephritis (abst)..... 658
Immunoglobulin A (sIgA)
possible role in urinary tract infection 759
Immunoglobulin G
in Heymann nephritis..... 498
role of human monocyte receptors in binding and catabolism of (abst)..... 181
Immunoglobulin synthesis
by peripheral blood mononuclear cells in minimal change nephrotic syndrome..... 380
Immunohistochemistry
in study of renin-containing cells in human glomerular and renal vascular diseases..... 375
Immunologic investigations
correlated with graft biopsy in renal transplantation S14-41
Immunologic monitoring
in renal transplantation..... S14-34
Immunological diseases
effects on renal transplantation..... S14-24
Immunosuppression
current views on *i.* for kidney transplantation (abst)... 427
steps in *i.* for renal transplantation S14-60
In vitro assay system
used to study compensatory renal growth 624
Indomethacin
alters site of norepinephrine's action on isolated perfused rat kidney (abst) 244
effects on
active proliferative lupus nephritis (abst)..... 779
papillary solute content in potassium deficient rat (abst) 268
renal function in normotensive males (abst) 247
Inflammation
in compensatory renal growth 603
Infrared spectrometry
and Raman microprobe in analysis of urinary calculi . 842
Inositol
uptake and renal function in isolated perfused rat kidney (abst) 224
Insulin
CAPD in 40-month experience of *i.*-dependent diabetic patients 40
effects of continuous subcutaneous *i.* on renal infusion in type I diabetes (abst) 779
(^{125}I)*i.* absorption during intermittent and continuous peritoneal dialysis 22
release in hyperosmolar states (abst) 237
Interferons
use in renal transplantation (abst) 778
International cooperative programs
potential for *i. c. p.* in renal transplantation discussed..... S14-66

Inter-racial study
of CAPD in South Africa (abst) 433
Interstitial fibrosis
of renal allografts in urinary tract obstruction (abst) ... 900
Intraperitoneal absorption
during intraperitoneal dialysis and CAPD 22
Introduction
to supplement on renal transplantation S14-1
Inulin
as a marker for glomerular filtration in preterm babies 407
Ionophore
divalent cation *i.* A23187, effects on rabbit renal cortical tubule bioenergetic function (abst) 222
Ischemia
acute renal failure induced by (abst) 427
Isometric exercise
renal humoral response to *i. e.* in hypertension (abst) 780
Isoniazid
treatment in membranoproliferative glomerulonephritis (abst) 435

J chain
in mesangial immune deposits of IgA nephropathy (abst) 658

Keto-acids
in low-protein diet in chronic renal failure (abst) 433
Kidney, remnant
blunted responsiveness of *r. k.* to changes in physical factors (abst) 215

Laboratory quality control
used in National Cooperative Dialysis Study S13-31
Lactate
role in CAPD (abst) 429
D-lactate
utilization and renal handling of *D-l.* in humans (abst) 225
Leukocyte mobilization
in experimental uremia 312
Lifecath® peritoneal implant
study of 46 consecutive patients with (abst) 142
Limb
of Henle's loop, thick ascending
cell death mediated by transport activity in *l. H. l.* in perfused kidney (abst) 221
thick ascending
in vivo study of *t. a. l.* transport in potassium-depleted rats (abst) 265
preparation of tubule suspension from rabbit kidney (abst) 221
Lipid peroxidation
NADPH-induced chemiluminescence and *l. p.* in kidney microsomes 691
Lithium ions
effects on Na^+/H^+ antiporter (abst) 240
Liver
disturbed volume homeostasis in cirrhosis of 303
Liver disease, chronic
in hemodialysis (abst) 548
Luminal membrane permeability
decreased in proximal tubules of hypothyroid rats (abst) 251
Luminal membrane structures
regulated by osmotic water flow during ADH stimulation and washout in toad bladder (abst) 263

Lysosomal pH
effects on renal hydrolysis of absorbed protein (abst) 224

Macrophages
in renal disease 458
murine peritoneal *m.* in catabolism of soluble aggregates of IgG (abst) 185
Macrophage supernatants
modulation of mesangial cell fibronectin by (abst) 188
Magnesium
effects on
renin, aldosterone, cortisol, and ACTH (abst) 283
kidney and *m.* regulation, forum on 771
renal transport of *m.* in acid-base disturbances (abst) 113
Manganese
prevents hypoxemia-induced renal vasoconstriction (abst) 901
Mannitol
osmotic effect of *m.* on neonatal proximal tubule (abst) 259
used to prevent acute renal failure after kidney cadaver transplantation (abst) 779
Medullary collecting duct
thiazide diuretic effect on *m. c. d.* function 711
Membrane plasma exchange
treatment for severe renal transplantation rejection (abst) 433
Menendez, Eduardo Braun
compensatory renal growth symposium dedicated to .. 569
Mesangial function
and focal glomerular sclerosis in Adriamycin nephrosis (abst) 778
Mesangial immune deposits
J chain in *m. i. d.* of IgA nephropathy (abst) 658
Mesothelial cells
in peritonitis 823
Metabolic acidosis
and parathyroidectomy effects on Na^+-H^+ exchange in isolated renal brushborder membrane vesicles (abst) 212
chronic
and alkalosis, uniform ventilatory response to (abst) 236
blood ionized calcium effects on serum $1,25(OH)_2$ D_3 in (abst) 109
effects on vitamin D metabolism in humans (abst) ... 103
tissue oxygen delivery in (abst) 229
role of intracellular pH and cell transformation in (abst) 240
Metabolic alkalosis
effects on intestinal absorption of calcium and phosphorus (abst) 100
filtered bicarbonate load during recovery from *m. a.* (abst) 235
Metabolic diseases
effects on renal transplantation S14-24
Metanephros
development of *m.* in allogenic graft (abst) 902
Methylprednisolone
intravenous *m.* at time of renal transplantation (abst) 557
pulsetherapy
diuretic effect in nephrotic syndrome (abst) 133
in focal sclerosis and nephrotic syndrome (abst) 133

Microbiological aspects
of CAPD, forum on 83
Microcomputer simulation
of renal glomerular dynamics (abst) 432
β2-Microglobulin
and n-acetylglucosaminidase excretion in Sjögren syndrome and rheumatoid arthritis (abst)..... 134
used to monitor renal transplant function 767
Microperfusion study
in rat submaxillary duct..... 350
Microscopic aggregation index
in nephrotic syndrome 519
Mineral and bone metabolism
affected by dialysis prescription..... S13-73
Mineralocorticoid
effects on
extrarenal potassium homeostasis in anuria (abst)... 155
rabbit cortical collecting tubules (abst)..... 260
Mitochondrial transport functions
and renal metabolism 785
Molecule separation
by high performance liquid chromatography in uremia 764
Monoclonal antibody
analysis of glomerular leukocyte infiltration in human glomerulonephritis by *m. a.* (abst)..... 192
OKT series, used to study T-suppressor cell activity in type I membranoproliferative glomerulonephritis (abst) 657
Orthomune, T cell subsets determined by (abst) 656
Poly C9, renal deposition of (abst) 194
used to define T-lymphocyte subpopulations in uremia (abst) 659
Monoclonal markers
in human glomerular cells (abst) 182
Monocytes
role in extracapillary glomerulonephritis (abst)..... 658
Monocytic phagocytic defect
identified in nephritis 851
Mononuclear cells, inflammatory
characterized in autoimmune tubulointerstitial nephritis..... 448
Morbidity
m., mortality, and patient withdrawal..... S13-42
Morphometry
m. comparison of rabbit cortical connecting tubules and collecting ducts 358
Myeloma
effects on renal transplantation..... S14-24
Myocardial infarction
in renal allograft recipient (abst) 430

1-Napthol
excretory metabolism of (abst)..... 227
National Cooperative Dialysis Study
control of dialysis by a single-pool urea model..... S13-19
data management, analysis, and statistical methods in S13-26
development of protocol for S13-11
effects of
dialysis prescription on bone and mineral metabolism in..... S13-73
dialysis prescription on electrolyte and acid-base metabolism in S13-66
dialysis therapy on hematopoietic system in S13-95
electrophysiological and neurobehavioral responses to therapy in..... S13-58
hemodynamic and cardiac correlates of different hemodialysis regimes in..... S13-89
history and organization of *N.C.D.S.* in supplement on S13-1
laboratory quality control in S13-31
modeling success or failure of dialysis therapy in. S13-101
morbidity, mortality, and patient withdrawal in ... S13-42
nutritional status of population in S13-80
participation centers and patient population in S13-37
principles of prescribing dialysis therapy S13-113
psychosocial aspects of chronic hemodialysis..... S13-50
Natriuretic factor
relationship to naturiuresis of central volume expansion during day versus night (abst)..... 250
Necrosis
role of urinary concentrating ability in toxic papillary *n.* 705
Nephrectomy
and diabetes mellitus, renal growth rate in 643
bilateral, associated with renal transplantation S14-69
seven-eighths, proteinuria prevented in 473
unilateral, polyamine metabolism in compensatory renal growth after 581
Nephritis
anti-GBM, proteolysis of ^{125}I-rabbit Hageman factor during (abst)..... 191
autoimmune tubulointerstitial, inflammatory cells in... 448
autologous immune complex, suppression of 'B' cell response in (abst) 185
chronic interstitial
potassium homeostasis in (abst)..... 218
diffuse proliferative, systemic lupus erythematosus in (abst) 131
effects of Chinese herbs on cationized-bovine serum albumin *n.* (abst) 181
experimental
immunity and immunosuppression in (abst)..... 186
experimental nephrotoxic
severity of injury in (abst)..... 431
filtration fraction in active proliferative lupus *n.* (abst) 779
Heyman *n.*
antigen, immunocytochemical localization of (abst). 185
antigenic determinants by rat Fx1A and antigen(s) in normal glomeruli and in immune deposits of *H. n.* (abst) 179
in situ immune deposit formation in active and passive *H. n.* 498
reaction to *H. n.* after immunization (abst) 188
immune complex
heterogeneity of glomerular permeability in (abst)... 184
influence of ureteral obstruction on immune complex mediated tubulointerstitial *n.* (abst)..... 182
lupus
elevated fibrinolysis inhibitors in (abst) 193
long-term follow-up classified by WHO histologic criteria (abst)..... 116
severe *l.*, short-term prognosis in (abst)..... 129
studied with Gallium scans in systemic lupus erythematosus (abst) 117
study of predictive features in *l. n.* by life-table and discriminant analysis (abst)..... 192
tubulointerstitial changes in (abst)..... 196
monocytic phagocytic defect identified in 851
monocytic phagocytic defect in subpopulation of (abst) 196
murine interstitial, adoptive transfer of (abst)..... 191

nephrotoxic serum
glomerular thromboxane synthesis in (abst) 186
glomerular arachidonate lipoxygenation in (abst) 186
spontaneous interstitial, model of autoimmune renal disease (abst) 187
streptococcus-associated, in rabbits (abst) 178
Nephrocalcinosis
age-related (abst) 114
Nephrolithiasis
idiopathic
abnormal proximal and distal nephron functions in (abst) 131
Nephrons
fat deposits in *n.* of starved rodents (abst) 903
Nephron filtration rate
affected by proximal tubular collection pressure in unilateral nephrectomy (abst) 252
Nephropathy
analgesic
effect on renal transplantation S14-24
focal segmental glomerulosclerosis in (abst) 900
associated with heroin (abst) 119
Berger, histologic pattern, blood pressure, and renin in (abst) 559
cimetidine, associated with cell-mediated immunity (abst) 140
cyclosporin A, interstitial cell infiltrate in (abst) 198
diabetic, clinical imperatives in S14-16
endstage diabetic, hemodialysis or renal transplantation (abst) 552
experimental membranous, glomerular permeability in (abst) 190
extramembranous, in children (abst) 434
idiopathic membranous, steroid and chorambucil treatment in (abst) 554
IgA
abnormalities of immune regulation in (abst) 553
J chain in mesangial immunodeposits of (abst) 554
natural history and histopathology of (abst) 193
IgM, question of two variants (abst) 193
lesion of fenoprofen in *n.* (abst) 198
lupus, reversal of renal failure in (abst) 132
membranous, proteinuria in 807
mesangial IgA, macroscopic hematuria in 393
minimal change, T lymphocyte subpopulations and lymphocyte function in *m. c. n.* during remission (abst) 194
obstructive, pathophysiology of, forum on 414
prostaglandin-vasopressin interactions in sickle cell *n.* (abst) 780
sickle cell
increased frequency of painful crisis after cadaver kidney transplantation in (abst) 287
prostaglandin-vasopressin interactions in (abst) 277
renal lesions in (abst) 131
Nephrosis
aminonucleoside, decrease in anionic charge sites in lamina rara externa in (abst) 187
immune and protamine-heparin aggregates in Adriamycin *n.* (abst) 778
impaired renal mevalonate metabolism in (abst) 223
mesangial function and focal glomerular sclerosis in Adriamycin *n.* (abst) 778
Nephrostolithotomy
approach to renal and ureteral calculi (abst) 119
Nephrostomy
percutaneous large-bore size (abst) 130
Nephrotic syndrome
adriamycin, glomerular hemodynamics and permselectivity (abst) 246
aminonucleoside, glycosaminoglycan metabolism in (abst) 224
and idiopathic membranous glomerulopathy, renal vein thrombosis in 368
and poststreptococcal glomerulonephritis in Zimbabwe (abst) 434
and renal vein thrombosis, treated with thrombectomy and anticoagulants (abst) 139
effects of acetazolamide on calcium and phosphate metabolism in (abst) 659
epithelial polyanionic coat and changes in foot processes in (abst) 657
glomerular ^{35}S-glycosaminoglycan metabolism in aminonucleoside-induced *n. s.* (abst) 181
impaired granulocyte phagocytosis and bacterocidal activity (abst) 135
labeled albumin method in (abst) 123
management of *n.s.* in African and Indian children (abst) 434
minimal change
immunoglobulin synthesis by peripheral blood mononuclear cells in 380
treated with low dose hydrocortisone (abst) 135
pharmacokinetics and protein binding of prednisolone in 876
plasma volume measurements surveyed in (abst) 780
quantitative indices of aminonucleoside-induced *n. s.* (abst) 188
red blood cell aggregation in 519
role of renal prostaglandins in (abst) 555
spontaneous recovery of *n. s.* associated with tolmetin (abst) 127
treated with thymus factor and lerami (abst) 562
zinc metabolism in (abst) 129
Nephrotoxicity
aminoglycosides, role of basolateral membranes in (abst) 205
experimental gentamicin, modified by increase in dietary calcium (abst) 207
of lysozyme (abst) 180
Neuromuscular hyperexcitability
in hypocalcemia and hypomagnesemia (abst) 107
Nicotinamide
effects on NAD content in proximal tubules (abst) 222
Nicotinamide adenine dinucleotide (NAD)
interaction with renal brushborder membrane (abst) ... 102
Nicotinamide adenine dinucleotide phosphate
chemiluminescence induced by NADPH in kidney microsomes 691
Nisoldpine
increases GFR in vasoconstricted isolated perfused rat kidney (abst) 246
Norepinephrine
affected by chlorthalidone in essential hypertension ... 320
in acute renal failure (abst) 281
NSAID's
effects on solute excretion in humans (abst) 275
^{31}P Nuclear magnetic resonance
used to study
ischemic human kidneys in acute renal failure (abst) 202

renal ischemia (abst) 207
Nucleotides
inhibitor of sodium-dependent phosphorus uptake by brushborder membrane of proximal tubules (abst) ... 103
Nutrition
in population studied in National Cooperative Dialysis Study S13-80

Organic molecules
in nonuremic polycystic kidney disease 514
Osteodystrophy, renal
correlation between bone histology and CT scan in (abst) 108
effects of trace elements on development of (abst) 155
etiologic factors in (abst) 111
long-term study of *r. o.* in dialysis (abst) 111
r. o., 25 hydroxycholecalciferol, and aluminum levels in CAPD 15
therapeutic parathyroid autotransplantation in (abst) .. 122
Osteomalacia
aluminum-induced role of chronic renal failure in animal model of 327
effects of aluminum injections (abst) 100
in chronic renal failure before dialysis (abst) 552
parathyroid gland responsiveness to acute hypocalcemia in dialysis *o.* 725
vitamin D therapy in aluminum-related *o.* (abst) 107
Oubain
effects of renin inhibition and renal vasoconstriction (abst) 276
Oxalate
accumulation in rat renal cortical slices (abst) 220
secretion, role in hyperoxaluria and calcium *o.* nephrolithiasis (abst) 96
Oxytocin
secretion by conscious Brattleboro homozygous rats during dehydration (abst) 254

$Paco_2$
effects on collecting duct hydrogen secretion in intact dog (abst) 228
Papillary necrosis
observed by sonography in renal allograft (abst) 904
Para-aminohippurate
effects on urate transport in rat proximal tubule 832
Paraquat poisoning
treatment of (abst) 136
Parathyroid hormone
as naturally occurring calcium ionophore (abst) 110
bovine 1-34, kidney and skeleton in metabolism of (abst) 104
effects on
enzymatic phosolipid methylation (abst) 97
skeletal muscle and role in uremic myopathy (abst). 212
in diabetes mellitus and endstage renal disease (abst) . 553
in patients with diabetes mellitus and endstage renal disease on chronic hemodialysis (abst) 157
increases ADP-ribosylation of canine renal brushborder membrane proteins (abst) 100
influence on net rate of fluid absorption in in vitro pars recta (abst) 108
influenced by aluminum in hemodialysis (abst) 560
inhibiting effects on voltage-dependent calcium uptake in brushborder membrane vesicles (abst) 101
mechanism of desensitization to PTH in dietary hyperparathyroidism (abst) 285
response to
hypocalcemia in dialysis osteomalacia (abst) 94
hypocalcemia in dialysis patients with osteitis fibrosa (abst) 113
role in phosphate homeostasis in uremia 674
status in proximal brushborder membrane and whole kidney (abst) 900
stimulates phospholipid phosphorylation in basosuppression of PTH secretion by aluminum 699
lateral membranes of renal tubular cells (abst) 98
Pco_2
measured in vivo in rabbit kidney and liver (abst) 233
Pediatric nephrology
acute poststreptococcal glomerulonephritis and rheumatic fever in same patient (abst) 195
altered hemostasis in children with nephrotic syndrome compared with adults (abst) 556
altered mineral homeostasis in nephrotic syndrome (abst) 100
anti-DNA antibodies in isolated circulating immune complexes in congenital nephrotic syndrome and SLE (abst) 195
biopsy for children with hematuria (abst) 138
cadaveric renal transplants in children less than 6 years old (abst) 116
cadaveric versus related living donor transplants in (abst) 430
comparison of
CAPD and hemodialysis in (abst) 143
GFR measurements in children after kidney transplantation 410
complement activation and factor VIII abnormalities in hemolytic-uremic syndrome (abst) 659
CAPD in children with acute renal failure (abst) 556
correlation between hypotransferrinemia and hypogammaglobulinemia in childhood nephrotic syndrome (abst) 199
effects of dietary phosphate on plasma $1,25(OH)_2D$ and serum iPTH in moderate renal insufficiency (abst) ... 108
effects of dihydrotachysterol, 25-OHD_3, and $1,25(OH)_2D_3$ on growth velocity in chronic renal failure (abst) 106
erythrocyte Na^+ and K^+ transport systems in children with Bartter syndrome 530
extramembranous nephropathy in (abst) 434
Fc-receptor function in Henoch-Schönlein disease in childhood (abst) 556
growth and nutritional status in children with CAPD (abst) 159
HLA phenotypes and clinical course of idiopathic nephrotic syndrome in children (abst) 556
herpes virus infections in *p.* renal transplant recipients (abst) 297
hypercalcemia during 1,25-vitamin-D_3 treatment (abst) 118
idiopathic and SLE-associated membranous glomerulonephropathy compared in 52 children (abst) 195
inulin as marker for glomerular filtration in preterm babies 407
mesangial immunoglobulin A nephropathy in (abst) ... 125
nephrotic syndrome in African and Indian children (abst) 434
protein balance and intake in hemodialyzed children (abst) 149

"prune belly" syndrome associated with renal transplantation in ... S14-24
renal problems in acute infective endocarditis in (abst) 434
renal transplantation, successful without donor specific transfusion in (abst) ... 294
selective binding of IgG4 and other negatively charged proteins in normal and diabetic kidneys (abst) ... 195
serum RIA-somatomedin-C in children and adolescents with endstage renal disease (abst) ... 217
Pentose
effects of *p.* pathway on renin release (abst) ... 225
Peripheral blood mononuclear cells
effects on immunoglobulin synthesis in minimal change nephrotic syndrome ... 380
Peritoneal morphology
affected by infectious peritonitis and mechanical injury 823
Peritonitis
in comparison of CAPD and home hemodialysis ... 51
in CAPD (abst) ... 903
in CAPD in Johannesburg Hospital (abst) ... 429
in 1981 study of CAPD on three continents ... 3
infectious, peritoneal transport properties in ... 823
prevention in CAPD (abst) ... 549
pH
intracellular
effects of secondary hypocapnia on ... 336
of granular and mitochondria rich cells of turtle bladder (abst) ... 239
regulation in hepatocytes (abst) ... 237
Phagocytosis
in experimental uremia ... 312
Pharmacokinetics
and protein binding of prednisolone in nephrotic syndrome ... 876
Phosphatase
alkaline
characterization in canine renal cortical brushborder membranes (abst) ... 114
enzymatic removal of from renal brushborder membrane (abst) ... 114
Phosphate
calcium and renal *p.* handling and parathyroid activity in pregnancy (abst) ... 660
effects on
limited availability of *p.* on proximal renal function (abst) ... 96
lysozymuria and lysosomal enzymuria (abst) ... 220
p. depletion on blood pressure (abst) ... 97
inorganic, binding on isolated brushborder membrane (abst) ... 95
metabolism affected by acetazolamide in nephrotic syndrome (abst) ... 659
pH dependence of *p.* absorption in rat renal proximal tubule (abst) ... 561
p. transport
in proximal brushborder membrane and whole kidney (abst) ... 900
in rabbit proximal tubule ... 674
of superficial and deep nephrons in response to parathyroid hormone (abst) ... 101
reabsorption inhibition induced by calcitonin (abst) ... 95
regulatory role of cytosolic redox on *p.* transport (abst) ... 114
secretion in vitamin D-depleted and uremic rats (abst) ... 903
tubular adaptation of *p.* influenced by luminal pH (abst) ... 109
uptake by renal brushborder membranes affected by filtered load and parathyroid hormone (abst) ... 104
uptake capacity in brushborder membrane from human kidney (abst) ... 96
Phosphatidylcholine synthesis
during compensatory renal growth (abst) ... 224
Phosphaturia
dopamine-induced (abst) ... 94
in rat after salivariadenectomy (abst) ... 111
perfusate inorganic phosphorus concentration in (abst) ... 110
Phosphorus
wasted in elderly by parathyroid hormone mechanism (abst) ... 94
Pituitary
role in acute unilateral nephrectomy (abst) ... 262
Plasma exchange
treatment in acute vascular rejection (abst) ... 551
Plasma flow
p. f. dependence of proximal fluid reabsorption (abst) ... 260
Plasma renin activity
systemic, during renal autoregulation in trained, chronically catheterized conscious rats (abst) ... 242
Plasma volume
survey of *p. v.* measurements in nephrotic syndrome (abst) ... 780
Plasmapheresis
comparison between double filtration and standard centrifugation *p.* in SLE (abst) ... 115
in Goodpasture syndrome and systemic lupus erythematosus (abst) ... 433
in renal transplantation ... S14-82
Platelets
in vivo *p.* activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients ... 506
indium oxine-labelled, aid in diagnosis of renal transplantation rejection (abst) ... 432
Platelet aggregation
in hemolytic uremic syndrome (abst) ... 431
Polyacrylonitryl membrane
compared to cuprophan *m.* in hemodialysis ... 738
Polyamine metabolism
in compensatory renal growth ... 581
Polycystic kidney disease
adult, radiologic methods of diagnosis (abst) ... 134
functional deterioration in ... 526
genetic susceptibility to steroid-induced *p. k. d.* in inbred mice (abst) ... 180
renal cyst epithelial transport in nonuremic *p. k. d.* ... 514
review of 53 adult patients (abst) ... 120
tubular basement membrane changes in (abst) ... 193
Polydipsia
and polyuria in phosphate-depleted rats (abst) ... 98
role in chronic hypercalcemia ... 489
Polypeptide growth factors
in compensatory renal growth ... 603
Polyuria
and polydypsia in phosphate-depleted rats (abst) ... 98
Postglomerular capillary permeability
determined in dogs (abst) ... 249
Postischemic hydronephrosis
used in method to visualize vas afferens and efferens in vivo ... 794

Potassium
depletion
cortical and papillary micropuncture evaluation of renal concentrating defect of *p. d.* (abst) 249
distal nephron hydrogen secretion (abst) 234
metabolic alkalosis of Cl^- deficiency (abst) 235
renal response of *p.*-depleted rats to extracellular fluid volume expansion, deoxycorticosterone acetate, furosemide, and chlorothiazide (abst) 255
effects of
acute *p.* infusion on cortical loop segment chloride uptake and plasma renin activity (abst) 280
acute *p.* replenishment on sodium, chloride, and *p.* reabsorption by Henle's loop (abst) 268
p. depletion on loop function (abst) 262
impaired renal and extrarenal *p.* adaptation in old rats 684
protection against renal tubule lesions in sodium chloride-fed rats (abst) 187
Potassium flux coefficient
in proximal convoluted tubule (abst) 259
Potassium ion transport
increased cell K^+ permeability in cortical collecting tubule (abst) 267
stimulated by aldosterone and insulin in cultured kidney cells (abst) 278
Potassium salts
effects on urine acid base parameters and citrate clearance in recurrent uric acid stone formers (abst) 226
Prazosin
hypotensive effect of *p.* (abst) 904
used to induce renin release (abst) 899
Prednisolone
in nephrotic syndrome 876
reduced *p.* bioavailability during rifampicin treatment (abst) 551
therapy in renal transplantation (abst) 429
Pregnancy
calcium and phosphate renal handling and parathyroid activity in (abst) 660
interrelationships between norepinephrine, prostaglandin E, and systemic blood pressure in *p.* rats (abst) 281
Proline
uptake by human renal brushborder membrane vesicles (abst) 223
Propranolol
prazosin-induced renin release blocked by (abst) 899
Prostacyclin
as major metabolite of arachidonic acid in canine blood vessels and renal cortex (abst) 272
effects of jaundiced human serum on vascular *p.* production by rat aorta (abst) 284
in vivo production of *p.* in Dahl salt-sensitive and -resistant rats (abst) 278
Prostaglandins
and vasopressin, effects on cyclic AMP synthesis (abst) 283
E_2
affected by bradykinin in hydronephrotic kidney 458
effects in proximal segment of rabbit nephron (abst) 97
in renal papilla influences sodium dependence in hypertension (abst) 280
inhibits hydrogen secretion in turtle urinary bladder (abst) 228
effects of *p.* metabolism alteration on intestinal calcium absorption (abst) 112
formed by isolated rat glomeruli in Goldblatt hypertension (abst) 285
modulate angiotensin II-stimulated glomerular contractility (abst) 284
renal *p.*
effects on reflex vasoconstrictor response to somatic receptor stimulation (abst) 244
role in chronic hypercalcemia 489
synthesis of
glomerular *p. s.* linked to phosphatidylinositol turnover (abst) 278
with intramembranous particle aggregates, and water permeability in toad urinary bladder (abst) 258
urinary E_2
age related to *u.* PGE_2 excretion in normal and hypertensive men (abst) 281
poor indicator of PGE_2 in renal papilla (abst) 279
Prostaglandin endoperoxide metabolism
in congenital unilateral hydronephrotic and unilateral ureteral obstruction rats (abst) 275
Prostaglandin-vasopressin
in sickle cell nephropathy (abst) 780
Protamine sulfate
effects on
cellular pathway in Necturus gallbladder (abst) 264
peritoneal clearance of CAPD (abst) 159
Protein
low *p.* diet with keto-acids in chronic renal failure (abst) 433
Protein, actin-binding
identification and phosphorylation of *a.-b. p.* in toad bladder and egg (abst) 221
Protein binding
and pharmacokinetics of prednisolone in nephrotic syndrome 876
Protein catabolism
effects of vitamin D on *p. c.* of muscle from uremic rats 465
Protein restriction
used to preserve renal structure and function in rats with reduced nephron mass (abst) 218
Protein synthesis
affected by aluminum 699
involvement in renin release (abst) 899
Proteinase activity, neutral
produced in vitro by cells of glomerular mesangium ... 342
Proteinuria
adriamycin-induced *p.*, new model of glomerular focal sclerosis (abst) 211
as early marker of renal transplant rejection and poor steroid response (abst) 291
as predictor of aminoglycoside nephrotoxicity (abst) .. 128
chronic, adriamycin-induced (abst) 192
glomerular sieving of anionic and neutral bovine albumins due to hexadimethrine or adriamycin (abst). 179
hexadimethrine-induced (abst) 183
in intact and splenectomized dogs after exercise (abst) 779
in membranous nephropathy 807
in treated essential hypertension (abst) 126
induced by
prednisone in nephrotic syndrome (abst) 562
reversible polycation (abst) 201
nephrotic range, in immunoglobulin A nephritis (abst) 140

prevented by dietary tryptophan supplementation 473
quantitated by random "spot" urine sample (abst) 124
reduced by DMSO in membranous nephropathy (abst) 186
terminal complement pathway in *p.* of chronic serum sickness (abst) 182
Proton permeability
of renal brushborder membranes (abst) 241
Proximal renal tubular dysfunction
in severe burns (abst) 129
Psychogenic polydipsia
nocturnal hyposthenuria and polyuria in (abst) 127
Psychosocial study
of chronic hemodialysis in National Cooperative Dialysis Study S13-50
Pulmonary functions
in high volume, low frequency CAPD 64
Pyelonephritis
Gardnerella vaginalis in sterile *p.* 862
Pyrazinoate
effects on urate transport in dog renal brushborder membrane vesicles (abst) 256
Pyridoxine therapy
effects on plasma oxalic acid in patients on RDT (abst) 563

Raman microprobe
and infrared spectrometry in analysis of urinary calculi 842
Reactive oxygen species
enzymatically induced production of *r. o. s.* by isolated rat glomeruli (abst) 226
Rectal gland plasma membrane vesicles
ion fluxes and furosemide binding in (abst) 257
REDY
aluminum leakage from *REDY* sorbent cartridge 536
Rejection
acute interstitial and acute vascular *r.* in renal transplantation S14-41
Renal angiotensin converting enzyme
catalytic properties of amphiphatic and hydrophilic form of *r. a. c. e.* (abst) 273
Renal artery constriction
renin release following *r. a. c.* (abst) 899
Renal artery stenosis
DTPA renal scans and I-131 hippuran renograms to assess *r. a. s.* (abst) 173
diagnosed by noninvasive echo-Doppler method (abst) 116
occurring after renal transplantation S14-54
Renal biopsy
percutaneous
hematomas following (abst) 130
study of 200 angiographically controlled *p. r. b.* (abst) 137
value in infective endocarditis (abst) 434
Renal blood flow
autoregulation of in acute ischemic renal failure 717
autoregulation of (abst) 428
in clipped and unclipped kidney 816
in young rat affected by uninephrectomy and microsphere size (abst) 242
Renal calculi
associated with acetazolamide therapy (abst) 137
Renal compensatory hypertrophy
affected by calcium and calcium regulating hormones (abst) 902
Renal cortex and medulla
homogenous preparations of cultured tubular segments from (abst) 222
Renal denervation
chronic, return of afferent activity after (abst) 173
Renal deposits
IgA subclasses in *r. d.* of Berger and Henoch-Schönlein glomerulonephritis (abst) 658
Renal disease
alters cortical interstitial cell function 458
and autoimmunity, influenced by interaction of mutant lymphoproliferation gene and strain background (abst) 189
associated with chronic plumbism in gout (abst) 134
endstage
chronic hemodialysis discontinued in (abst) 145
effects of CAPD on anemia of 744
effects of CAPD on anemia of (abst) 779
E.S.R.D. Amendment to the Social Security Act regarding dialysis therapy cost S13-8
40-month experience of CAPD in insulin-dependent diabetic patients with *e. r. d.* 40
incidence and prevalence in eastern United States (abst) 136
nonenzymatically glucosylated serum proteins in (abst) 149
1974–1981 study in Michigan (abst) 140
study of 1982 registration of *e. r. d.* patients and treatment facilities in South Africa (abst) 428
hemodynamically mediated glomerular injury and progressive nature of *r. d.*, forum on 647
malignant, effects on renal transplantation S14-24
prevented by eicosapentenoic acid in MRL-lpr mice (abst) 184
Renal dysfunction
and renin *d.* (abst) 432
as possible cause of essential hypertension 870
Renal failure
and thrombotic microangiopathy, associated with antineoplastic chemotherapy (abst) 133
plasmapheresis-induced recovery from *r. f.* in mesangiocapillary glomerulonephritis (abst) 562
urinary diagnostic indices associated with carbon tetrachloride intoxication (abst) 135
XAD-4 hemoperfusion for digoxin poisoning in (abst) . 126
Renal failure, acute
abnormal muscle protein turnover and glucose uptake in (abst) 202
absence of glomerular endothelial pore size differences in (abst) 201
adenine nucleotide profile used in (abst) 208
and hypercalcemia, angiotensin II in (abst) 201
and rhabdomyolysis, forum on 888
brain energy metabolism in (abst) 206
caused by cis-diamminedichloroplatinum in nephrectomized rats (abst) 204
complication in aortic aneurysm surgery (abst) 148
dietary sodium deprivation in gentamicin nephrotoxicity (abst) 200
dopamine-furosemide therapy in (abst) 564
due to acute tubular necrosis in lupus nephritis (abst) . 119
during converting enzyme inhibition in renal artery stenosis (abst) 138
effects of
continuous hemofiltration in (abst) 564
d-propranolol on postischemic *a. r. f.* (abst) 204
minimal hypotension on (abst) 207

salt and furosemide on gentamicin-induced *a. r. f.* (abst) 201
factor VIII, related antigen, and coagulation test in (abst) 564
in vivo origin of mitochondrial calcium overload during nephrotoxic *a. r. f.* (abst) 209
induced by gentamicin and influenced by verapamil (abst) 204
influence of captopril on thromboxane production in (abst) 205
intrarenal oxygen profiles in initiation phase of $HgCl_2$-induced *a. r. f.* (abst) 209
ischemic
alterations in vascular function and morphology in . 717
effects of converting enzyme inhibitor (MK 241) on 902
beta-2-microglobulin used to diagnose potential post-transplant *a. r. f.* 767
organic anions exacerbate experimental *a. r. f.* (abst) . 210
pathogenesis and prevention of (abst) 427
penicillin-induced hemorrhage, common in (abst) 200
potassium handling in cisplatin-induced *a. r. f.* in rats (abst) 208
preventing postischemic *a. r. f.* (abst) 200
prevention of *a. r. f.* with mannitol after kidney cadaver transplantation (abst) 779
raised glomerulocapillary resistance in $HgCl_2$ *a. r. f.* (abst) 206
sequential changes in mitochondrial function in ischemic *a. r. f.* (abst) 209
structural renal abnormalities in gentamicin-induced *a. r. f.* (abst) 207
treated with parenteral nutrition with increased nitrogen intake (abst) 123
Renal failure, chronic
altered prostaglandin-mediated adherent cell suppressor activity in (abst) 197
alterations of sodium-potassium pump in erythrocytes from patients with *c. r. f.* (abst) 215
among racial groups in Natal, South Africa (abst) 428
course of XAD-4 resin hemoperfusion in *r. f.* and digoxin toxicity 79
diminished baroreceptor function and vascular response in *c. r. f.* (abst) 213
effect of acute 25-hydroxyvitamin D_3 therapy in vitamin D metabolite concentration in 401
erythropoietin and inhibitors of erythropoiesis in anemia of *c. r. f.* (abst) 217
hypercholesterolemia and hypoapoproteinuria in *c. r. f.* after renal transplantation (abst) 558
in systemic lupus erythematosus (abst) 144
lead toxicity indicated in (abst) 125
low protein diet with keto-acids in (abst) 433
massive gastrointestinal hemorrhage and rectal ulcers in (abst) 124
mechanism of impaired urinary concentration ability in (abst) 658
rapid saline infusion study of extracellular fluid volume in (abst) 216
reduced extravascular T4 binding in (abst) 127
renal vesicle glutamine transport in health and *c. r. f.* (abst) 219
reproductive function in adolescent females during (abst) 147
role in aluminum-induced osteomalacia 327
role of dialysate acetate in energy metabolism during hemodialysis of patients with *r. f.* 57
sodium adaptation in (abst) 220
suppressor cells assayed in (abst) 431
transplantation as therapy for S14-4
uremia, increased brain calcium, and parathyroid hormone on changes in encephalogram in *c. r. f.* (abst) 210
Renal failure, early
role of 1,25 dihydroxy-vitamin D_3 in *e. r. f.* (abst) 219
Renal failure, progressive
no development of *p. r. f.* in dogs with remnant kidney (abst) 211
Renal function
in polycystic kidney disease 526
Renal glomerular dynamics
microcomputer simulation of (abst) 432
Renal glucose transport
in pregnant rats (abst) 270
Renal growth, compensatory
affected by age 599
and adenosine 588
in hypertensive rats 635
dedication of symposium on 569
humoral factors in regulation of 611
in experimental diabetes mellitus 643
in response to unilateral ureteral obstruction 594
in vitro evidence from tissue culture to prove rabbit and human *r. g.* factor 624
introduction to symposium on 571
messenger RNA regulation during 575
polyamine metabolism in 581
polypeptide growth factors in 603
renotrophic factors in urine in 616
renotrophic growth factor in cancer patient sera after cancer-bearing kidney removed 632
Renal hemodynamics
affected by infrarenal intraaortic balloon pumping (abst) 241
autoregulation by contralateral kidneys in hypertension (abst) 247
Renal histology
effects of exercise on (abst) 194
Renal humoral response
to isometric exercise in hypertension (abst) 780
Renal Ia antigens
role in mechanism of immunological renal diseases (abst) 191
Renal insufficiency, chronic
anion handling by choroid plexus in 387
increased splanchnic production of glucose in (abst) 660
Renal ischemia
effects of chronic uninephrectomy in (abst) 203
effects on proximal tubule fluid and glucose reabsorption (abst) 205
role in tubular injury after temporary *r. i.* (abst) 203
Renal ischemia, acute
impaired urinary acidification following *a. r. i.* in dog (abst) 209
Renal metabolism
and mitochondrial transport functions 785
segmental distribution of DNA polymerase activity in *r. m.* (abst) 220
Renal microsomes
NADPH-induced chemiluminescence and lipid peroxidation in 691
Renal microvessels, isolated
response to intraluminal pressure, norepinephrine, and angiotensin II (abst) 243

Renal nerve activity
in saline volume expansion (abst) ... 253
Renal ontogenic stages
identified by monoclonal antibodies (abst) ... 188
Renal papillary blood flow
direct determination of (abst) ... 245
Renal perfusion pressure
effects on papillary plasma flow and relation to sodium excretion in spontaneous hypertension (abst) ... 245
Renal response
to volume deprivation (abst) ... 432
to volume deprivation in sodium-depleted subjects (abst) ... 432
Renal sodium homeostasis
state during angiotensin converting enzyme inhibition in the rat (abst) ... 258
Renal tubular acidosis
type I, clinical and laboratory findings in 53 patients (abst) ... 118
Renal tubular cells
anion selectivity effects on *r. t. c.* Na^+-H^+ exchange (abst) ... 229
cultured, acute toxicity of mercury on (abst) ... 181
Renal tubular cell pH
simultaneous measurement by DMO and ^{31}P-NMR (abst) ... 228
Renal tubular system
destroyed by postischemic hydronephrosis ... 794
Renal vasoconstriction
hypoxemia-induced *r. v.* prevented by manganese (abst) ... 901
Renal vasodilatation
mechanism with captopril (abst) ... 286
Renal vein thrombosis
diagnosed by ultrasonic echo-Doppler flowmetry ... 882
in idiopathic membrane glomerulopathy and nephrotic syndrome ... 368
Renin
and blood pressure, divergent response at lactate threshold of exercise (abst) ... 287
and renal dysfunction (abst) ... 432
aortic *r.* levels in rats with plasma *r.* levels (abst) ... 900
effects on blood pressure in dehydration (abst) ... 900
r.-containing cells in human glomerular and renal vascular diseases ... 375
Renin release
following renal artery constriction (abst) ... 899
mechanism for increased *r. r.* in adrenalectomized rat (abst) ... 286
Renin-angiotensin system
blockade of *r.-a. s.* in hypertension and clipped kidney 816
Renorenal reflexes
natriuretic responses to mechano- and chemoreceptor stimulation (abst) ... 260
Renotropin
in compensatory renal growth in humans and rabbits . 624
in hypertensive rats ... 635
Rhabdomyolysis
and acute renal failure, forum on ... 888
RNA, messenger
regulation during compensatory renal growth ... 575
Ricinoleate
effects on rat colon permselectivity (abst) ... 102
Rubidium transport
in rat medullary thick ascending limb (abst) ... 271

^{14}C-Salicylate
transported by isolated and perfused proximal tubule (abst) ... 903
Sclerosis
focal glomerular *s.* and mesangial function in Adriamycin nephrosis (abst) ... 778
Seniquantitative assessment
in study of renin-containing cells in human glomerular and renal vascular diseases ... 375
Serotonin
intrarenal formation from 5-hydroxytryptophan (abst). 225
Silicon
concentrations in brain mitochondria of normal and uremic rats (abst) ... 95
Silicon elastomer
accumulation in regular hemodialysis (abst) ... 548
SITS
effects in lumen and bath on urate transport by isolated, perfused snake renal tubules (abst) ... 263
Sodium
absorption
glucocorticoid-induced *s. a.*, not due to cross over binding to aldosterone receptors (abst) ... 284
affected by chlorthalidone in essential hypertension ... 320
balance
as determinant of PG_{12} production by isolated rat aorta (abst) ... 277
in toxic papillary necrosis ... 705
depletion
renal response to fluid deprivation in (abst) ... 432
excretion
affected by infection during unilateral sustained partial ureteral obstruction in dog (abst) ... 256
permeability
effects on *s. p.* of luminal membrane vesicles from toad bladder (abst) ... 252
reabsorption
succinate and protein requirement for *s. r.* by rat papillary collecting ducts (abst) ... 266
regulation
mechanism of *s. r.* of glomerular angiotensin receptors (abst) ... 274
of *s.* transport tracked by ^{31}P-NMR (abst) ... 99
relationship between intracellular *s.* and hemodialysis bath *s.* level (abst) ... 214
requirements of *s.* for $1,25(OH)_2D_3$-stimulated calcium and phosphate transport (abst) ... 103
retention
in kidneys in cirrhosis of liver ... 303
transport
affected by aldosterone and dexamethasone in distal rat colon (abst) ... 282
Sodium-calcium exchange
effects on regulation of vascular smooth muscle tone (abst) ... 176
Sodium chloride
increases prostaglandin E_2 binding to rat renal medullary receptors (abst) ... 271
permeability
affected by amiloride and SITS in isolated perfused rabbit proximal tubule (abst) ... 269
reflection coefficient
measured by video camera and recorder across basolateral cell membranes (abst) ... 270
transport
in medullary thick ascending limb, inhibited by PGE_2 (abst) ... 253
Sodium ion/glucose cotransport
affected by ambient ionic environment in rabbit renal brushborder membrane vesicles (abst) ... 266

Sodium ion/hydrogen ion antiporter
effects on total *s. i.* flux across luminal membrane of proximal tubule (abst) ... 264
of rabbit proximal tubule confined to luminal membrane (abst) ... 233
Sodium ion/potassium ion transport
in erythrocytes of children with Bartter syndrome ... 530
Sodium-potassium-ATPase
in developing rabbit early juxtamedullary proximal convoluted tubule (abst) ... 238
in thin limbs of rat nephron (abst) ... 255
vascular smooth muscle cell, effects of Pb++, Hg++, Cd++, and Ca++ on (abst) ... 177
Sonography
used to observe papillary necrosis in renal allograft (abst) ... 904
South Africa
study of endstage renal disease patients and treatment facilities in 1982 study in (abst) ... 428
Splenectomy
associated with renal transplantation ... S14-69
proteinuria in intact and *s.* dogs after exercise (abst) . 779
Staphylococcus aureus
in experimental uremia ... 312
Structure-function monitoring
in renal transplantation ... S14-34
Submaxillary duct
relation of dark cells to transport of H^+/HCO_3 and K^+ ions in ... 350
Sucralfate
phosphate-binding effect of *s.*. in dialysis (abst) ... 160
Sugar
uptake into primary cell culture of dog kidney proximal tubular cells (abst) ... 271
Suppressor cells
assayed in chronic renal failure (abst) ... 431
Systemic lupus erythematosus
plasmapheresis in Goodpasture syndrome and *s. l. e.* (abst) ... 433

T cell
in autoimmune tubulointerstitial nephritis ... 448
subsets of *T c.* monitored in renal transplantation (abst) ... 656
T-lymphocyte subpopulations in uremic patients on dialysis (abst) ... 659
T-suppressor cell activity in type I membranoproliferative glomerulonephritis (abst) ... 657
^{99m}Tc pertechnetate
in choroid plexus in renal insufficiency ... 387
Thiazide diuretics
effects on medullary collecting duct function ... 711
used to control renal calculi ... 665
Thoracic duct drainage
in renal transplantation ... S14-74
T cell subpopulations of peripheral blood and thoracic duct lymphocytes as predictors of rejection in (abst) ... 287
Thromboxane
as early indicator of renal allograft rejection ... S14-34
mediated by calcium in unilateral ureteral obstruction in rat model (abst) ... 200
Thyroid hormone
effects on
sodium ion transport response to aldosterone in cultured epithelial cells (abst) ... 282
Tissue injury monitoring
in renal transplantation ... S14-34
Tolerance
definition of *t.* in renal transplantation ... S14-4
Total lymphoid irradiation (TLI)
cadaveric renal transplantation after TLI in diabetes ... S14-69
treatment in renal transplantation ... S14-10
Trace elements
in peritoneal dialysis, hemodialysis, and uremia ... 9
Transepithelial voltage
in reptilian- and mammalian-type nephrons in Japanese quail (abst) ... 263
positive, origin in salamander renal diluting segment (abst) ... 266
Transplantation, renal
antilymphocyte globulin and thoracic duct drainage in ... S14-74
bacteriuria and proteinuria in diabetic kidney transplant recipients (abst) ... 293
blood transfusion for ... S14-20
cadaver *r. t.* across blood group barrier (abst) ... 550
cadaver *r. t.* after total lymphoid irradiation in diabetes ... S14-69
comparison of methods of GFR measurement in children after ... 410
current views on immunosuppression for (abst) ... 427
demographics and gross anatomy of post-transplant hyperparathyroidism (abst) ... 292
diabetic nephropathy in ... S14-16
discussion on ethics in ... S14-90
early graft dysfunction effects on long-term survival (abst) ... 295
early indicators of renal allograft rejection in ... S14-34
effects of recipient's disease on results of *r. t.* ... S14-24
for high-risk patients ... S14-10
graft biopsy in ... S14-41
high risk of leukopenia and role of lithium in cadaveric *r. t.* (abst) ... 293
histological course of chronic hepatitis B-associated liver disease in (abst) ... 294
immune tolerance induced by platelet transfusion in Rhesus monkeys (abst) ... 294
immunoglobulin production in *r. t.* recipients (abst) ... 292
importance of r. t ... S14-3
improved survival through HLA-DR-MT-matching (abst) ... 556
in patients over 50 years old (abst) ... 430
indium oxine-labelled platelets as aid to diagnose rejections in (abst) ... 432
intensive plasma exchange therapy of acute *r. t.* rejection (abst) ... 290
interaction between cytomegalovirus infection and *r. t.* rejection ... S14-46
interferons and *r. t.* (abst) ... 778
interval antilymphoblast globular therapy in high risk cadaveric *r. t.* patients (abst) ... 291
introduction to supplement on ... S14-1
Lewis and other blood group systems in cadaver *r. t.* (abst) ... 550
long-term follow-up
after stopping prednisone in *t.* recipients (abst) ... 295
of renal function in donors (abst) ... 124
lymphocyte reactions of peripheral blood and thoracic duct lymphocytes from *r. t.* patients (abst) ... 293
mannitol used to prevent acute renal failure after cadaver *r. t.* (abst) ... 779
measurements of circulating immune complexes before and after (abst) ... 902

membrane plasma exchange as treatment in severe *r. t.* rejection (abst) ... 433
morbidity in long-term survivals of kidney transplants (abst) ... 296
noninvasive monitoring of *r. t.* function ... 767
parathyroid function after more than 4 years of stable cadaveric *r. t.* (abst) ... 297
plasma prednisolone levels and kinetics in (abst) ... 551
plasmapheresis in ... S14-82
post-*r. t.* erythrocytosis, a review of 53 patients (abst) ... 298
potential for international cooperative programs in ... S14-66
predisolone therapy in (abst) ... 429
primary cytomegalovirus infection after *r. t.* (abst) ... 296
prospective DR-matching in cadaveric *r. t.* (abst) ... 297
radiolabelled platelets and prostacyclin in diagnosis and treatment of *t.* rejection (abst) ... 551
randomized prospective study of donor specific transfusion in 1-haplo disparate related *r. t.* (abst) ... 289
rejection in *r. t.* as defined by renal biopsy lesions ... S14-41
renal artery stenosis after ... S14-54
renin dependency of hypertension after *r. t.* (abst) ... 298
review of 53 patients with post *r. t.* erythrocytosos ... 731
review of *r. t.* ... S14-4
role of cold-reactive alloantibodies in causing allograft malfunction immediately post-*t.* (abst) ... 292
search for optimizing corticosteroid administration in ... S14-85
serological status of cytomegalovirus and outcome of ... S14-50
significance of preformed cytotoxic cells in (abst) ... 291
steps in immunosuppression for ... S14-60
study of blood transfusions on cadaveric transplants (abst) ... 429
successful *t.* corrects impaired blood viscosity of chronically hemodialyzed patients (abst) ... 298
survival after HLA-A- and B-matched blood transfusions (abst) ... 550
T cell subsets monitored in (abst) ... 656
^{99m}Tc-DTPA renal scan used in early diagnosis of rejection (abst) ... 295
transfusion protocol using HLA typed blood donors (abst) ... 293
Western Pacific Regional Renal Transplant Donor Referral Program (WESTPAC) (abst) ... 294
Tryptophan, dietary
prevents proteinuria in seven-eighths nephrectomy ... 473
Tubules
adaptation of phosphate transport in rabbit proximal *t.* in uremia ... 674
isolated perfused mesonephric *t.*, transport in (abst) ... 268
isolated proximal *t.*, transport of magnesium and sulfate by *i. p. t.* of winter flounder (abst) ... 250
proximal (kidney) *t.*, water movement without solutes throughout *p. t.* (abst) ... 252
proximal convoluted *t.*, luminal and peritubular solutes composition and intracellular potential of *p. c. t.* (abst) ... 251
single isolated perfused *t.* of shark rectal gland (abst) ... 255
transport of ^{14}C-salicylate by isolated and perfused proximal *t.* (abst) ... 903
Tubuloglomerular feedback
affected by salt depletion and salt loading (abst) ... 271
influence on acute renal failure (abst) ... 902
reset by humoral factor in tubular fluid (abst) ... 244
signals, mobilization of feedback receptor cytosolic calcium during *t. f. s.* (abst) ... 241

UDF-glucuronyl transferase
in vivo and in vitro sex differences in renal UDF-*g.* in rat (abst) ... 225
Ultrafiltration
and diffusion effects on cardiac output and organ blood flow (abst) ... 562
Urate
absorption
affected by SITS, DIDS, and furosemide in rat proximal tubule (abst) ... 269
and PAH transport in basolateral membrane vesicles (abst) ... 258
transport of *u.* affected by anion exchange inhibitors and para-aminohippurate ... 832
Urate salts
interaction with urinary macromolecular inhibitors of calcium oxalate nucleation and crystal growth ... 838
Urea kinetics
use in acutely ill patients (abst) ... 128
Urea model
control of dialysis by single-pool *u. m.* ... S13-19
Urea movement
across erythrocyte membrane during hemodialysis ... 866
Urea permeability
of toad bladder in hyperosmotic media (abst) ... 257
Urea transport
in isolated, perfused thick ascending limbs and collecting ducts from rats (abst) ... 260
Uremia
bleeding time in *u.* shortened by 1-deamino-8-D-arginine vasopressin (abst) ... 132
effects of
amino acid infusions on cell metabolism in hemodialyzed *u.* (abst) ... 218
exercise on muscle sensitivity to insulin in *u.* (abst) 212
insulin on hemicorpus preparations from normal and *u.* rats (abst) ... 218
parathyroid hormone on human polymorphonuclear leukocytes in (abst) ... 105
vitamin D metabolites on protein catabolism of muscle from *u.* rats ... 465
erythropoietin in *u.* anemic sheep (abst) ... 213
experimental, cardiac weight and beta catecholaminergic response in (abst) ... 561
evidence for tubular secretion of compounds retained in *u.* (abst) ... 212
functional profile of isolated *u.* nephron ... 674
high performance liquid chromatography used to separate one *u.* middle molecule fraction ... 764
ileal calcium and phosphate secretion in vitamin D-depleted and *u.* rats (abst) ... 903
in diabetic nephropathy ... S14-16
increased neurominidase activity in *u.* (abst) ... 216
insulin binding to human erythrocyte insulin receptors in *u.* by hemodialysis (abst) ... 561
insulin resistance in *u.*, specific for glucose metabolism (abst) ... 222
intestinal generation of precarcinogen mitroso-dimethylamine (NDMA) in *u.* (abst) ... 216
liver hypothyroidism in *u.* rat model (abst) ... 217
mitochondrial calcium levels in chronically *u.* rats (abst) ... 210

muscular damage in (abst) 560
nutritional treatment in (abst) 561
natural killer cell activity in renal allograft recipients and *u.* hemodialyzed patients (abst) 656
phosphate restriction effects on decrease of Tm_{PO_4}/GFR in *u.* (abst) 216
protein restriction and renal function in *u.* rat (abst) ... 217
reduction in prednisolone in *u.* (abst) 115
renin activity and hemodynamic response to isolated ultrafiltration in conscious *u.* dogs (abst) 168
suppression of secondary hyperparathyroidism by $1,25(OH)_2D_3$ in (abst) 162
T-lymphocyte subpopulations defined by monoclonal antibodies in *u.* patients on dialysis (abst) 659
terminal, beta adrenergic modulation of extrarenal potassium disposal in (abst) 555
trace elements in peritoneal dialysis, hemodialysis, and *u.* 9
vitamin D deficiency in (abst) 101

Uremia, acute
cardiac β-receptor response reduced in (abst) 150
effects on acid base balance (abst) 234

Uremia, chronic
effect of vitamin B6 deficiency on plasma amino acids in (abst) 165
5 years use of charcoal hemoperfusion in (abst) 656
in vivo aluminum absorption by duodenum in *c. u.* rats (abst) 213

Uremia, chronic experimental
alterations in gamma glutamyl transpeptidase with *c. e. u.* (abst) 220

Uremia, experimental
cardiac weight and beta catecholaminergic response in (abst) 561
effects of verapamil on defective 1,25-dihydroxycholecalciferol synthesis and duodenal calcium absorption in (abst) 214
host immune status in 312

Uremic myopathy
hyperparathyroidism as cofactor of (abst) 656

Uremic polyneuropathy
response to dialysis and hyperalimentation (abst) 134

Ureteral obstruction, unilateral
renal growth in response to 594

Urinary calculi
infrared spectrometry and Raman microprobe in analysis of *u. c.* 842

Urinary concentrating ability
in chronic renal failure (abst) 658
role in generation of toxic papillary necrosis 705

Urinary macromolecules
interaction with calcium oxalate nucleation and crystal growth 838

Urinary tract anomalies
effects on renal transplantation S14-24

Urinary tract disease
Gardnerella vaginalis in 862

Urinary tract infections
comparison of methods of diagnosis (abst) 136
low urinary sIgA associated with *u. t. i.* 759

Urinary tract obstruction
interstitial fibrosis of renal allografts in *u. t. o.* (abst) . 900

Urine
intravenous reinfusion of 616
renotrophic factors in 616

Urine acidification
after spironolactone and amiloride (abst) 133

Urolithiasis, idiopathic
developments in treatment of (abst) 901

Vas afferens and efferens
new method to visualize *v. a.* and *e.* of glomerular microcirculation 794

Vascular diseases
effects on renal transplantation S14-24

Vascular lesions
in acute ischemic renal failure 717

Vasopressin
and other cyclic AMP-inducing agents, effects on cultured rabbit nephron segments (abst) 286
decreases papillary plasma flow, GFR, and ERPF through different receptor subtypes (abst) 245
effects on
arterial pressure in adrenalectomy (abst) 168
blood pressure in dehydration (abst) 900
in cirrhosis of liver 303
induces growth of renal epithelial cells (abst) 227
modulated by endogenous kallikrein-kinin system in rat (abst) 272
osmotic and nonosmotic release in health and disease (abst) 427
secretion regulated in pregnant rat (abst) 249
v. antagonist-associated aquaresis in primates (abst) ... 259

Vasopressin-prostaglandins
in sickle cell nephropathy (abst) 780

Venous pressure elevation
influence on transcapillary fluid and protein movements in human forearms (abst) 248

Virological studies
correlated with graft biopsies in renal transplantation S14-41

Virus
challenge of *v.* in experimental uremia 312

Vitamin
D metabolites
effects of acute 25 hydroxyvitamin D_3 therapy on *v. D. m.* concentration in chronic renal failure 401
effects on
phosphate fluxes in rat enterocytes 102
protein catabolism of muscle from uremic rats 465
D therapy, effects of bone aluminum intoxication on (abst) 99
$1,25(OH)_2$-vitamin D_3(1,25D) production in hypophosphatemia (abst) 102
in vitro modulation of renal 25-hydroxyvitamin D_3 metabolism by $1,25\text{-}(OH)_2\text{-}D_3$ and calcium (abst) 94
24,25 dihydroxyvitamin D, evidence for extra-renal production of 401
25 hydroxycholecalciferol, histological renal osteodystrophy, and aluminum levels in CAPD 15
25-hydroxyvitamin-D_3-24R- and 1 α-hydroxylases, activity in nephron and isolated renal cells (abst) 111
uremic rats depleted of *v. D* (abst) 903

Volume deprivation
renal response to (abst) 432
renal response to *v. d.* in sodium-depleted subjects (abst) 432

Volume expansion
effects on late proximal tubules bicarbonate absorption

in vivo microperfused proximal convoluted tubule (abst) 228
hormonal responses to *v. e.* induced by saline infusion (abst) 120
central, catecholamine and dopamine response to (abst) 128
proximal reabsorption of HCO_3, chloride, and water during isohydric extracellular fluid *v. e.* (abst) 237
Volume homeostasis
disturbed in cirrhosis of liver 303
Volume loading
evaluated on return of renal function of ice-stored kidneys in dog (abst) 288
Volume regulation
in humans during neck-out immersion in high specific gravity medium (abst) 242

Water channel
in toad urinary bladder (abst) 262
Wilms tumor
effects on renal transplantation S14-24

XAD-4
course of *XAD-4* resin hemoperfusion in renal failure and digoxin toxicity 79

KIDNEY INTERNATIONAL

Volume 23, Number 1, January 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

Proceedings from THE SECOND INTERNATIONAL SYMPOSIUM ON PERITONEAL DIALYSIS held at the International Congress Center in Berlin, Federal Republic of Germany, June 16–19, 1981

SYMPOSIUM ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS

Introduction. *Gerhard M. Gahl, Fred S. T. Boen, and Karl D. Nolph* 2

Continuous ambulatory peritoneal dialysis in Australia, Europe, and the United States: 1981. *Karl D. Nolph, Fred S. T. Boen, Peter C. Farrell, and Keith W. Pyle* 3

Comparison of trace elements in peritoneal dialysis, hemodialysis, and uremia. *Napier M. Thomson, Brian J. Stevens, Timothy J. Humphery, and Robert C. Atkins* 9

Histological renal osteodystrophy, and 25 hydroxycholecalciferol and aluminum levels in patients on continuous ambulatory peritoneal dialysis. *Raman Gokal, Jose M. Ramos, Hewett A. Ellis, Ian Parkinson, Vicky Sweetman, Jim Dewar, Michael K. Ward, and David N. S. Kerr* 15

Intraperitoneal (^{125}I) insulin absorption during intermittent and continuous peritoneal dialysis. *Tor-Erik Wideröe, Leif C. Smeby, Knut J. Berg, Störker Jörstad, and Tor M. Svartås* 22

Adaptation of CAPD patients to the continuous peritoneal energy uptake. *Hans von Baeyer, Gerhard M. Gahl, Hans Riedinger, Ruth Borowzak, Rüdiger Averdunk, Randolph Schurig, and Michael Kessel* 29

The influence of solution composition on protein loss during peritoneal dialysis. *Frederick N. Miller, Karl D. Nolph, Michael I. Sorkin, and Hans J. Gloor* 35

Continuous ambulatory peritoneal dialysis in insulin-dependent diabetic patients: A 40-month experience. *Jacques Rottembourg, Yassim El Shahat, Athanasios Agrafiotis, Yvette Thuillier, François de Groc, Claude Jacobs, and Marcel Legrain* 40

Influence of continuous ambulatory peritoneal dialysis on the autonomic nervous system. *Pietro Zucchelli, Carla Chiarini, Ezio Degli Esposti, Luigi Fabbri, Antonio Santoro, Alessandra Sturani, and Alessandro Zuccalà* 46

CLINICAL INVESTIGATION

Comparison of home hemodialysis to continuous ambulatory peritoneal dialysis. *Jack Rubin, Tom Barnes, Peggy Burns, Ricé Ray, Nancy Teal, Eric Hellems, and John Bower* 51

Contribution of dialysate acetate to energy metabolism: Metabolic implications. *Charles L. Skutches, Miles H. Sigler, Brendan P. Teehan, Joseph H. Cooper, and George A. Reichard* 57

High volume, low frequency continuous ambulatory peritoneal dialysis. *Zbylut J. Twardowski, Barbara F. Prowant, Karl D. Nolph, Alfonso J. Martinez, and Lawrence M. Lampton* 64

Hormonal responses to acute volume changes in anephric subjects. *C. Robert Cooke, Donald S. Gann, Paul K. Whelton, Tah Hsiung Hsu, Turner Bledsoe, Michael A. Moore, and W. Gordon Walker* 71

TECHNICAL NOTE

XAD-4 resin hemoperfusion for digitoxic patients with renal failure. *Wendy E. Hoy, Thomas P. Gibson, Alejandro J. Rivero, Vijay K. Jain, Thomas T. Talley, Richard M. Bayer, Daniel F. Montondo, and Richard B. Freeman* 79

NEPHROLOGY FORUM

Microbiologic aspects of chronic ambulatory peritoneal dialysis. *Stephen I. Vas* 83

ABSTRACTS

American Society of Nephrology, Chicago, Illinois, December 12–14, 1982 93

ANNOUNCEMENTS 299

Indexed in Current Contents, SCI, ASCA, and ISI/BIOMED

KIDNEY INTERNATIONAL

Volume 23, Number 2, February 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Disturbed volume homeostasis in patients with cirrhosis of the liver. *Ori S. Better and Robert W. Schrier* 303

LABORATORY INVESTIGATION

Host immune status in uremia. IV. Phagocytosis and inflammatory response in vivo. *Jan Nelson, Douglas J. Ormrod, and Thomas E. Miller* 312

Antihypertensive mechanism of diuretic treatment with chlorthalidone. Complementary roles of sympathetic axis and sodium. *Peter Weidmann, Carlo Beretta-Piccoli, Andreas Meier, Gerald Keusch, Zeev Glück, and Walter H. Ziegler* 320

Animal model of aluminum-induced osteomalacia: Role of chronic renal failure. *John A. Robertson, Arnold J. Felsenfeld, Carl C. Haygood, Paul Wilson, Cheryl Clarke, and Francisco Llach* . 327

Secondary hypocapnia fails to protect "whole body" intracellular pH during chronic HCl-acidosis in the dog. *David D. Clark, Bruce S. Chang, Serafino G. Garella, Jordan J. Cohen, and Nicolaos E. Madias* 336

Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. *David H. Lovett, R. Bernd Sterzel, Michael Kashgarian, and John L. Ryan* 342

Relation of dark cells to the transport of H^+/HCO_3^- and K^+ ions: A microperfusion study in the rat submaxillary duct. *Heinrich Knauf, Ralf Lübcke, Peter Röttger, Karl Baumann, and Gabriel Richet* 350

Morphometric comparison of rabbit cortical connecting tubules and collecting ducts. *Larry W. Welling, Andrew P. Evan, Dan J. Welling, and Vincent H. Gattone, III* 358

CLINICAL INVESTIGATION

Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: Incidence and significance. *Richard D. Wagoner, Anthony W. Stanson, Keith E. Holley, and Christine S. Winter* 368

Abnormalities of renin-containing cells in human glomerular and vascular renal diseases. *Dominique Nochy, Denis Barres, Jean-Pierre Camilleri, Jean Bariety, Pierre Corvol, and Joël Menard* . 375

Immunoglobulin synthesis by peripheral blood mononuclear cells in minimal change nephrotic syndrome. *Mary G. Beale, Geoffrey S. Nash, Michael J. Bertovich, and Richard P. MacDermott* .. 380

Altered anion handling by choroid plexus in renal insufficiency. *Julio V. Rivera, Rafael Ramírez-González, and Julio Morales* 387

Macroscopic hematuria in mesangial IgA nephropathy: Correlation with glomerular crescents and renal dysfunction. *William M. Bennett and Priscilla Kincaid-Smith* 393

Extra-renal production of 24,25 dihydroxyvitamin D in chronic renal failure during 25 hydroxyvitamin D_3 therapy. *Joseph E. Zerwekh, John J. McPhaul, Jr., Tom F. Parker, and Charles Y. C. Pak* . 401

TECHNICAL NOTES

Validation of inulin as a marker for glomerular filtration in preterm babies. *Malcolm G. Coulthard and Valerie Ruddock* 407

Measurement of glomerular filtration rate in children after renal transplantation. *Robert H. K. Mak, Jinan Al Dahhan, Denis Azzopardi, Milagros Bosque, Cyril Chantler, and George B. Haycock* . 410

NEPHROLOGY FORUM

Pathophysiology of obstructive nephropathy. *Saulo Klahr* 414

ABSTRACTS

South African Renal Society, Durban, South Africa, May 5–7, 1982 427

ANNOUNCEMENTS 436

Indexed in Current Contents, SCI, ASCA, and ISI/BIOMED

KIDNEY INTERNATIONAL

Volume 23, Number 3, March 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Glomerular cells in culture. *Jeffrey I. Kreisberg and Morris J. Karnovsky* 439

LABORATORY INVESTIGATION

Characterization of inflammatory cells in autoimmune tubulointerstitial nephritis in rats. *Francisco M. Mampaso and Curtis B. Wilson* 448

Renal disease profoundly alters cortical interstitial cell function. *Bernard B. Davis, David Thomasson, and Terry V. Zenser* 458

Effects of vitamin D metabolites on protein catabolism of muscle from uremic rats. *Herschel R. Harter, Stanley J. Birge, Kevin J. Martin, Saulo Klahr, and Irene E. Karl* 465

Dietary tryptophan supplementation prevents proteinuria in the seven-eighths nephrectomized rat. *George A. Kaysen and Jerald Kropp* 473

Disposal of ferritin in the glomerular mesangium of rats. *R. Bernd Sterzel, Mary Perfetto, Daniel Biemesderfer, and Michael Kashgarian* 480

Mechanism of concentrating defect in hypercalcemia. Role of polydipsia and prostaglandins. *Moshe Levi, Linda Peterson, and Tomas Berl* 489

Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. *Michael P. Madaio, David J. Salant, Andrew J. Cohen, Stephen Adler, and William G. Couser* 498

CLINICAL INVESTIGATION

In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients. *Geoffrey Frampton, Anwar Parbtani, Donatella Marchesi, Peter Duffus, Manuela Livio, Giuseppe Remuzzi, and John Stewart Cameron* 506

Renal cyst epithelial transport in non-uremic polycystic kidney disease. *Curtis G. Wickre and William M. Bennett* 514

Red blood cell aggregation in nephrotic syndrome. *Patrick Ozanne, Robert B. Francis, and Herbert J. Meiselman* 519

Rate of functional deterioration in polycystic kidney disease. *Kathrin A. Franz and François C. Reubi* 526

Erythrocyte Na^+ and K^+ transport systems in children with Bartter syndrome: Increase in passive sodium permeability. *Jean-Guy Mongeau, Ricardo Garay, Monique de Mendonca, Michel Broyer, and Philippe Meyer* 530

TECHNICAL NOTE

Aluminum leakage from REDY sorbent cartridge. *Warren B. Shapiro, Theodore P. Schilb, Clarence L. Waltrous, Steven R. Levy, and Jerome G. Porush* 536

NEPHROLOGY FORUM

Hypertension in the elderly. *Joseph Rosenfeld* 540

ABSTRACTS

XIXth Congress of the European Dialysis and Transplant Association, Madrid, Spain, September 6–9, 1982 548

ANNOUNCEMENTS 566

Indexed in Current Contents, SCI, ASCA, and ISI/BIOMED

KIDNEY INTERNATIONAL

Volume 23, Number 4, April 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

SYMPOSIUM ON COMPENSATORY RENAL GROWTH

DEDICATION

Dedication to Eduardo Braun Menendez: 1903 to 1959. *Juan C. Penhos* 569

INTRODUCTION

Compensatory renal growth symposium: An introduction. *Harry G. Preuss* 571

BIOCHEMISTRY AND PHYSIOLOGY OF COMPENSATORY RENAL GROWTH

Messenger RNA regulation during compensatory renal growth. *Andre J. Ouellette* 575

Polyamine metabolism in compensatory renal growth. *Howard A. Austin III, Herzl Goldin, DiAnna Gaydos, and Harry G. Preuss* 581

Adenosine and compensatory renal growth. *Michel Bergeron and Tina Hoang* 588

Renal growth in response to unilateral ureteral obstruction. *Steven J. Zelman, Terry V. Zenser, and Bernard B. Davis* 594

Effect of age on compensatory renal growth. *John P. Hayslett* 599

RENOTROPIC GROWTH FACTORS

Role of polypeptide growth factors in normal and abnormal growth. *Leonard M. Patt and John C. Houck* 603

Humoral factors in regulation of compensatory renal hypertrophy. *Ronald A. Malt* 611

Renotropic factors in urine. *Robert H. Harris, Michael K. Hise, and Christopher F. Best* 616

In vitro evidence from tissue cultures to prove existence of rabbit and human renotropic growth factor. *Nobuto Yamamoto, Hiroshi Kanetake, and Jun Yamada* 624

Renotropic growth factor found in cancer patient sera after removal of cancer-bearing kidney. *Jun Yamada, Hiroshi Kanetake, Yutaka Saito, Atsushi Kondo, and Nobuto Yamamoto* 632

COMPENSATORY RENAL GROWTH AND OTHER ASSOCIATIONS

Serum renotropic activity and renal growth in spontaneously hypertensive rats. *Harry G. Preuss and Herzl Goldin* 635

Renal hypertrophy in experimental diabetes mellitus. *Kjarten Seyer-Hansen* 643

NEPHROLOGY FORUM

Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. *Barry M. Brenner* 647

ABSTRACTS

Italian Society of Nephrology, Verona, Italy, June 10–12, 1982 656

ANNOUNCEMENTS 662

Indexed in Current Contents, SCI, ASCA, and ISI/BIOMED

KIDNEY INTERNATIONAL

Volume 23, Number 5, May 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Disorders of renal calcium excretion. *Roger A. L. Sutton* 665

LABORATORY INVESTIGATION

Functional profile of the isolated uremic nephron: Intrinsic adaptation of phosphate transport in the rabbit proximal tubule. *Norimoto Yanagawa, Robert A. Nissenson, Bruce Edwards, Patty Yeung, Walter Trizna, and Leon G. Fine* 674

Impaired renal and extrarenal potassium adaptation in old rats. *Howard H. Bengele, Robert Mathias, John H. Perkins, Eileen R. McNamara, and Edward A. Alexander* 684

NADPH-induced chemiluminescence and lipid peroxidation in kidney microsomes. *Sudhir V. Shah, Francisco C. Cruz, and William H. Baricos* 691

Suppression of parathyroid hormone secretion by aluminum. *Jeremiah Morrissey, Marcos Rothstein, Gilbert Mayor, and Eduardo Slatopolsky* 699

Role of urinary concentrating ability in the generation of toxic papillary necrosis. *Sandra Sabatini, Subbarayudu Koppera, José Manaligod, Jose A. L. Arruda, and Neil A. Kurtzman* 705

Thiazide diuretic effect on medullary collecting duct function in the rat. *Douglas R. Wilson, Ursula Honrath, and Harald Sonnenberg* 711

Alterations in vascular function and morphology in acute ischemic renal failure. *Erve Matthys, Marsha K. Patton, Richard W. Osgood, Manjeri A. Venkatachalam, and Jay H. Stein* 717

CLINICAL INVESTIGATION

Parathyroid gland responsiveness to acute hypocalcemia in dialysis osteomalacia. *Jeffrey A. Kraut, James H. Shinaberger, Frederick R. Singer, Donald J. Sherrard, Joan Saxton, Joseph H. Miller, Kiyoshi Kurokawa, and Jack W. Coburn* 725

Postrenal transplant erythrocytosis: A review of 53 patients. *Curtis G. Wickre, Douglas J. Norman, Alice Bennison, John M. Barry, and William M. Bennett* 731

Hypoxemia during hemodialysis: Effects of different membranes and dialysate compositions. *Wilfried A. De Backer, Gert A. Verpooten, Dirk J. Borgonjon, Paul A. Vermeire, Robert R. Lins, and Marc E. De Broe* 738

Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease. *Marc B. J. De Paepe, Karel H. G. Schelstraete, Severin M. G. Ringoir, and Norbert H. Lameire* . 744

An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis. *Harold K. Marder, Thomas H. Coleman, Judith Forristal, Linda Beischel, and Clark D. West* 749

Does low urinary sIgA predispose to urinary tract infection? *Gerd Riedasch, Peter Heck, Ernst Rauterberg, and Eberhard Ritz* 759

TECHNICAL NOTES

Separation of one uremic middle molecules fraction by high performance liquid chromatography. *Philippe Gallice, Nancy Fournier, Aimé Crevat, Michel Briot, Raymond Frayssinet, and Antoine Murisasco* 764

Noninvasive monitoring of renal transplant function by analysis of beta-$_2$-microglobulin. *Linda C. Edwards, J. Harold Helderman, L. Lee Hamm, David Ludwin, Peter Gailiunas, Jr., and Alan R. Hull* 767

NEPHROLOGY FORUM

The kidney and magnesium regulation. *John H. Dirks* 771

ABSTRACTS

Dutch Society of Nephrology, Rotterdam, The Netherlands, October 9, 1982 778

ANNOUNCEMENTS 781

Indexed in Current Contents, SCI, ASCA, and ISI/BIOMED

KIDNEY INTERNATIONAL

Volume 23, Number 6, June 1983

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Mitochondrial transport functions and renal metabolism. *David P. Simpson* 785

LABORATORY INVESTIGATION

Hydronephrosis: A new method to visualize vas afferens, efferens and glomerular network. *Michael Steinhausen, Hans Snoei, Niranjan Parekh, Rex Baker, and Paul C. Johnson* 794

Mediation of proteinuria in membranous nephropathy due to a planted glomerular antigen. *Stephen Adler, David J. Salant, John E. Dittmer, Helmut G. Rennke, Michael P. Madaio, and William G. Couser* 807

Effects of unclipping and converting enzyme inhibition on bilateral renal function in Goldblatt hypertensive rats. *Wann-Chu Huang and L. Gabriel Navar* 816

Acute changes in peritoneal morphology and transport properties with infectious peritonitis and mechanical injury. *Christian Verger, Alan Luger, Harold L. Moore, and Karl D. Nolph* 823

Effect of anion exchange inhibitors and para-amminohippurate on the transport of urate in the rat proximal tubule. *Edward J. Weinman, Steven C. Sansom, Stephen Bennett, and Andrew M. Kahn* . 832

Natural urinary macromolecular inhibitors: Attenuation of inhibitory activity by urate salts. *Joseph E. Zerwekh, Karen Holt, and Charles Y. C. Pak* 838

Infrared spectrometry and Raman microprobe in the analysis of urinary calculi. *Michel Daudon, Marie France Protat, Rene Jean Reveillaud, and Helgard Jaeschke-Boyer* 842

CLINICAL INVESTIGATION

Identification of monocyte phagocytic defect in a subpopulation of patients with nephritis. *Yuet M. Ooi and Boon S. Ooi* 851

Antiglomerular basement membrane antibody: Antibody specificity in different forms of glomerulonephritis. *Jörgen Wieslander, Per Bygren, and Dick Heinegård* 855

Unconventional bacteria in urinary tract disease: *Gardnerella vaginalis*. *Kenneth F. Fairley and Douglas F. Birch* 862

Urea movement across erythrocyte membrane during artificial kidney treatment. *Alfred K. Cheung, Michael F. Alford, Marcella M. Wilson, John K. Leypoldt, and Lee W. Henderson* ... 866

Renal dysfunction as a possible cause of essential hypertension in predisposed subjects. *Giuseppe Bianchi, Daniele Cusi, Cristina Barlassina, G. Pietro Lupi, Patrizia Ferrari, Giovanni Battista Picotti, Massimo Gatti, and Elio Polli* 870

Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis. *Harald Bergrem* 876

TECHNICAL NOTE

Noninvasive diagnosis of renal vein thrombosis by ultrasonic echo-Doppler flowmetry. *Pratap S. Avasthi, Ernest R. Greene, Christopher Scholler, and Charles R. Fowler* 882

NEPHROLOGY FORUM

Acute renal failure and rhabdomyolysis. *Nishio Honda* 888

ABSTRACTS

Swiss Society of Nephrology, Bern, Switzerland, December 10, 1982 899

ANNOUNCEMENTS 905

INDEXES 911